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Human ageing is characterised by reduced skeletal muscle function and increased incidence of a wide 
range of pathologies. The prevalence of muscle dysfunction in elderly populations represents a 
significant burden on healthcare due to the increased risk of injury, and difficulty in maintaining 
activities of daily living. Skeletal muscle dysfunction is also an important factor in age related 
diseases such as chronic obstructive pulmonary disease (COPD) and diabetes. Revealing the 
molecular alterations that occur in skeletal muscle of the elderly is therefore clearly an important 
step towards understanding an important aspect of the ageing process. 
This thesis describes the application of advanced computational techniques designed to “learn” the 
structure of molecular networks to understanding human skeletal muscle ageing.  Using this 
approach we have been able to discover a link between protein translation and age-dependent 
metabolic reprogramming. Experimental validation using the haploinsufficient eukaryotic initiation 
factor 6 (eIF6) mouse confirmed this important hypothesis  and revealed a substantial molecular 
reprogramming. The role of eIF6 in skeletal muscle and myoblasts was further investigated, revealing 
potential up and down-stream signalling mechanisms. 
The process of angiogenesis is an important step in morphogenesis including systems as diverse as 
muscle regeneration and tumour growth. This thesis presents the first temporal model of 
transcriptional alterations in tumour and the surrounding stroma during vascularisation. The 
application of reverse engineering approaches that are able to integrate perturbation data lead to 
the hypothesis that modulation of the proinflammatory cytokine IL1α may be an important upstream 
event in angiogenesis 





This thesis would not be possible without the large network of friends and collaborators who have 
worked with me and offered support and friendly guidance along the way. 
In no particular order, I would like to thank the following for their help and advice: Dan Tennant for 
isolating mitochondria from skeletal muscle and regularly working 12 hour days to do so, Stuart 
Egginton for performing countless sample collections for us and providing excellent expert advice, 
Dada Pisconti for help with the analysis of satellite cells and Stefano Biffo and his lab. I would like to 
thank Andreas Bikfalvi and Roy Bicknell for their advice and support towards the glioblastoma 
project, and Sarah Durant for the huge number of hours she spent in the lab producing the samples 
we needed.  
I would like to extend my heartfelt thanks to everyone in our lab, past and present, for teaching and 
putting up with my stubborn questions over the 4 years of my PhD: Phil, Wazeer, Nil, Rita, Jaanika, 
Peter, John H, John A, Danilo and Michela. 
I would like to thank Francesco Falciani for being a fantastic, supportive supervisor and not giving up 
hope that I would finish my PhD even in the face of stubborn apathy. A lesser supervisor would 
certainly not have led me to pass my doctorate. 
Finally, I would like to thank Emily, who put up with my months of anxiety, anguish and anti-social 
behaviour, as well as providing a proofreading service second to none. 
Thank you all.  
COMMON ABBREVIATIONS USED IN THIS THESIS 
 
AMPK AMP-activated protein kinase 
ANOVA Analysis of variance 
BP Gene ontology - biological process 
CC Gene ontology - cellular compartment 
CM Connectivity map (Broad Institute) 
COPD Chronic obstructive pulmonary disease 
Cy3 Cyanine 3 dye 
Cy5 Cyanine 5 dye 
DAVID DAVID Bioinformatics Resources 6.7 
EDTA Ethylenediaminetetraacetic acid 
EIF Eukaryotic initiation factor 
FDR False discovery rate 
GC-RMA Robust multi-array average with non-specific binding estimates 
GSEA Gene set enrichment analysis 
H2O2 Hydrogen peroxide 
HDAC Histone deacetylase 
HIF Hypoxia inducible factor (HIF1α) 
HOPACH Hierarchical Ordered Partitioning and Collapsing Hybrid algorithm 
INSR Insulin receptor 
IPA Ingenuity Pathway Analysis 
KEGG Kyoto Encyclopedia of Genes and Genomes 
LDA Linear discriminant analysis 
LOESS Regression based microarray normalisation procedure 
MAS5 Microarray suit 5 (Affymetrix) normalisation algorithm 
MF Gene ontology - molecular function 
MI Mutual information 
Myod Myogenic differentiation 1 
ox. phos. Oxidative phosphorylation 
PBS phosphate buffered saline 
PCA Principle component analysis 
PGC-1α Peroxisome proliferator-activated receptor gamma coactivator 1-
alpha 
RMA Robust multi-array average microarray normalisation 
ROS Reactive oxygen species 
SAM Significance Analysis of Microarrays 
TCA Tricarboxylic acid cycle 
VEGF Vascular endothelial growth factor (VEGF-A) 
VL vastus lateralis muscle 
DXA Dual-energy X-ray absorptiometry 






CHAPTER 1 ............................................................................................................................................... 1 
INTRODUCTION ....................................................................................................................................... 1 
1.2 Mammalian Skeletal muscle ................................................................................................... 1 
1.1.1 The structure and function of mammalian skeletal muscle ............................................ 2 
1.1.2 Skeletal muscle fibre types .............................................................................................. 3 
1.1.3 Skeletal muscle regeneration and repair ........................................................................ 4 
1.2 Skeletal muscle in elderly populations .................................................................................... 5 
1.2.1 The balance between protein synthesis and proteolysis ................................................ 6 
1.2.2 Mitochondrial dysfunction .............................................................................................. 7 
1.2.3 The role of inflammation and insulin resistance ........................................................... 10 
1.3 Interventions to prevent skeletal muscle dysfunction .......................................................... 11 
1.3.1 Hormone Replacement Therapy ................................................................................... 11 
1.3.2 Physical exercise training .............................................................................................. 12 
1.4 The regulation of angiogenesis ............................................................................................. 13 
1.5 The application of systems biology approaches to human health ....................................... 14 
1.5.1 From raw data to processed expression data ............................................................... 15 
1.5.2 Detecting gene expression patterns ............................................................................. 17 
1.5.3 Defining transcriptional signatures of perturbations .................................................... 18 
1.5.4 Constructing biological networks .................................................................................. 20 
1.6 Application of systems biology to skeletal muscle function and angiogenesis .................... 21 
1.6.1 Skeletal muscle .............................................................................................................. 21 
1.6.2 Angiogenesis.................................................................................................................. 23 
CHAPTER 2 ............................................................................................................................................. 25 
INFERENCE AND ANALYSIS OF TRANSCRIPTIONAL NETWORKS REPRESENTING AGEING HUMAN 
SKELETAL MUSCLES ............................................................................................................................... 25 
2.1 Introduction .......................................................................................................................... 25 
2.2 Methods ................................................................................................................................ 27 
2.2.1 Selection of public domain microarray datasets ........................................................... 27 
2.2.2 Affymetrix microarray processing ................................................................................. 30 
2.2.3 Illumina microarray processing ..................................................................................... 30 
2.2.4 Integration of microarray data from multiple studies .................................................. 30 
2.2.5 Detecting and comparing differentially expressed genes ............................................. 31 
2.2.6 Constructing and visualising transcriptional networks ................................................. 32 
2.2.7 Identification of network modules ................................................................................ 32 
2.3 Results ................................................................................................................................... 35 
2.3.1 Integration of expression profiling datasets representing human healthy skeletal 
muscles  ....................................................................................................................................... 35 
2.3.2 Differential gene expression in elderly human skeletal muscles ......................................... 37 
2.3.3  Inference of gene regulatory networks representing young and elderly skeletal 
muscles  ....................................................................................................................................... 42 
2.3.4 Community analysis of muscle transcriptional networks reveals functionally enriched 
age-specific modules ..................................................................................................................... 44 
2.3.5 Mapping age dependent differential gene expression on the integrated transcriptional 
network  ....................................................................................................................................... 49 
2.3.6 Transcriptional response to physical exercise affects specific network modules ........ 53 
2.4 Discussion .............................................................................................................................. 56 
2.4.1 The transcriptional signature of ageing skeletal muscle ............................................... 56 
2.4.2 The construction of gene co-expression networks in young and elderly skeletal muscle 
  ....................................................................................................................................... 57 
2.4.3 The expression of genes in distinct network modules responds to physical exercise .. 59 
2.4.4 Control of translation and metabolism in response to cellular signaling ..................... 60 
CHAPTER 3 ............................................................................................................................................. 61 
EUKARYOTIC INITIATION FACTORS ARE POTENTIAL REGULATORS OF MUSCLE BIOENERGETICS AND 
REMODELLING ....................................................................................................................................... 61 
3.1 Introduction .......................................................................................................................... 61 
3.2 Methods ................................................................................................................................ 63 
3.2.1 Inferring gene-gene correlations using Spearman’s rank correlation .......................... 63 
3.2.2 Linear Discriminant Analysis ......................................................................................... 63 
3.2.3 Gene ontology and pathway enrichment ..................................................................... 63 
3.2.4 Collection of skeletal muscle ......................................................................................... 64 
3.2.5 Transcriptional profiling of Eif6+/- mouse skeletal muscle ............................................ 64 
3.2.6 Proteomics analysis of mitochondria purified from Eif6+/- skeletal muscle .................. 65 
3.2.7 Connectivity Map and Ingenuity analysis ...................................................................... 65 
3.3 Results ................................................................................................................................... 66 
3.3.1 Correlation analysis links the expression of EIFs to energy metabolism and tissue 
remodelling ................................................................................................................................... 66 
3.3.2 Eif6 inactivation in mice is consistent with the human muscle biopsies network ........ 69 
3.3.3 The transcriptional state of the Eif6 haploinsufficient mouse recapitulates the 
functional profile of the inferred human EIF6 network neighbourhood ...................................... 72 
3.3.4 Ingenuity Pathway Analysis of the Eif6+/- transcriptional signature .............................. 75 
3.3.5 Protein expression in Eif6+/- skeletal muscle mitochondria .......................................... 78 
3.3.6 Lysine acetylation is a predicted mechanism of eIF6 control of transcription ............. 81 
3.4 Discussion .............................................................................................................................. 83 
3.4.1 The role of eukaryotic initiation factors ........................................................................ 83 
3.4.2 Eif6 haploinsufficiency controls expression of energy metabolism genes and proteins .. 
  ....................................................................................................................................... 84 
3.4.3 Depletion of eIF6 produces a signature associated with HDAC inhibitor treatment .... 86 
CHAPTER 4 ............................................................................................................................................. 88 
SIGNALS LINKING EIF6 TO MITOCHONDRIAL FUNCTION, OXIDATIVE STRESS AND SKELETAL MUSCLE 
REGENERATION ..................................................................................................................................... 88 
4.1 Introduction .......................................................................................................................... 88 
4.2 Methods ................................................................................................................................ 90 
4.2.1 Use of existing microarray studies ................................................................................ 90 
4.2.2 Additional procedures applied to existing studies ........................................................ 91 
4.2.3 Eif6+/- satellite cell culture and transcriptional profiling ............................................... 91 
4.2.4 Functional enrichment analysis ..................................................................................... 92 
4.3 Results ................................................................................................................................... 93 
4.3.1 Eif6 is up-regulated in mouse hypoxic skeletal muscle ................................................. 93 
4.3.2 eIF6 acts up-stream of PGC-1α...................................................................................... 96 
4.3.3 Expression of Eif6 is increased in response to high levels of hydrogen peroxide ......... 98 
4.3.4 Expression of EIF6 modulates genes linked to an increase in serum protein 
carbonylation .............................................................................................................................. 100 
4.3.5 Eif6 is up-regulated during skeletal muscle satellite cell activation ........................... 103 
4.3.6 Eif6 is down-regulated during muscle satellite cell differentiation ............................ 105 
4.3.7 Transcriptional profiling of Eif6+/- primary satellite cells reveals differential expression 
of energy metabolism genes ....................................................................................................... 108 
4.4 Discussion ............................................................................................................................ 111 
4.4.1 Eif6 expression is controlled by hypoxia ..................................................................... 111 
4.4.2 Eif6 controls gene expression in satellite cells in a cell-autonomous manner ........... 112 
CHAPTER 5 ........................................................................................................................................... 114 
MODELLING THE INTERACTION BETWEEN TUMOUR AND STROMA IN AN IN VIVO MODEL OF 
ANGIOGENESIS .................................................................................................................................... 114 
5.1 Introduction ........................................................................................................................ 114 
5.2 Methods .............................................................................................................................. 117 
5.2.1 Overview of the Analysis Strategy ............................................................................... 117 
5.2.2 Cells and Embryos ....................................................................................................... 117 
5.2.3 Microarray profiling .................................................................................................... 118 
5.2.4 Differential expression and cluster analysis ................................................................ 119 
5.2.5 Constructing correlation based co-expression networks ............................................ 120 
5.2.6 Constructing ODE-based networks ............................................................................. 120 
5.2.7 Validation of the network connections using the in vitro treatment expression profiles 
  ..................................................................................................................................... 121 
5.3 Results ................................................................................................................................. 122 
5.3.1 Transcriptional response of normal and tumour tissues in the CAM model .............. 122 
5.3.2 Inference of a high-level dynamical model representing stroma-tumour interaction 125 
5.3.3 CAM transcriptional response to VEGF is predicted by the high-level dynamical model .. 127 
5.3.4 Defining transcriptional signatures of cytokines and growth factors in tumour cells 129 
5.3.5 Validating sub-networks of the co-expression network using the in vitro treatments .... 
  ..................................................................................................................................... 133 
5.3.6 High resolution, gene-level dynamical modelling identifies IL1α as a key factor driving 
tumour implantation in the CAM ................................................................................................ 136 
5.3.7 High resolution dynamical modelling linking soluble factor gene expression to effector 
functions, confirms IL1α as a key factor driving tumour implantation in the CAM .................... 138 
5.4 Discussion ............................................................................................................................ 141 
5.4.1 The role of IL1α in controlling angiogenesis ............................................................... 142 
5.4.2 Angiogenesis in skeletal muscle .................................................................................. 143 
CHAPTER 6 ........................................................................................................................................... 144 
CONCLUDING STATEMENT AND FUTURE DIRECTIONS ....................................................................... 144 
APPENDIX ............................................................................................................................................ 147 
Appendix 3A .................................................................................................................................... 147 
KEGG pathway enrichment within the neighbourhood of EIF2S2 (FDR < 25%) .......................... 147 
KEGG pathway enrichment within the neighbourhood of EIF3J (FDR < 25%) ............................ 150 
Appendix 3B .................................................................................................................................... 153 
Appendix 5A .................................................................................................................................... 155 
REFERENCES ........................................................................................................................................ 156 
 
  
LIST OF FIGURES 
 
Figure 1.1 – The structure of mammalian skeletal muscle ................................................................... 2 
Figure 1.2 – Example of Principle Component Analysis and hierarchical clustering .......................... 17 
 
Figure 2.1 – The distribution of samples according to age for each study identified in the GEO 
search (from Table 2.1). ....................................................................................................................... 29 
Figure 2.2 – The data integration strategy using ComBat. .................................................................. 31 
Figure 2.3 – The application of a resampling procedure to empirically define an MI threshold ...... 33 
Figure 2.4 – Principle component analysis reveals systemic batch effects related to both microarray 
platform and dataset ............................................................................................................................ 36 
Figure 2.5 – The gene level overlaps between the differentially expressed genes identified by the 
Melov study and the meta-analysis. .................................................................................................... 40 
Figure 2.6 – Graphical representation of the young and elderly muscle networks. .......................... 43 
Figure 2.7 – The union of the young and elderly networks ................................................................ 45 
Figure 2.8 – Modules are characterised by age specific edges and inter-module connections ........ 46 
Figure 2.9 – GLay modularisation of a lower threshold network recapitulates the network modules.
 ............................................................................................................................................................... 48 
Figure 2.10 – Network modules are enriched with genes differentially expressed with age ........... 50 
Figure 2.11 – Common transcriptional signature of age in humans and mice ................................... 52 
Figure 2.12 - Specific network modules are enriched with genes responsive to training ................. 55 
Figure 2.13 – Modularisation of separate young and elderly networks recapitulates the findings of 
the union network ................................................................................................................................ 59 
 
Figure 3.1 – Enrichment of energy metabolism KEGG pathways within genes correlated to 
expression of eukaryotic initiation factors .......................................................................................... 67 
Figure 3.2 – EIF6 is correlated to energy metabolism pathways in an age-dependent manner ....... 69 
Figure 3.3- Functional similarities between the human EIF6 correlation neighbourhood and the 
Eif6+/- soleus muscle in mice ................................................................................................................. 73 
Figure 3.4 – Enrichment of eIF6 regulated genes in the human network modules ........................... 74 
Figure 3.5 – Ingenuity networks showing genes down-stream of INSR and PGC-1α that are 
differentially expressed in Eif6+/- muscle ............................................................................................. 77 
Figure 3.6 – Mitochondrial protein expression separates wild type and heterozygous samples in a 
PCA ........................................................................................................................................................ 79 
Figure 3.7 – Mapping the differentially expressed proteins to mitochondrial functions. ................. 80 
Figure 3.8 – The role if eIF6 in ribosome 80S assembly ...................................................................... 84 
 
Figure 4.1 – Hypoxia modulates Eif6 expression and targets distinct network modules .................. 95 
Figure 4.2 – PGC-1α is down-stream of eIF6 and targets module M2 and M3 in the muscle network
 ............................................................................................................................................................... 97 
Figure 4.3 – Cluster analysis of genes modulated by H2O2.................................................................. 99 
Figure 4.4 – Eif6 expression in response to H2O2 treatment ............................................................. 100 
Figure 4.5 – Energy metabolism genes linked to ROS damage are regulated by Eif6 
haploinsufficiency ............................................................................................................................... 102 
Figure 4.6 – Activation of satellite cells induces expression of Eif6 and genes modulated by Eif6 
haploinsufficiency ............................................................................................................................... 105 
Figure 4.7 – The functional profile of differentiating satellite cells is consistent with the expression 
of Eif6 and PGC-1α .............................................................................................................................. 106 
Figure 4.8 – PCA reveals a similar response to induction of differentiation in Eif6+/+ and Eif6+/- 
satellite cells ....................................................................................................................................... 108 
Figure 4.9 – The functional profiles of Eif6+/- satellite cells reveal cell autonomous effects ........... 109 
 
Figure 5.1- Overview of the implantation and analysis strategy ...................................................... 116 
Figure 5.2 – Cluster analysis and functional profiling of the five time domains (stroma) ............... 123 
Figure 5.3 – Cluster analysis and functional profiling of the 5 time domains (tumour) .................. 124 
Figure 5.4 – Tumour and stroma co-expression network ................................................................. 126 
Figure 5. 5 – VEGF targets are enriched down-stream of VEGF in the network ............................... 127 
Figure 5.6 – Hierarchical clustering of transcriptional and functional profiles of the U87 treatments
 ............................................................................................................................................................. 131 
Figure 5.7 – Sub-network of the co-expression network validated by the U87 in vitro treatments 135 
Figure 5.8 – ODE-based networks representing gene level interactions in the tumour and stroma
 ............................................................................................................................................................. 137 
Figure 5.9 – ODE-based networks of soluble factor gene expression and effector functions ......... 140 
  
LIST OF TABLES 
 
Table 1.1- Characteristics of different skeletal muscle fibre types ....................................................... 4 
Table 1.2 – The effect of acetylation on metabolic enzymes .............................................................. 10 
 
Table 2.1 - Microarray datasets identified in the GEO search ............................................................ 29 
Table 2.2 – The properties of sparse networks generated from the young and elderly data at a 
range of MI thresholds ......................................................................................................................... 34 
Table 2.3 – The number of differentially expressed probes and genes before and after the ComBat 
procedure .............................................................................................................................................. 36 
Table 2.4 – Differentially expressed genes between young males and females in the meta-analysis 
data ....................................................................................................................................................... 38 
Table 2.5 – Functional analysis of genes differentially expressed in skeletal muscle of elderly 
individuals ............................................................................................................................................. 39 
Table 2.6 – Down-regulated functional terms in common between the meta-analysis and the Melov 
study ...................................................................................................................................................... 41 
Table 2.7 – Up-regulated functional terms in common between the meta-analysis and the Melov 
study. .................................................................................................................................................... 42 
Table 2.8 – Properties of the GLay modules ........................................................................................ 45 
Table 2.9 – Functional analysis of each network module reveals distinct functional profiles .......... 47 
Table 2.10 – Functional analysis of genes responding to endurance training in skeletal muscle ..... 54 
 
Table 3.1 – Functional analysis of differentially expressed genes in Eif6+/- soleus muscle ................ 71 
Table 3.2 – Functional analysis of the Eif6+/- gastrocnemius muscle .................................................. 72 
Table 3.3 – Ingenuity Pathway Analysis predicts up-stream regulators of eIF6 targets .................... 76 
Table 3.4 – Functional analysis of differentially expressed proteins .................................................. 80 
Table 3.5 – Transcriptional signatures with significant overlap to the Eif6+/- signature. ................... 82 
Table 3.6 – Properties of eIF6 in yeast and mammalian systems ....................................................... 85 
 
Table 4.1 – Summary of the studies used in this analysis. .................................................................. 90 
Table 4.2 – Functional analysis of hypoxic skeletal muscle in mice ................................................... 94 
Table 4.3 – Functional analysis of genes modulated by hypoxia and Eif6 haploinsufficiency .......... 95 
Table 4.4 – Functional analysis of the overlap between PGC-1α and Eif6+/- targets .......................... 97 
Table 4.5 – Functional analysis of differentially expressed genes in activated satellite cells ......... 104 
Table 4.6 – Functional analysis of genes up-regulated during satellite cell differentiation and Eif6 
haploinsufficiency ............................................................................................................................... 106 
Table 4.7 – Differentially expressed genes between satellite cells .................................................. 109 
 
Table 5.1 – Functional analysis of VEGF responsive genes in the CAM ............................................ 128 
Table 5.2 – Summary of the functional profiles of key clusters ........................................................ 129 
Table 5.3 – Growth factors, cytokines, chemokines and receptors in the stroma and tumour ...... 130 
Table 5.4 – Transcriptional profiling of U87 cells following treatment with 15 soluble factors ..... 130 
Table 5.5 – Functional analysis of genes regulated by VEGF treatment of U87 cells in vitro .......... 133 






1.2 Mammalian Skeletal muscle 
 
Humans have evolved a complex musculoskeletal system which provides structural support and 
motor control. Movement is coordinated by the motor cortex via the central nervous system which 
stimulates contraction in voluntary skeletal muscles. Muscle contraction provides the force needed 
to move and support the body during all of its normal activities of daily living. Skeletal muscle 
function is impaired in ageing, a condition known as sarcopenia. This has recently been precisely 
defined according to physiological measurements of walking speed and muscle mass compared to 
young people in order to aid medical diagnosis [1]. Impairment of skeletal muscle function is also a 
contributing factor to diseases such as COPD [2], as well as being a key player in the development of 
insulin resistance and type 2 diabetes [3]. At the epidemiological level, muscle weakness is a strong 
and independent predictor of all-cause mortality in older adults [4][5][6]. 
In the following sections, the structure and function of skeletal muscle will be described. The effects 
of ageing and age-related diseases on skeletal muscle function will be reviewed, including popular 
intervention strategies that target muscle dysfunction such as hormone replacement therapy and 
physical training. The use of functional genomics and systems biology approaches has led to a greater 
understanding of skeletal muscle function in recent years. These approaches and key findings will 




1.1.1 The structure and function of mammalian skeletal muscle 
 
Skeletal muscles which can be controlled at will, termed voluntary muscles, are stimulated through 
the propagation of action potentials from the source, typically a neuronal cell, to a neuromuscular 
junction (NMJ) which is directly connected to muscle fibres [7] (Figure 1.1A). By releasing the 
neurotransmitter acetylcholine the NMJ stimulates contraction of muscle fibres. Each skeletal muscle 
is connected to multiple NMJs. This allows for the great range of precision and scale of movement 
many mammals are capable of. 
 
Figure 1.1 – The structure of mammalian skeletal muscle 
Panel A shows the arrangement of skeletal muscle fibres into bundles or fascicles, surrounded by 
support components such as blood vessels. Panel B shows the arrangement of actin and myosin 
filaments within the sarcomere. The myosin filaments move along the actin filaments away from the 
M line towards the Z disks, causing contraction of the sarcomere. Image source: en.wikipedia.net 
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Skeletal muscles are composed of bundles or fascicles of parallel muscle fibres (Figure 1.1A). Each 
muscle fibre is a multi-nucleated cell formed from the fusion of multiple myoblasts during 
development. A population of myoblast precursor cells or satellite cells remain into adulthood and 
can be found within the endomysium. Here they lie in a quiescent state until injury or anabolic 
stimuli cause them to activate and re-enter the cell cycle [8]. Satellite cells repair existing fibres or 
form new muscle fibres [9]. The muscle is provided with oxygen and nutrients by blood vessels within 
the perimysium, which also contains the nerves.  
Within muscle fibres are many chains of fibrous proteins known as myofibrils which contain a thin 
filament, actin, and a thick filament, myosin (Figure 1.1B). These filaments are arranged into units 
called sarcomeres. Stimulation of the neuromuscular junction causes the propagation of an action 
potential across the skeletal muscle fibres. Excitation-contraction coupling then causes myosin 
filaments to move along the actin filaments by repeated mechanical movements powered by ATP 
hydrolysis [10] [11] [12] [13]. The actin filaments are fixed to the end structures of the sarcomere, 
the Z discs. The movement of myosin along the actin filaments towards the Z discs pulls the Z discs 
closer together and subsequently shortens the overall length of the muscle. The simultaneous 
stimulation of many sarcomeres provides the contraction force of the muscle. 
 
1.1.2 Skeletal muscle fibre types 
 
Skeletal muscle fibres can be classified as type I or type II fibres. These have a different performance, 
and are characterised by different myosin isoforms [14] and metabolic capacity [15].  
Type I skeletal muscle fibres are responsible for postural support of the body and endurance exercise 
and are required to be highly resistant to fatigue. They have a very high density of mitochondria in 
order to maintain ATP production by oxidative phosphorylation and express a “slow” isoform of 
myosin which hydrolyses ATP at a slower rate, thereby decreasing both the speed of contraction and 
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the maximum amount of force that can be generated (Table 1.1). On the other hand, type II skeletal 
muscles fibres are used during periods of high activity such as resistance training and are less 
resistant to fatigue. They rely more heavily on generation of ATP by glycolysis. These fibres express a 
“fast” isoform of myosin which hydrolyses ATP quickly allowing for a greater speed of contraction 
and increased force generation (Table 1.1). 
 
Table 1.1- Characteristics of different skeletal muscle fibre types 
 
Skeletal muscles are made up of different proportions of fibre types dependent on the role of the 
muscle. In humans this ranges from more glycolytic muscles such as the vastus lateralis which has an 
average of 50% type I fibres to the predominantly oxidative soleus, which has an average of 80% type 
I fibres [16]. 
 
1.1.3 Skeletal muscle regeneration and repair 
 
Skeletal muscle fibres are inevitably damaged during exercise and injury, and old fibres need to be 
replaced throughout life. When a muscle fibre is damaged and becomes necrotic, phagocytic 
inflammatory cells remove the debris prior to regeneration. Regeneration is the task of a population 
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of progenitor cells, called satellite cells, which reside under the basal lamina of muscle fibres in a 
quiescent state [17]. Satellite cells possess the ability to respond to skeletal muscle damage by 
activating a program of expansion, proliferation, differentiation and finally fusion with existing fibres. 
After each period of muscle regeneration, a proportion of the expanded satellite cell population 
remains undifferentiated and replenishes the pool of quiescent satellite cells [18].   
There are a number of key regulators of satellite cell function. The activation of satellite cells involves 
the up-regulation of myogenic factors such as Myf5 and MyoD [19], followed by the up-regulation of 
myogenin during differentiation. Together these factors dynamically control the transition of satellite 
cells from re-entry into the cell cycle (MyoD) to terminal differentiation (myogenin). Mice lacking 
both Myf5 and MyoD are lacking myoblasts, myofibres and in fact expression of any muscle specific 
mRNAs, highlighting the requirement of these genes for the development of skeletal muscle [20]. 
Notch signalling is important in maintenance of satellite cell quiescence. When Notch signalling is 
disrupted satellite cells prematurely differentiate and undergo fusion [21]. The activation of satellite 
cells is mediated by nitric oxide production by nitric oxide synthase (NOS) in response to mechanical 
stimulation of muscle. NO stimulates the release of hepatocyte growth factor (HGF) by activating 
metalloproteinases (MMPs). HGF then binds to the receptor c-Met which induces activation of the 
satellite cell [22]. Other growth factors and inflammatory cytokines also play important roles in 
skeletal muscle regeneration such as IL-4, IL-6, LIF, TGF-β and TNF-α, IGFs and FGFs [23]. For 
example, IGF-1 activates Myf5 and the myogenic program [24] and FGF2 promotes proliferation of 
satellite cells which is controlled by sprouty1 (Spry1) in old age [25]. 
 
1.2 Skeletal muscle in elderly populations 
 
The skeletal muscles of elderly individuals begin to show differences to young muscles as early as the 
4th decade of life. These include a decrease in fibre cross sectional area, muscle strength and muscle 
quality (measured as muscle strength normalised for fat free mass) and an accumulation of 
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intramuscular lipids [26] [27] [28] [29] [30] [31] [32] [33]. The decline in skeletal muscle area 
accelerates during the later stages of life, with studies reporting an average reduction in muscle area 
of 40% between 20 and 80 year old healthy men [29] [34]. The loss of muscle area is mainly due to a 
decrease in muscle fibre number; however a decrease in type II fibre size has been observed relative 
to type I fibres in mixed fibre type muscles [29]. Studies utilising standard force measurements, DXA 
and CT scanning have shown that the rate of decline of muscle strength is not proportional to the 
loss of muscle mass, indicating that muscle quality (force per unit of muscle mass) is reduced [32] 
[33].  Another key aspect of muscle ageing is an age dependent decline in exercise capacity. This is 
coupled to a decline in VO2 max (the capacity of the body to deliver and utilise oxygen during 
exercise) of approximately 30% between 20-29 year olds and those over 70 [35]. These findings 
suggest additional alterations in elderly muscle other than a reduction in muscle mass that affect 
muscle function. This question has been intensely studied in recent years and benefitted greatly from 
modern analytical techniques.  
 
1.2.1 The balance between protein synthesis and proteolysis 
 
Skeletal muscle is a highly plastic tissue which responds to anabolic stimuli such as physical training 
by increasing metabolic capacity [36] and fibre area, regardless of fibre type [37]. Conversely, elderly 
populations tend to expend less energy and do less physical exercise and show a loss of fibre area. 
This has been linked to a decrease in the rate of protein synthesis in elderly individuals [35]. This 
includes synthesis of specific muscle proteins such as myofibrillar proteins [38] [39], myosin heavy 
chain (MHC) [40] and mitochondrial proteins [41]. This decrease is linked to a relative reduction in 
gene expression of myosin 2a and 2x/b isoforms [42]. However, it should be noted that more recent 
measures of protein synthesis have reported no difference in baseline protein synthesis in healthy 
physically active elderly individuals, suggesting that lifestyle is a determining factor [43] [44]. The 
research community appears to support the hypothesis that basal protein synthesis and breakdown 
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are not significantly different in elderly individuals without accompanying factors such as a sedentary 
lifestyle; however the limits of current technology and the large inter-subject variance make 
coordinate but small differences difficult to measure [45]. The ingestion of amino acids in amounts 
similar to a daily meal stimulates muscle protein synthesis. This has been shown to be attenuated in 
the elderly and is thought to be a significant contributor to the age-dependent decline in muscle 
mass [45] [44]. Relatively little attention has been paid to the impact of muscle protein breakdown to 
the overall decline in muscle mass in the elderly. It is a well-established concept that muscle atrophy 
occurs when basal protein breakdown overtakes protein synthesis, such as during limb 
immobilisation or periods of extended disuse [46]. Genes such as TGF-β [47] and myostatin [48] have 
been shown to regulate the ubiquitin ligases Murf1 and MAFbx (atrogin-1) which control 
ubiquitination mediated proteolysis and thus skeletal muscle atrophy, however there exact roles in 
ageing remain contradictory [49] [50] [51]. Myostatin has been shown to inhibit the IGF1 pathway 
[48]. IGF1 is one of the key factors inducing hypertrophy and thus preventing skeletal muscle 
atrophy. Induction of IGF1 expression in mouse skeletal muscle reversed the age related loss of fibres 
and reduction in muscle strength [52]. IGF1 has been shown to limit fibrosis, accelerate muscle 
regeneration and modulate the inflammatory response to muscle injury by decreasing the expression 
of tumour necrosis factor alpha (TNFα) and interleukin 1 beta (IL1β) [53]. Studies have shown that 
insulin availability decreases the rate of muscle protein breakdown [54] [54]; however the exact 
dynamics and mechanism of action of insulin on muscle protein turnover are still unclear [55]. 
 
1.2.2 Mitochondrial dysfunction 
 
Research aiming to understand the role of mitochondria in skeletal muscle ageing has grown 
substantially in recent years. In 1956 Harman proposed the “free-radical theory of ageing”, outlining 
the theory that oxygen free radicals cause cellular damage which accumulates during the lifetime of 
an organism [56]. This research was supported by work showing how anti-oxidant compounds extend 
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the average lifespan of multiple animal models including mice [57]. In 1972, Harman proposed that 
mitochondria were the main component of the free-radical theory of ageing, based on the 
observations that anti-oxidants that were not able to penetrate mitochondria failed to extend 
maximum lifespan [58]. Reactive oxygen species (ROS) are predominantly produced in the 
mitochondria as a by-product of oxidative phosphorylation and can damage proteins, RNA and DNA. 
Mice constitutively expressing the free radical scavenging enzyme catalase in mitochondria of muscle 
have been shown to have an increased average lifespan, produce less ROS, obtain less oxidative 
damage and accumulate less mitochondrial DNA abnormalities with ageing [59]. Mitochondria have 
been the focus of research investigating the various facets of ROS mediated signalling and damage in 
skeletal muscle during ageing, and pathologies effecting skeletal muscle functions such as COPD. ROS 
induced damage includes irreversible carbonylation of amino acid side chains of proteins and lipid 
peroxidation [60]. Protein carbonylation has been linked to decreases in creatine kinase activity in 
vastus lateralis of COPD patients, potentially impacting on skeletal muscle metabolic capacity [61].  
Mitochondrial function declines with age in human skeletal muscle [62]. This includes a decrease in 
the rate of mitochondrial protein synthesis occurring by middle age [41], decreased activity of 
mitochondrial enzymes such as cytochrome C and citrate synthase [41], an accumulation of mtDNA 
damage linked to a decrease in ATP production rate [63] and an overall decrease in oxidative capacity 
coupled with a decrease in mitochondrial content volume [64].  
It is thought that due to their proximity to the source of ROS release mitochondrial DNA and proteins 
accumulate oxidative damage at an accelerated rate. Mitochondrial proteins with oxidative damage 
are degraded by Lon protease, which is expressed at lower levels in elderly muscle of mice [65]. It has 
recently been shown that Lon protease regulates mitochondrial transcription through the 
degradation of the mitochondrial transcription factor A (TFAM) [66]. However, if oxidative damage 
becomes extreme, the damaged proteins have a destabilising effect on the mitochondrial membrane 
potential and cause fission of the damaged region which is then degraded by lysosomes [67]. Mouse 
models expressing the lysosome associated protein LAMP2A showed improved mitochondrial 
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function in old age compared to wild types due an increased rate of removing damaged proteins 
[68]. Mitochondrial DNA damage has been linked to sarcopenia. Wanagat et al revealed that within 
skeletal muscles of rats the fibres harbouring greater amounts of mtDNA damage were co-localised 
with electron transport chain abnormalities, increased ROS release and fibre atrophy [69].  
Several key proteins have emerged as regulators of mitochondrial function in skeletal muscle. Chief 
amongst them is the transcriptional factor PGC-1α (peroxisome proliferator-activated receptor 
gamma co-activator 1-alpha), which stimulates mitochondrial biogenesis by activating down-stream 
factors such as nuclear respiratory factor 1 (NRF1) and TFAM [70]. PGC-1α mRNA levels are 
decreased in muscles of elderly individuals [71]. Mice with constitutive PGC-1α expression in skeletal 
muscles show impressive improvements in whole body health including improved mitochondrial 
function, increased insulin sensitivity, decreased sarcopenia, decreased chronic inflammation and 
preserved neuromuscular junctions in old age [72]. Further studies have shown that PGC-1α drives 
the formation of slow-twitch muscle fibres in mice [73], controls the expression of the insulin 
sensitive glucose transporter GLUT4 by co-activation of MEF2C [74] and controls oxidative function in 
response to nutrient sensing by mTOR through a YY1-PGC-1α complex [75].  
Another important regulator of energy production is AMP-activated protein kinase (AMPK). 
Activation of AMPK increases fatty acid oxidation and activity of mitochondrial enzymes in skeletal 
muscle [76].  It regulates mitochondrial biogenesis by activation of NRF-1 [77] and is required for 
mitochondrial biogenesis in skeletal muscle in response to energy stress [78]. In muscles of rats and 
mice, the activity of AMPK is blunted in old age leading to a reduction in AMPK mediated 
mitochondrial biogenesis [79] and an accompanying decrease in PGC-1α expression [80].  
Protein acetylation is emerging as a key regulatory mechanism of both activity and abundance of 
metabolic enzymes including those in the mitochondria [81] [82] (Table 1.2). Exciting recent work has 
linked together activity of AMPK to NAD-dependent deacetylase sirtuin-1 (SIRT1) mediated protein 
deacetylation, including PGC-1α [83]. Canto et al describe a mechanism by which AMPK acts as an 
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energy sensor, which regulates NAD+ levels, this in turn modulates SIRT1 activity which activates 
PGC-1α in times of energy deprivation [83]. 
 
Table 1.2 – The effect of acetylation on metabolic enzymes 
This table is adapted from a review by Yue Xiong and shows the effect of acetylation on well-known 
metabolic enzymes and superoxide dismutase 2 (SOD2). For the full table see [84]. 
 
1.2.3 The role of insulin resistance 
 
The majority of dietary glucose is transported to peripheral tissues such as skeletal muscles. This is 
dependent on insulin which is released in response to increased concentrations of blood glucose and 
stimulates the transport of glucose into muscle cells through insulin responsive transporters such as 
GLUT4 [85]. Glucose can then be stored for later use as glycogen or utilised for ATP production. 
Indeed, insulin stimulation of vastus lateralis muscle in healthy humans causes an increase in ATP 
production capacity of up to 42% accompanied by an increase in mRNA levels of mitochondrial 
proteins and an increase in mitochondrial protein synthesis [86]. Skeletal muscle represents a major 
site of insulin resistance in obese, diabetic, and to a lesser extent elderly individuals [87]. Type 2 
diabetes is an increasing problem in elderly populations and is associated with increased prevalence 
of obesity. In elderly individuals the levels of plasma glucose and insulin response was higher 
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compared to young people after a glucose tolerance test, although the changes were modest [88].  In 
many elderly individuals the build-up of both intra and extra-cellular adipose deposits occurs in 
skeletal muscle. In obese individuals adiposity is a major contributor to insulin resistance and 
incidence of type 2 diabetes. Yu et al have shown that increased concentration of free fatty acids in 
the muscle leads to the activation of protein kinase C (PKC-θ). This in turn triggers a signalling 
cascade resulting in decreased insulin receptor 1 (IRS1) signalling and lower glucose transport [89]. 
Petersen et al revealed that insulin resistance in elderly muscle is related to increases in 
intramyocellular fatty acids, which may be due to decreased mitochondrial oxidative metabolic 
activity. They propose that this is consistent with an age-related decline in mitochondrial DNA quality 
and mitochondrial density [90]. 
 
1.3 Interventions to prevent skeletal muscle dysfunction 
 
1.3.1 Hormone Replacement Therapy 
 
A decrease in levels of testosterone is associated with old age [91]. In elderly men, treatment with 
relatively high doses of testosterone does increase muscle mass and strength [92]. However the risks 
of prolonged testosterone treatment are many and most likely overshadow the benefits. 
Another potential hormone replacement therapy which has become extremely common is growth 
hormone (GH) supplementation. GH levels drop with age [93], and supplementation does appear to 
improve muscle mass and exercise capacity marginally [94], however the incidence of side effects 




1.3.2 Physical exercise training 
 
There is an outstanding body of research supporting the role of physical exercise in improving 
skeletal muscle function and in fact, whole body function and health. Physical exercise has been 
shown to have a beneficial effect on patients with a wide range of conditions including type 2 
diabetes [96], COPD [97], pulmonary hypertension [98], asthma [99] and heart failure [100]. Many 
different avenues of research have been considered including type of exercise (resistance training or 
endurance training), exercise intensity, impact on ageing and age related diseases such as COPD and 
type 2 diabetes.  
The effects of physical exercise training can go some way towards reversing the age related decline in 
muscle function. Endurance exercise can increase overall muscle protein synthesis and mRNA levels 
of mitochondrial proteins [35] [36], induces PGC-1α expression [35] [101] [102] and increases 
metabolic enzyme activity and aerobic capacity in both young and elderly individuals [35]. It has been 
shown in mice that the population of satellite cells in elderly muscle is reduced, as well as their 
proliferative potential [103]. Endurance exercise in rats increased the myogenic capacity and number 
of satellite cells residing on myofibres compared to young rats [104]. Resistance exercise is routinely 
used as an intervention to combat sarcopenia. A sixteen week resistance exercise program is 
sufficient to significantly improve muscle strength, increase muscle cross sectional area and increase 
the proportion of type IIa fibres in both young and elderly men and women [105]. Resistance exercise 
increases muscle protein synthesis of MHC and mixed muscle protein [106]. However, it is important 
to note that the response to physical exercise training is highly heterogeneous between individuals, 
with increases in VO2 max ranging from 0-100% [107] and gains in muscle strength ranging from 3-
28% [108]. Analysis of molecular networks of skeletal muscle ageing and response to exercise have 
recently been generated from databases of existing knowledge, and suggest that age-related 




1.4 The regulation of angiogenesis  
 
Angiogenesis is the process by which the existing vasculature is extended by the growth of new blood 
vessels. In physiological conditions the activation of angiogenesis depends on a fall in oxygen tension 
(hypoxia) due to either an increase in oxygen demand by the surrounding tissue, or a decrease in the 
oxygen concentration in the blood. Hypoxia leads to stabilisation of the HIF-1α subunit of the hypoxia 
inducible factor (HIF-1) transcription factor which is degraded in normoxic conditions [109]. HIF-1 
then activates an extensive transcriptional program including key pro-angiogenic factors such as 
vascular endothelial growth factor (VEGF) [110], VEGF receptor-1 (Flt-1) [111], nitric oxide synthase 2 
(NOS2) [112] and others [113]. Many of the factors involved in angiogenesis are responsible for the 
recruitment and proliferation of endothelial cells which form the new blood vessels. 
Hypoxia, HIF-1, growth factor and cytokine signalling plays a key role in both physiological and 
pathological angiogenesis. In human skeletal muscle PGC-1α and VEGF [114] are up-regulated in 
response to exercise. Up-regulation of PGC-1α leads to increased oxygen consumption in the muscle 
due to a shift towards oxidative metabolism and a subsequent stabilisation of HIF-1α and activation 
of pro-angiogenic HIF-1 transcriptional targets [115].  
Angiogenesis is perhaps most well studied in the context of tumour progression. As tumours develop 
and grow larger they have a greater oxygen demand. Without an adequate supply of oxygen and 
metabolites a tumour cannot grow larger than a few mm’s in diameter [116]. One of the most 
aggressive human tumours, glioblastoma, up-regulates VEGF in response to hypoxia [117] [118]. 
VEGF signalling through the receptor KDR activates pathways controlling endothelial cell migration, 
proliferation and survival. However, many other growth factors and cytokines such as IL8, IL1, FGF2, 
GCSF, IGF1, ANGPT2, CXCR4 and CXCL12 also play a role in tumour angiogenesis [119]. Counteracting 
the pro-angiogenic factors are a number of anti-angiogenesis factors such thrombospondin 1 
(THBS1), endostatin, canstatin, tumstatin, interferon-α and interferon-β [120]. The onset of 
angiogenesis relies on the balance between pro and anti-angiogenesis factors, termed the 
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“angiogenic switch”. When the activity of pro-angiogenic factors outweighs the anti-angiogenesis 
factors the angiogenic program is initiated and tumour growth occurs [120]. 
 
1.5 The application of systems biology approaches to human health 
 
The advent of functional genomics has made it possible to measure gene, protein and metabolite 
concentration in single experiments at a genome wide scale. The goal of researchers employing 
systems biology approaches is to develop and utilise analysis pipelines able to effectively generate 
novel hypothesis from this data. These hypotheses should be both relevant and testable given our 
current knowledge of the physiology of the experimental system.  
The first commercially available systems for measuring genome wide gene expression using 
microarray technology appeared over a decade ago. Using precise probe spotting or 
photolithographic synthesis, oligonucleotides complimentary to all known mRNAs in an organism can 
be printed to microarray slides. These oligos will hybridise to complimentary mRNAs from cells or 
tissues. Precise measurement of relative gene expression is achieved by incorporation of a 
fluorescent dye into the mRNA sample prior to hybridisation. After washing off unbound mRNAs, a 
high-resolution laser scanning device captures the fluorescence signal from labelled mRNA bound to 
each microarray probe. The signal intensity is proportional to the amount of bound mRNA, which is 
dependent on the abundance of transcript within the cells. Modern microarrays allow the 
transcriptional profiling of over 30,000 unique genes in 8 samples simultaneously.  
The use of protein mass spectrometry (MS) allows the measurement of thousands of proteins in a 
single experiment. Multiple platforms are widely used, with the more common methods such as 
Matrix-assisted laser desorption/ionization – time of flight (MALDI-TOF) able to generate peptide 
mass fingerprints at a rapid rate. In a MALDI-TOF analysis, proteins are first digested to create 
proteolytic fragments (peptides), which are then analysed by MS. The mass fingerprint of the 
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peptides can then be matched to known proteins by comparison to a database of mass fingerprints 
generated by virtual digestion of each protein in the sequence database. Any unmatched peptides 
can be sequenced using a further round of MS if necessary, followed by protein identification by 
sequence homology. 
At the final step of the “omics” cascade is metabolomics, or the systems level analysis of metabolite 
concentrations in biological samples. Similar to MS proteomics, the aim of MS metabolomics is to 
generate metabolite fingerprints (whole metabolome, hypothesis generating) or metabolite profiles 
(targeted pathways, hypothesis driven). Unlike proteins and nucleotides which have well defined 
sequence databases, metabolite identification relies on mass spectra alone. Some large libraries of 
spectra are currently available, however metabolite identification remains as a bottleneck in 
metabolomics analysis [121]. 
The analysis of transcriptional data generated using whole genome microarray profiling is amongst 
the better developed areas of omics data analysis. This thesis utilises multiple large-scale 
transcriptomics datasets to study muscle ageing and a dynamical model of angiogenesis. In this 
section an overview of microarray data generation and analysis will be described. Many of these 
approaches are applicable to large datasets generated using different functional genomics 
approaches, however as we have focussed on gene expression the methodology is described in that 
context. The recent advances in our understanding of skeletal muscle biology and angiogenesis that 
have originated from studies utilising systems biology approaches will be outlined in the following 
section. 
 
1.5.1 From raw data to processed expression data  
 
Raw microarray data covering the entire genome consists of fluorescence intensity values 
representative of the relative concentration of mRNAs from the starting tissue or cell culture. Firstly, 
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the range of intensity values, which exist on a multiplicative scale, is normally log2 transformed in 
order to represent the highly asymmetric signal distribution as a symmetrical normal distribution. In 
practice, this allows the representation of gene repression and induction on a comparable scale. This 
data is subject to experimental, biological and technical variation, which must be corrected before 
the data can be analysed. Therefore, the first step in microarray data analysis consists of a 
normalisation procedure aimed to remove the experimental and technical variance and ensure the 
data is comparable across multiple arrays. 
There are a number of popular methods used for microarray data normalisation depending on the 
microarray technology. So called “one colour” microarrays are hybridised to a single mRNA sample 
labelled with a fluorescent dye, typically Cy3. “Two colour” microarray analysis involves competitive 
hybridisation of two mRNA samples, normally a control and a treatment, labelled with different dyes, 
typically Cy3 and Cy5. The fluorescent signal of each dye for each gene can be converted into a ratio, 
allowing the comparison of two samples with a single microarray. Both approaches have strengths 
and weaknesses. One colour hybridisations generate relative abundances for each gene and data 
that is comparable between multiple experimental conditions. Two colour hybridisations reduce the 
experimental cost at the risk of low data precision in the case of a low quality sample. One-colour 
Affymetrix microarrays are designed with 11-20 probes that match different locations across gene 
transcripts. Methods such as RMA [122], MAS5 [123]and GC-RMA [124] that have been developed to 
take advantage of this feature allow the unsupervised normalisation and probe set averaging of 
Affymetrix data. While these normalisation methods are conceptually very similar, GC-RMA has been 
found to introduce artificial correlations into transcriptional data while MAS5 introduced the least 
[125]. Therefore use of GC-RMA could have a detrimental impact on many statistical procedures. 
Data produced using other microarray platforms such as Agilent is most commonly normalised using 
quantile normalisation [126]. This method assumes that the distribution of signal intensities is almost 
equal in all samples. For each value on the microarray, the quantile is calculated and matched to the 
corresponding quantile of the reference distribution of probe intensities across all arrays. The 
original value is then transformed to the corresponding value from the reference distribution. This 
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brings the distribution of all the microarrays in line with each other. Two-colour microarray data can 
be normalised using the popular LOESS algorithm, which effectively generates expression ratios 
between control and treatment samples while removing technical variation [127]. 
 
1.5.2 Detecting gene expression patterns 
 
Gene expression is a dynamic process in which stimuli such as hypoxia or exercise induce a transient 
production and repression of a set of mRNAs. Patterns of expression over time and across multiple 
stimuli can be captured using data analysis techniques. Several techniques can be used for this  
 
Figure 1.2 – Example of Principle Component Analysis and hierarchical clustering 
Panel A shows the separation of two groups of samples based on the projection of the first two 
principle components (PCs) onto a 2D plot. Principle components are uncorrelated variables derived 
from the original data which are representative of variation within the data. The first principle 
component (PC1) represents the largest amount of variance, and each successive component 
represents variance that is uncorrelated to all those preceding it. In the example in panel A, the first 
principle component separates both sample groups, suggesting that disease status is responsible for 
the largest source of variation. Panel B shows an example of hierarchical clustering applied to gene 
expression. A similarity metric is calculated between all samples, such as correlation or Euclidian 
distance, and this is used to organise the samples in a dendrogram such that highly correlated 




purpose, they allow data exploration to identify gene or sample clusters on the basis of their 
molecular state. Principal Component Analysis (PCA) is one such technique that reduces the 
dimensionality of large datasets while retaining the majority of the information. Very often, PCA is 
used as a data visualization technique in the form of 2D or 3D plots [128] (Figure 1.2A).   
Cluster analysis is a different technique that can achieve similar results. It aims at identifying groups 
of genes or samples with similar expression profiles. By using a measure of cluster homogeneity 
some of these procedures (e.g. HOPACH [129]) are able to objectively distinguish the number of true 
clusters in the data. In the case of cluster analysis the relationship between samples and/or genes is 
often visualised using a dendrogram (Figure 1.2B). 
 
1.5.3 Defining transcriptional signatures of perturbations 
 
Large-scale transcriptomics experiments can be complex and cover multiple time points and 
treatments or they can be as simple as a single treatment. In either case identification of the genes 
differentially expressed between the sample groups is a key step.  
Several statistical techniques and software packages have been developed for this purpose. The 
choice of methodology depends on the experimental design. A t-test, analysis of variance (ANOVA) or 
Significance Analysis for Microarrays (SAM) [130] can be used to identify genes, proteins or 
metabolites that are differentially expressed between two groups of paired or unpaired samples. On 
the other hand, Analysis of variance (ANOVA) and SAM can be applied to compare multiple groups of 
samples. Two-way ANOVA can be applied to designs integrating multiple experimental factors within 
groups. SAM and Bayesian Estimation of Temporal Regulation (BETR) [131] can identify differentially 
expressed genes in time-course experiments. SAM allows the user to control the false discovery rate 
(FDR), however when using a t-test or ANOVA it is important to control for multiple comparisons. 
This can be done using a method to estimate the FDR such as that proposed by Benjamini and 
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Hochberg [132]. An FDR threshold of less than 10% is commonly used to define the upper limits of 
statistical significance. 
Modern whole genome microarrays routinely provide expression measurements for 20,000-30,000 
unique genes. Thousands of these genes may be differentially expressed, making interpretation of 
the results a serious challenge. One way to reduce the complexity of the analysis is to define groups 
of genes that perform similar biological functions such as a class of enzymes, membrane bound 
proteins, transcription factors and many others. The Gene Ontology database [133] contains many 
thousands of these gene sets. Using software tools such as DAVID [134] it is possible to statistically 
determine whether a particular gene set is overrepresented in a list of differentially expressed genes, 
taking into account the overall abundance of that gene set in the genome. Alternatively, GSEA [135] 
detects enrichment of functional groups within lists of genes ranked by a metric such as the t-statistic 
or logged fold change and allows the specification of many custom gene sets which can be tested 
simultaneously. For this reason GSEA can be used to identify coordinate changes in expression of 
functional groups in data that may only present a few differentially expressed genes. 
The Gene Ontology database contains both well-defined and predicted functional annotation of 
genes. Other database tools such as KEGG and Ingenuity Pathway Systems (IPA) contain only curated 
information. KEGG is a set of experimentally validated pathways across many organisms which can 
be queried through DAVID. IPA is a powerful tool containing relationships described in the literature 
between genes, proteins, metabolites and drugs. The suite of analysis tools offered by IPA includes 
prediction of up-stream effector molecules of a particular set of genes and identification of 
interaction networks enriched with genes of interest. 
Using these tools it is possible to build up a “functional profile” of a given treatment which can be 




1.5.4 Constructing biological networks 
 
A difficult challenge in the analysis of gene expression data is to formulate hypotheses from the 
analysis of very large datasets. Unfortunately this is a difficult task and the relatively simple data 
exploration techniques I have outlined above are not sufficient to achieve this task. 
Network inference methodologies are able to capture statistical dependencies between variables 
and “learn” the structure of underlying biological networks from observational data. The decision of 
which method to use is dependent on the biological question and the design of the experiments. 
Networks can be generated containing many thousands of nodes by using a pairwise score of 
dependency such as correlation or mutual information. The nodes are connected by connections, 
called arcs or edges, which represent the statistical dependency between the two genes, proteins or 
other entities. In this context, one of the most popular tools for inferring large networks, ARACNE 
[136], infers large networks based on mutual information (MI). Mutual information provide a 
measure of how much variation in one variable (for example, a gene) is explainable by the variation 
in a second variable. Therefore it is able to detect non-linear relationships such as those present in 
biological systems. ARACNE allows simple thresholding of the network through the input of a desired 
p-value or MI threshold [137]. Unlike other network inference frameworks such as Bayesian 
networks which are suitable for small networks usually consisting of less than 100 nodes, ARACNE 
has been designed specifically to utilise microarray expression profiles to reconstruct networks with 
sufficient levels of complexity to represent eukaryotic systems. ARACNE also makes use of the data 
processing inequality (DPI), which provides a framework to remove indirect relationships within 
networks. This is an important step when reconstructing precise networks such as the first 
neighbours of transcription factors, which are very likely to produce a large number of indirect 
downstream effects. 
Large mutual information based networks need to be represented in an organised manner in order 
to be interpreted. Adjusting the position of each node in the network in accordance with its 
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connectivity to surrounding nodes is an effective way of visualising large networks so that highly 
interconnected clusters of nodes become spatially distinct. Objective network community detection 
algorithms such as those available within the GLay [138] or MCODE [139] packages can be applied 
which will identify distinct sub-networks.  MCODE is suitable for identifying small intra-connected 
clusters with very high modularity scores within large networks; however this can be hard to 
interpret in a biological setting due to the large number of clusters and the number of unclustered 
genes. GLay has a higher sensitivity than MCODE with a slightly lower specificity, leading to a smaller 
number of larger clusters at the cost of a slightly reduced modularity score. The fast-greedy 
algorithm within GLay (implemented by Wakita et al [140]) improves the community detection by 
controlling the merging of smaller clusters using a cluster size and density parameter, leading to a 
more balanced distribution of cluster sizes. In practice, analysis pipelines designed to functionally 
annotate large networks such as those presented in this thesis are facilitated by the use of GLay. 
Both of these approaches are available in the open-source Cytoscape  software [141]. 
Mutual information and correlation based networks do not infer the directionality of network 
connections. By using ordinary differential equation (ODE)-based network inference techniques the 
directionality of network connections can be identified [142] [143]. Due to the computational power 
needed to infer ODE networks it is limited to a small number of nodes, generally 50 or less. ODE 
networks can be useful when applied to a smaller, targeted set of genes such as transcription factors 
that are regulated in response to a perturbation. 
 
1.6 Application of systems biology to skeletal muscle function and 
angiogenesis 
 




The application of transcriptional profiling and systems biology techniques has revealed alterations in 
gene expression underlying many issues affecting human health. In this section the approaches and 
findings of several key studies focusing on skeletal muscle function and angiogenesis will be 
described. 
Welle et al identified a comprehensive set of over 1000 probes differentially expressed between 
muscle of young and elderly people including over 100 genes involved in energy metabolism which 
were down-regulated in elderly muscle [144]. The transcriptional profiling of young and elderly 
muscle performed by Melov et al. [145] and Zahn et al. [146] was consistent with a decrease in 
expression of energy metabolism genes with age. The Melov study also identified up-regulation of 
genes related to DNA repair and cell death in elderly muscle. In contrast, a recent study by Phillips et 
al. compared the transcriptional signature of 3 independent studies [145] [147] [108] of ageing 
muscle and concluded that no common signature of ageing could be detected. By using a relatively 
large clinical dataset (n=52) they identified 580 genes correlated significantly with age which were 
enriched with genes related to muscle disorders but not mitochondrial metabolism. Phillips et al 
suggest that the inconsistency between the transcriptional signatures is due to the substantial 
differences in physical fitness between the study groups and that mitochondrial dysfunction is 
unlikely to be attributed to ageing per se. 
Giresi et al. generated a predictive model of sarcopenia in vastus lateralis muscle using a supervised 
classification technique that identified 45 genes which achieved 75% classification accuracy when 
distinguishing young and elderly muscle in an independent dataset [148]. Amongst the gene 
signature was Forkhead Box O3 (FOXO3A) and CCAAT/Enhancer Binding Protein Beta (CEBPβ), which 
were recently shown to play a key role in AMPK mediated control of muscle autophagy in mice [149] 
and up-regulation of the ubiquitin ligase MAFbx respectively [150]. Abadi et al identified a 
transcriptional signature of muscle disuse and atrophy including down-regulation of mitochondrial 
metabolism genes and up-regulation of protein degradation related genes (including Murf1 and 
MAFbx) in response to muscle immobilisation [151]. This was linked to decreased protein content of 
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cytochrome C oxidase, decreased mTOR phosphorylation and increased protein ubiquitination. Reich 
et al. found similar transcriptional changes in response to muscle immobilisation (increased 
expression of protein ubiquitination genes, decreased expression of mitochondrial metabolism 
genes) as well as identifying an increase in genes related to oxidative stress [152]. Furthermore, 
reloading of the muscle did not fully reverse these expression changes. 
Several studies have used transcriptional profiling to investigate the effects of physical training on 
gene expression. Radom-Aizik et al. reported up-regulation of genes related to mitochondrial 
metabolism and down-regulation of genes linked to protein catabolism in response to 3 months of 
training [153]. Melov et al. showed that the transcriptional profiles of a subset of genes in skeletal 
muscle of elderly individuals after 6 months of training resembled that of younger individuals [145]. 
Molecular networks underlying normal healthy skeletal muscle function regardless of age or gender 
have previously been defined by combining a meta-analysis approach with canonical pathway 
databases (KEGG) and existing literature [154]. The authors make use of existing microarray data 
from over 250 healthy muscle biopsies as well as a range of other tissues (fat, liver, kidney, brain, skin 
and hair) to identify mRNAs under or over-expressed in skeletal muscle. This information was 
combined with existing pathway information to create networks. These networks, which represent 
excitation, mechanical transmission, energy metabolism and signalling cascades, are a 




The process of angiogenesis involves the coordination of endothelial cell proliferation, migration and 
extracellular matrix remodelling. Abdollahi et al. analysed the transcriptional profiles of 
microvasculature endothelial cells treated with pro and anti-angiogenesis factors (VEGF, FGF2, 
endostatin) and identified 600 unique genes that responded inversely to pro and anti-angiogenic 
factors [155]. By using data mining of the current literature and online databases they identified 
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interactions between these genes and constructed an “angiogenesis network”. One of the pro-
angiogenic hubs, PPAR-δ, was confirmed to be an important regulator of tumour vascularisation that 
correlated with tumour progression in clinical samples. Anders et al. performed a meta-analysis of 15 
cancer microarray studies (979 samples) aiming to identify a signature of angiogenesis related genes 
common to human cancers [156]. They identified 25 genes able to classify cancer and healthy tissues 
with a high accuracy. These genes were related to angiogenesis such as CXCL12, TGFBR3, CCL2, 
PDGFRA and SPARC-1. However, genes previously reported as pro-angiogenic such as VEGF, IL8 and 
MMP2 were not identified as part of the signature, suggesting that additional post-transcriptional 
regulation and the contribution of the tumour microenvironment could be important factors in the 
role of these genes. This finding was consistent with a second study by Liang-Hui et al. which used 
machine-learning techniques to construct a network of protein-protein interactions in the 
neighbourhood of a set of 84 well known angiogenesis related factors [157]. None of the VEGF 
proteins or receptors were hub genes in the network, however all of them were present. This lends 
weight to the argument that angiogenesis is controlled by the interactions of a large network of 
factors. 
In conclusion, systems biology approaches have revealed novel insights that are key to our 
understanding of skeletal muscle ageing, exercise and angiogenesis. As the availability of functional 
genomics data increases, there is a need to understand the underlying structure of relationships 
between genes, proteins and metabolites in order to interpret and integrate data from multiple 
domains. The use of network inference methods can provide the underlying networks at a genome 
wide scale if sufficient observational data is available. The use of network inference methods has so 
far not been applied to skeletal muscle ageing and angiogenesis despite representing attractive 
targets for study, due to the availability of functional genomics data and significant impacts on 
human health. This thesis has developed network models of muscle ageing and angiogenesis in order 
to delineate the transcriptional reprogramming that characterises these processes. A number of 




INFERENCE AND ANALYSIS OF TRANSCRIPTIONAL NETWORKS 




Sarcopenia, described as age related skeletal muscle dysfunction and atrophy, is a condition intrinsic 
to human health and has a substantial impact on conditions such as cancer cachexia [158], COPD 
[159] and other movement impairing disabilities [160] [161]. Muscle weakness can significantly 
impact on quality of life and life expectancy [162] [163] [164]. Management of sarcopenia is 
therefore an important factor in disease management. Interventions to combat the loss of muscle 
function in various clinical populations have been reported including hormone supplementation, 
pharmacological treatment and exercise training [165] [166]. Physical exercise is recognised as one of 
the best options for improving skeletal muscle function, regardless of age. It has been shown to 
improve inflammatory status [167], strength [105], and metabolic capacity [36]. 
Some of the molecular events underlying skeletal muscle ageing, such as an increase in nitric oxide 
synthase expression [168], a disruption in the hypoxia response pathways (e.g. loss of PGC-1α target 
activation) [169], and a decrease in protein synthesis following anabolic stimuli [44] have been 
intensively studied for their potential involvement in muscle wasting in humans and animal models. 
Recently, the role of mitochondrial dysfunction in ageing muscle has been highlighted. Mitochondrial 
respiratory efficiency is an important determinant of activities of daily living in elderly people such as 
walking speed [170]. There is a decline in respiratory chain function and accumulation of mtDNA 
mutations with age in skeletal muscle [63], accompanied by a decrease in expression of proteins and 
mRNAs related to mitochondrial function [145]. An accumulation of mitochondrial DNA mutations 
has been shown to induce mitochondrial dysfunction and increase apoptosis and sarcopenia [171].  
The generation of reactive oxygen species (ROS) within mitochondria has been found to induce 
mitochondrial dysfunction, leading to age dependent muscle atrophy [172] and insulin resistance 
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[173]. A recent study in which the antioxidant enzyme catalase was stably expressed in mitochondria 
of elderly mice resulted in decreased mitochondrial dysfunction, suggesting that mitochondrial ROS 
scavenging can prevent age-related mitochondrial dysfunction [80].  
However, despite intense efforts it is not yet clear what molecular mechanisms control muscle 
wasting and in particular mitochondrial dysfunction. A number of groups have applied omics-based 
approaches to characterise the molecular state of muscles in COPD [174], diabetes [175] and ageing 
[145]. With a few isolated exceptions, such as the role of PGC-1α in diabetes [176] and the 
contribution of histone deacetylases (HDACs) to muscle wasting in COPD [174], this approach has 
failed to provide a framework for developing robust hypotheses on the mechanisms underlying 
muscle dysfunction.  The main reason for this is the difficulty in integrating genome-wide descriptive 
data into an interpretative model that allows the identification of the driving factors of the 
degeneration process. 
Here we address this issue by using a network biology approach designed to infer age specific gene 
regulatory networks from expression-profiling data derived from multiple independent studies. Our 
analysis revealed that networks representing young and elderly muscles are characterised by several 
distinct functional modules. Further analysis revealed a link between the expression of ribosomal 
proteins and age-dependent, transcriptional uncoupling of genes encoding for oxidative 
phosphorylation enzymes. This specific finding allowed us to formulate the hypothesis that the 
uncoupling of translation and energy related gene expression might be at the heart of mitochondrial 




2.2.1 Selection of public domain microarray datasets  
 
Publically available microarray studies used in this work were either downloaded from the online 
microarray database Gene Expression Omnibus (GEO) (www.ncbi.nlm.nih.gov/geo) as raw data or 
obtained directly from the author.  
To select potential microarray datasets to integrate as part of the skeletal muscle meta-analysis we 
searched GEO using the terms “skeletal muscle” and filtered the results to include only human data.  
We further refined the selection by outlining a set of specific biological and technological criteria 
(Table 2.1). These are:  
 Biopsy from vastus lateralis muscle using a standard needle technique 
 Use of the Affymetrix microarray platform  
By using these strict criteria we can improve the likelihood that the data integration method will 
correctly preserve the true transcriptional state of each muscle biopsy by decreasing the number of 
confounding factors that need to be considered. From these datasets we selected only those that 
used the Affymetrix U133A or U133 Plus 2 platform in order to maximise the number of shared 
probes between all studies in the meta-analysis, resulting in a 22,215 probes representing 13,116 
unique genes. Some of the samples within these studies originate from volunteers who are 
undergoing interventions such as training or treatment for significant pathologies, as we are 
interested in the baseline transcriptional state of healthy muscle in young and elderly people these 
samples were removed. We defined young (N = 55, 18-30 years) and elderly (N = 78, 60-80 years) age 









GEO Title Author Year Platform Sex Integrated 
[148] GSE1428 Skeletal muscle sarcopenia Giresi PG, 
et al 
2004 U133A Male Yes 
[151] GSE14901 Limb immobilization induces a 
coordinate down-regulation 
of mitochondrial and other 
metabolic pathways in men 
and women 
Abadi A, et 
al 
2009 Plus 2.0 Mixed Yes 
[153] GSE1786 Vastus lateralis biopsies from 
healthy trained and sedentary 
males 
Radom-
Aizik S, et 
al 
2004 U133A Male Yes 
[177] GSE19420 Skeletal muscle mitochondrial 





FH, et al 
2009 Plus 2.0 Mixed Yes 
[152] GSE21496 Effects of 48h Lower Limb 




2010 Plus 2.0 Male Yes 
[178] GSE9419 The skeletal muscle transcript 
profile reflects responses to 
inadequate protein intake in 





2007 Plus 2.0 Male Yes 
[179] GSE9676 Effects of sex and age on 
skeletal muscle gene 
expression in normal men and 
women 
Welle S, et 
al 
2007 U133A Mixed Yes 
[174] Un-
released 
Effects of training on COPD 
patients with varying BMI 
Turan N, et 
al 
2009 Plus 2.0 Mixed Yes 
[180] GSE1832 Time and Exercise effects on 
Human Skeletal Muscle 
Zambon 
AC, et al 
2003 U95A Male No 
[181] GSE18583 Baseline skeletal muscle gene 
expression 
Keller P, et 
al 
2009 Plus 2.0 Male No 
[182] GSE18732 mRNA expression data from 
skeletal muscle of type 2 
diabetes 
Gallagher 
IJ, et al 
2010 Plus2.0 Mixed No 
[183] GSE9105 Effect of Acute Physiologic 
Hyperinsulinemia on Gene 
Expression in Human Skeletal 
Muscle in vivo 
Coletta DK, 
et al 
2008 U133A Mixed No 
[184] GSE22309 Expression data from human 
skeletal muscle 
Wu X, et al 2007 U95A Mixed No 
[185] GSE7146 Effect of insulin infusion on 











2009 Plus 2.0 Mixed No 
Table 2.1 – Microarray datasets identified in the GEO search 
Microarray studies within the NCBI Gene Expression Omnibus (GEO) database matching the initial 
search criteria. Studies that were integrated into the meta-analysis contained young and/or elderly 






Figure 2.1 – The distribution of samples according to age for each study identified in the GEO 
search (from Table 2.1).  
The age groups used in the meta-analysis correspond to the area either side of the grey section. 
Studies containing samples within both the acceptable age range and the grey section were removed 
unless they provided the age of each sample, in which case only the unsuitable samples were 
removed. Numeric labels indicate reference numbers. 
Table 2. 1 
We used an independent dataset produced by Melov et al (GEO accession GSE8479) to identify genes 
differentially expressed in young and elderly human skeletal muscle and between elderly untrained 
and trained muscle. The training regime and generation of the transcriptomics data is described in 
ref [145]. Briefly, they selected healthy elderly (N = 25) and young (N = 26) men and women and 
obtained a resting muscle biopsy from the vastus lateralis. 14 elderly volunteers underwent 26 weeks 
of resistance exercise training and a muscle biopsy was obtained after completion of the program 
with a 48hr recovery period following the final session. Transcriptional profiles were generated using 
Illumina Human Ref-8 microarrays. 
We used a dataset produced by Edwards et al (GEO accession GSE6323) [187] to identify genes 
differentially expressed in skeletal muscle of young (5 month) and elderly mice (25 month) 
C57BL/6NHsd mice. Gastrocnemius muscle was extracted from each mouse and snap frozen before 




2.2.2 Affymetrix microarray processing 
 
Affymetrix microarray datasets were individually summarised and normalised using either the MAS5 
or RMA algorithm. MAS5 has been applied to studies integrated into the meta-analysis. MAS5 has 
been shown to perform well when assessing normalisation methods for their effects on downstream 
network inference applications [125]. For other microarray studies used in this analysis such as the 
comparison between young and elderly mice, the data was summarised and normalised using the 
popular RMA algorithm with quantile normalisation. 
2.2.3 Illumina microarray processing 
 
The study of Melov et al is hybridised to Illumina Human Ref-8 microarrays. The Illumina microarray 
methodology includes the generation of confidence values (p value) comparing the signal of each 
probe to the background signal. All probes with a non-significant detection p value (p > 0.05) across 
more than 50% of samples were removed. The data was then quantile normalised resulting in a final 
dataset of 11,339 genes. 
2.2.4 Integration of microarray data from multiple studies 
 
We have integrated samples from studies hybridised to Affymetrix microarrays. The data integration 
strategy is outlined in Figure 2.2. There are a number of standard approaches for processing 
Affymetrix data, such as MAS5 normalisation. However these do not account for batch-to-batch 
variation between microarrays. Microarray signal intensity is sensitive to factors such as 
environmental conditions, reagents and small differences in procedures by research staff. These can 
cause small but coordinate differences between studies, even if the underlying biological finding is 





Figure 2.2 – The data integration strategy using ComBat.  
This figure shows the tests using SAM and PCA that were applied to both the pre-processed and 
integrated data to identify the effects of confounding factors such as microarray platform, sex and 
experimental variation on the integration process. 
 
ComBat was run using the recommended settings with age defined as a covariate, in order to 
preserve the variation due to age. We used PCA and SAM before and after the batch correction 
process to assess the variation between the samples, and thus the effectiveness of the integration. 
PCA analysis was performed using the prcomp command in the R software package. Using PCA we 
can gain a visual measure of the batch effects between the samples in terms of their laboratory of 
origin, microarray platform and age group. We found that prior to the batch correction the PCA 
revealed systematic batch effects within the data relating to dataset and microarray platform, and 
that these effects were not present after integration using ComBat (section 2.3.1 - Figure 2.4).  
2.2.5 Detecting and comparing differentially expressed genes 
 
Differentially expressed genes were detected using the Significance Analysis of Microarrays (SAM) 
[130] method. Unless stated, a significance threshold of 1% FDR was applied. Where sets of 
differentially expressed genes were tested for their level of overlap a resampling procedure was used 
to generate a statistical likelihood (p-value) of obtaining that level of overlap by chance. This was 
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done by generating a large null distribution, taking as a background the full potential overlap 
between the two experimental platforms in terms of gene names or probe IDs. Human and mouse 
homologs were identified using the Mouse Genome Informatics database 
(www.informatics.jax.org/). Functional annotation of gene lists was performed using the online gene 
ontology analysis tool DAVID [134] and applying a 10% FDR threshold. 
2.2.6 Constructing and visualising transcriptional networks 
 
In order to infer gene-to-gene connections in young and elderly muscles we used the well-validated 
network inference methodology ARACNE [137]. An ARACNE mutual information (MI) matrix has been 
generated for both young and elderly age groups, independently. In order to ensure that the 
inference of gene connections was not affected by sample size, we have used a resampling 
procedure to direct the choice of a statistical threshold at which the number of significant 
connections in both young and elderly individuals is independent from any differences in the number 
of samples (Figure 2.3). Two sparse networks representing the two age groups were then generated 
using a mutual information cut off of 0.25, which corresponds to a p value < 10-9 for both age groups 
(Table 2.2). This corresponds to an average of less than 1 false positive connection within the 
network. Networks were visualised using a force driven layout as implemented in the network 
visualization software Cytoscape [141]. 
2.2.7 Identification of network modules 
 
Modules of highly connected genes within the network were identified using the network community 
detection algorithm GLay [138] using the recommended settings. The GLay algorithm is implemented 
in the Cytoscape plugin ClusterMaker [189]. Enrichment of gene sets corresponding to GLay modules 
and other custom gene lists within transcriptional signatures such as ageing was tested using the 
Gene Set Enrichment Analysis (GSEA) tool [135]. Transcriptional signatures were ranked according to 
the fold change or t-statistic, and a q-value (FDR) was calculated by GSEA for enrichment of gene sets 
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within the top or bottom of the ranked list. A q-value (FDR) of 10% or lower (unless stated) was used 
to define statistically significant enrichment.  
 
 
Figure 2.3 – The application of a resampling procedure to empirically define an MI threshold 
This figure shows the mutual information threshold at which the average number of edges in the 
elderly network is comparable to the number of edges in networks generated from resampled 
elderly data. The number of samples chosen during resampling was identical to the number of young 





Table 2.2 – The properties of sparse networks generated from the young and elderly data at a 








2.3.1 Integration of expression profiling datasets representing human healthy 
skeletal muscles 
 
In order to develop a sufficiently large dataset to allow network inference, we first searched the 
public domain database gene expression omnibus (GEO) for expression profiling datasets 
representing skeletal muscle biopsy samples. We focused on vastus lateralis as this muscle was the 
most represented in the database. 
We could identify 8 datasets (Table 2.1) covering a broad age range (18-80 years old) and 
representing over 300 biopsies (see Figure 2.1 for a schematic overview of the relationship between 
samples, age and study).  Two subsets of samples were then defined to represent young (55 samples 
representing the 18-30 age range) and elderly (78 samples representing the 60-80 age range) healthy 
individuals. Datasets were then integrated using the Bayesian data normalisation method ComBat, a 
procedure designed to minimise batch effects while retaining variation associated to a given 
biological signal (age).  
ComBat successfully removed differences related to non-biological factors while maximising age 
related gene expression signatures. We found that prior to correction 45%, 52.6% and 99.99% of 
probes within the dataset were detected as significantly different between age, microarray platform 
and clinical study respectively. This was reduced to 26.5%, 0% and 1.4% respectively after processing 
the data with ComBat (Table 2.3). The small number of genes that were significant between studies 
had 100% overlap with genes differentially expressed between age groups. These results were 
consistent with visualisation of the samples using PCA (Figure 2.4), proving that from a statistical 
perspective, the integration procedure removed 99% of non-biological effects while maintaining 








Figure 2.4 – Principle component analysis reveals systemic batch effects related to both microarray 
platform and dataset 
PCA was applied to the young and elderly data combined.  Panel A - PCA before ComBat correction 





Further evidence of the effectiveness of our data integration strategy came from the analysis of the 
expression of genes located on the X and Y-chromosomes. We reasoned that if the data integration 
procedure truly removed non-biological variation without creating artefacts we should be able to 
identify gender specific gene expression by comparing male and female biopsies. A previous study by 
Welle et al has identified differentially expressed genes between male and female skeletal muscle 
[179]. Unsurprisingly, these included genes located on the X and Y chromosome. We used GSEA to 
test whether the transcriptional differences between skeletal muscle from male and females in the 
meta-analysis dataset was similar to a that published by Welle et al. We downloaded the 
differentially expressed genes identified by the Welle study. In the meta-analysis, the differences 
between male and females were highly similar to those identified in the Welle study (FDR < 0.001%). 
This was true for differentially expressed genes detected in the Welle study at multiple significance 
thresholds (1%, 5%, 10% FDR). We also found that genes relating to sex-specific differences such as 
those located on the X and Y chromosomes were significantly different between young males and 
females in the meta-analysis dataset (Table 2.4). Genes up-regulated in female muscle include XIST 
which is responsible for inactivation of one copy of the X-chromosome in females [190] and GRB10 
and oestrogen receptor 1 (ESR1) which are involved in hormone signalling [191]. Down-regulated 
genes include 8 Y-linked genes such as RPS4Y1, EIF1AY, and DDX3Y.  
 
2.3.2 Differential gene expression in elderly human skeletal muscles 
 
Having developed a high-quality integrated dataset we set to identify and functionally characterise 
differentially expressed genes between the two age groups. We reasoned that, because of the larger 
number of samples in the integrated dataset, our analysis would be more effective than others 
previously reported based on the individual studies.  
We identified 1549 genes up-regulated and 1930 genes down-regulated in old human muscles at a 




Table 2.4 – Differentially expressed genes between young males and females in the meta-analysis 
data  
38 genes were detected as differentially expressed between young male and female muscle at 1% 
FDR. Table A shows the sum of genes from each chromosome shows X and Y linked genes are the 
most prevalent. Table B shows genes highly expressed in female muscle. Table C shows genes under 
expressed in female muscle. 
 
revealed significantly enriched functional terms (Table 2.5). Briefly, the down-regulated genes were 
enriched in functions related to oxidative metabolism and mitochondrial biogenesis such as oxidative 
phosphorylation, TCA cycle, mitochondrial ribosome, pyruvate metabolic process and protein 
targeting in mitochondrion. The up-regulated genes were enriched in terms such as RNA Splicing, 





Table 2.5 – Functional analysis of genes differentially expressed in skeletal muscle of elderly 
individuals 
Gene Ontology categories: CC – cellular compartment, BP – biological process, MF – molecular 
function, KEGG – pathway within the KEGG database.  
 
In order to test whether our approach could detect novel age related functional processes, we 
compared the meta-analysis with a re-analysis of the independent Melov study performed by Melov 
et al. The analysis of the Melov dataset identified a similar number of differentially expressed genes 
between skeletal muscle of young and elderly people (1470 genes up-regulated and 1454 genes 
down-regulated, FDR < 1%). There was a highly significant overlap between the genes identified in 
the meta-analysis dataset (32% of up-regulated genes and 43% of down-regulated genes in the 




Figure 2.5 – The gene level overlaps between the differentially expressed genes identified by the 
Melov study and the meta-analysis. 
*The overlap in both cases is highly significant. Panel A – p value: 3.26e-110. Panel B - p-value 5.79e-188 
We then performed a more detailed functional analysis of the shared and unique differentially 
expressed genes in each dataset (Table 2.6, Table 2.7). This comparison revealed that both analyses 
were characterised by an age related down-regulation of genes involved in energy metabolism and 
general mitochondrial function. This includes genes involved in oxidative phosphorylation, 
carbohydrate metabolism such as the TCA cycle  and glycolysis, components of the mitochondrial 
ribosome  and genes involved in mitochondrial transport, fatty acid oxidation  and cell redox 
homeostasis. Functional terms enriched in the common up-regulated genes include contractile fibre, 
regulators of apoptosis, components of RNA processing and RNA splicing pathways, components of 




Table 2.6 – Down-regulated functional terms in common between the meta-analysis and the Melov 
study 
At the threshold used to define differentially expressed genes in our analysis, several functions were 
enriched in either the meta-analysis or Melov data only. In the meta-analysis, this included up-
regulation of genes related to RNA processing (RNA binding, RNA splicing), intracellular transport and 
negative regulation of gene expression. Terms enriched in down-regulated genes specific to the 
meta-analysis were related to ubiquitin-mediated proteolysis and lipase activity. Functional terms 
specific to the genes up-regulated in the Melov data include regulation of transcription, cytoskeletal 
protein binding and telomere maintenance. The functions specific to genes down-regulated in the 
Melov dataset represent a further set of mitochondria related functions. We conclude that despite 
less than a 50% overlap in the genes detected by both studies, the functional profiles of elderly 




Table 2.7 – Up-regulated functional terms in common between the meta-analysis and the Melov 
study. 
 
additional functional enrichment not identified by analysis of the Melov data at an identical statistical 
threshold.  
2.3.3  Inference of gene regulatory networks representing young and elderly 
skeletal muscles 
 
Using our meta-analysis dataset and the well-validated network inference platform ARACNE, we 
constructed mutual information based transcriptional networks for both young and elderly human 
skeletal muscle. This allowed us to investigate the hypothesis that core molecular networks 





Figure 2.6 – Graphical representation of the young and elderly muscle networks. 
Panel A and B show the young and elderly networks respectively organised using a force directed 
layout. The edges have been colour coded for visual accuracy (red = edge in elderly network, green = 
edge in young network, blue = edge common to both networks).  
 
age related muscle dysfunction. The networks representing young and elderly muscle contain 505 
and 674 nodes and 2203 and 3107 edges respectively (Figure 2.6). These networks, which represent 
only highly significant interactions, were significantly different with only 312 nodes and 1064 edges 
shared between the two age groups.  
In order to visualise and compare the two networks we generated the union of the young and elderly 
muscle networks and visualised the resulting network using a force driven layout (Figure 2.7A). The 





2.3.4 Community analysis of muscle transcriptional networks reveals 
functionally enriched age-specific modules 
 
Visual inspection of the integrated network led us to formulate the hypothesis that there were very 
distinct age specific network modules. We tested this hypothesis by applying the network community 
detection algorithm GLay [138], a procedure that automatically identifies clusters of nodes (modules) 
with a high interconnectivity. GLay identified 30 distinct network modules, seven of which consisted 
of more than 30 genes, representing 73% of the total number of nodes (Figure 2.7B and Table 2.8). 
We found that with the exception of module M1 that contained the largest number of age 
independent edges, all modules were characterised by a high frequency of age specific edges (up to 
90%, modules M2 - M7) (Figure 2.8B, Table 2.8). We found that the connectivity between the 
modules was low, with the exception of the 3 centrally positioned modules M1, M2 and M3 (Figure 
2.8A). We then tested the hypothesis that network modules, defined on the basis of connectivity, 
may also represent specific biological functions. Functional analysis of genes in each module indeed 
confirmed that this hypothesis was correct (Table 2.9).  
Module M1 represents a large number of ribosome related genes such as large and small cytosolic 
ribosomal subunits and eukaryotic initiation factors (EIF3F, EIFG, EIF3H, EIF3L, EIF1), as well as a 
number of muscle fibre constituents (such as TNNC1, TNNC2, ACTA1, MYH2) and 
glycolysis/gluconeogenesis related genes (PFKM, ENO3, ALDOA, GAPDH, PGM1). The age-specific 
properties of this module suggest that both age groups possess many of these connections. Module 
M2 is composed of connections predominantly present in young muscle only (74%) and contains 66% 
(39/59) of the oxidative phosphorylation genes present in the network as well as components of the 
mitochondrial ribosome. Module M2 is highly connected to module M1 (Figure 2.8A). The 112 






Figure 2.7 – The union of the young and elderly networks 
Panel A shows the union of the young and elderly networks, revealing age specific sub-networks. 
Network edges have been colour coded according to the age group of origin as in Figure 2.6. Panel B 
shows that the results of the GLay modularisation closely match the visually identifiable sub-
networks within panel A. Modules are labelled M1-M7 and labels have been mapped to Panel A. The 
modules in panel B are colour coded for visual effect only. Panel A and B have been organised using a 
force-driven layout. 
 
Table 2.8 – Properties of the GLay modules 
The age group of origin of the edges connecting the 3 central network modules (M1-3) is shown in 






Figure 2.8 – Modules are characterised by age specific edges and inter-module connections 
Panel A shows the number of network edges connecting the modules. This shows the low 
connectivity between modules with the exception of M1 & M2 (112 edges) and M2 & M3 (102 
edges). Panel B shows the disparity of age-specific and shared edges in each GLay module and the 
inter-module connections 
 
present in young and elderly respectively, with a smaller number of shared connections (Table 2.8, 
Figure 2.8B). The 102 connections between M2 and M3 are mostly found in young muscle (71%). 
Module M3 consists of connections present primarily in elderly muscle (75%) and contains TCA cycle, 
oxidative phosphorylation, and pyruvate metabolism related genes. 12/14 (85.7%) of the TCA cycle 
genes present in the network are found in module M3, and the enrichment is highly significant (FDR 
< 2.0e-15).  The connectivity between module M3 and module M2 is highly specific for young muscle, 
thus we have identified module M3 as a component of energy metabolism that is disconnected to 




Table 2.9 – Functional analysis of each network module reveals distinct functional profiles 
in elderly individuals. The other modules are enriched in other important pathways within skeletal 
muscle. Module M7 is enriched with genes related to glycogen metabolism (such as AGL, PHKB, 
PPP1R2, PPP1R3A, PPP1R3C) and GTPase activity (such as RHOA, ARF1) two processes which have 
recently been linked in human cells [192]. Module M4 is enriched with inflammatory components 
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(such as CD46, C1R, C1S, and FN1), extracellular matrix remodelling (such as TIMP1, DCN, and 
MMP2), collagens, cell adhesion and blood vessel development (such as EPAS1, NRP1). Module M6 is 
enriched with genes related to proteolysis. Module M5 is enriched with oxidoreductases and 
aldehyde dehydrogenases. 
Analysis of networks created at a lower threshold (MI = 0.2, p-value < 10e-7) was consistent with the 
finding that the union of the young and elderly networks contains distinct network modules. At this 
threshold the union of the young and elderly networks contained 4638 nodes and 17950 edges. GLay 
clustering identified 567 modules within this network, of which 14 had more than 30 genes. We 
mapped the GLay clusters from the high-threshold network onto the modules generated from the 
low-threshold network, and found that each module remained clearly identifiable (Figure 2.9).  
 
Figure 2.9 – GLay modularisation of a lower threshold network recapitulates the network modules. 
This figure shows the results of GLay clustering on a lower threshold network. Each GLay cluster has 
been separated and represented as a sub-network. Network module labels correspond to the 
modules in the high threshold network and the nodes are colour coded to match. The connections 
shown in the inset table are between genes in modules M1-3 at the lower threshold 
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The connections between genes comprising the network modules were consistent with the high-
threshold network. Inter module connectivity between genes within module M1 and module M2 was 
split between edges significant in young (50.2%), shared (17.3%) and elderly (32.5%), this does 
represents a small shift towards connections in young between these modules. The connectivity 
between genes in M2 and M3 remained predominantly significant in young muscle (66.5%). There 
was an increase in the number of connections between module M1 and M3, and these connections 
were also specific to the young networks (70.1%). This shows that at a lower threshold the age-
specific properties of connections between network modules containing translation and energy 
metabolism genes are conserved.  
2.3.5 Mapping age dependent differential gene expression on the integrated 
transcriptional network 
 
Having shown that co-expression networks representing young and elderly skeletal muscle are very 
divergent with age we set to assess the relationship between co-transcription and levels of mRNA 
expression. We therefore mapped on to the network modules genes differentially expressed 
between young and elderly muscle (Figure 2.10A). Strikingly, 51.6% (306) of the total network nodes 
mapped to the 3479 genes differentially regulated in the two age groups. Using Gene Set Enrichment 
Analysis, we found that modules M2, M3 and M7 were enriched with down-regulated genes while 
modules M1, M4 and M6 were enriched with up-regulated genes (FDR < 0.1%). This shows us that 
the changes in gene-gene associations with age that have been identified by the network are 
accompanied by coordinated changes in gene expression between young and elderly muscle relating 
to specific molecular functions. More in depth functional analysis of the correspondence between 
changes in the mRNA levels and gene co-expression in the network modules revealed that genes up-
regulated in elderly muscle in module M1 include 12 ribosomal subunits, 5 components of muscle 




Figure 2.10 – Network modules are enriched with genes differentially expressed with age 
Panel A and B shows the up (red) and down (green) regulated genes in elderly human and mouse 
muscle respectively mapped to the network modules. The network modules have been represented 
as distinct sub-networks to aid distinction of enriched clusters. 
 
initiation factors (EIF3C, EIF3G), 3 genes related to proteolysis including proteasome subunits 
(PSMB1, PSMD4) and MYOZ1. Down-regulated genes in module M1 include 4 ribosomal subunits, 
the translation initiation factor EIF1, and PARK7 which has been shown to be part of the oxidative 
stress response in various cell types [193]. In module M2 the up-regulated genes include 2 
mitochondrial ribosomal subunits and the mitochondrial small molecule transporter VDAC 3. The 
down-regulated genes include 31 subunits of oxidative phosphorylation enzymes, 2 TCA cycle 
enzymes and 2 mitochondrial ribosomal subunits. There are no up-regulated genes in module M3. 
The down-regulated genes include 12 enzymes in the TCA cycle, 15 subunits of oxidative 
phosphorylation enzymes, 3 glycolysis enzymes, mitochondrial protein import (MTX2), lipid transport 
(APOO) and small molecule transporters SLC25A4 (ATP), SLC25A3 (phosphate) and VDAC2. In module 
51 
 
M7 the up-regulated genes include 2 cell adhesion molecules (CLDN5, PECAM1) and 3 genes related 
to protein transport (GDI1, USO1, ACTN4). The down-regulated genes in module M7 include 4 
enzymes involved in glycogen metabolism (PHKA1, PHKB, PPP1R3A, PPP1R3C), 3 genes related to 
regulation of translation (PAIP1, SELT, EIF4A2), skeletal muscle differentiation (RHOA, NOTCH3), 
genes related to mitochondrial functions such as VDAC1 (transport), HSPA9 (stress response), COX11 
(enzyme assembly), UCP3 (fatty acid export) and MFF (mitochondrial fission). The genes differentially 
expressed between young and elderly muscle that can be found in module M4 represent tissue 
remodelling and immune processes. Up-regulated genes include 3 genes related to blood vessel 
development (EPAS1, NRP1, IGF1). Down-regulated genes in module M4 include 14 genes related to 
extracellular matrix processes (including TIMP1, NOTCH2), 4 genes related to the activation of 
immune response and 6 genes related to cell adhesion. The up-regulated genes in module M6 
include 4 genes involved in RNA splicing (YTHDC1, LUC7L3, HNRNPA3, RBM39) and 3 cytoskeleton 
related genes (AKAP9, CBX1, DMD). 
Interestingly, the analysis of a gene expression dataset representing ageing in mice revealed a 
common transcriptional signature of ageing in mice and humans (Figure 2.11). We identified 1641 
genes down-regulated and 1431 genes up-regulated in elderly (25 months) versus young (5 months) 
mice (FDR < 5%). The overlap between genes up-regulated in elderly humans and mice was 
significant (p < 0.05, 15% of genes differentially expressed in aged mice). Functional analysis of the 
common up-regulated genes revealed enrichment of genes related to cytoskeleton, transcriptional 
regulation, cell death, RNA processing, GTPase signalling and cell cycle. The overlap between the 
genes down-regulated in elderly humans and mice was not significant (12% of genes differentially 
expressed in mice). However functional analysis reveals a common signature related to 




Figure 2.11 – Common transcriptional signature of age in humans and mice 
This figure shows the gene level overlap between a transcriptional signature of mouse ageing and the 
human ageing signature from the meta-analysis. The functional analysis was done using only the 
overlapping genes. A comparison was performed for up-regulated genes (red arrows) and down-
regulated genes (green arrows). 
 
components of oxidative phosphorylation, pyruvate metabolism and glucose metabolism. This shows 
that despite a low statistical power in the aged mice study (n = 4) compared to the human meta-
analysis, a common transcriptional signature of ageing muscle can be detected. We mapped the 
differentially expressed genes in elderly mice to the network modules, then using GSEA we tested if 
the genes from the modules in the human muscle network are enriched within the differentially 
expressed genes in elderly skeletal muscle of mice in the same way they are for human (Figure 
2.10B). We found that module M2 is significantly enriched with down-regulated genes in mouse and 
human. Module M1 and M6 are enriched in genes up-regulated in mouse and human, however 
Module M7 is enriched in genes up-regulated in the mouse and down-regulated in human. This 
shows that the functional modules within the network representing energy metabolism, translation, 
muscle fibre constituents and proteolysis contain genes that are differentially expressed in both 
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human and mouse skeletal muscle. However the modules relating to glycogen metabolism, GTPase 
signalling and extracellular matrix components are divergent between mice and human in terms of 
the changes in expression with ageing. 
 
2.3.6 Transcriptional response to physical exercise affects specific network 
modules 
 
We have shown that the transcriptional effects of ageing affect both the level of mRNA and the 
ability to co-ordinately regulate groups of functionally linked genes. Here we perform a similar 
analysis to test the hypothesis that response to exercise will also affect specific modules in the 
integrated network. 
We have used the publically available Melov et al microarray dataset [145] created from vastus 
lateralis skeletal muscle biopsies from elderly individuals who undertook a 6 month endurance 
training program. Melov et al. chose to control the family-wise error rate (FWER) to correct for 
multiple comparisons, a method that was appropriate for their study. This provides a low probability 
of any false positives amongst results at the expense of statistical power [194]. By using SAM, which 
controls the FDR, we were able to identify a larger selection of differentially expressed genes while 
maintaining only a 1% false positive selection. There were 1248 genes up-regulated in the trained 
individuals and 1507 genes down-regulated. We have used a gene ontology analysis to identify 
functional terms significantly enriched within the up and down-regulated genes (FDR < 10%) (Table 
2.10). Briefly, the up-regulated genes are enriched with terms such as localisation to mitochondria, 




Table 2.10 – Functional analysis of genes responding to endurance training in skeletal muscle 
 
complex assembly, RNA elongation and pyruvate metabolism. The down-regulated terms in response 
to training include protein transport, contractile fibres, protein kinase activity, protein catabolism, 
response to hormone stimulus, cell cycle, muscle cell differentiation and cellular response to stress. 
We have mapped the differentially expressed genes in response to training on to the human muscle 
network (Figure 2.12). There is a striking difference between the transcriptional signature of elderly 
muscle and that of exercise training.  
Whereas module M2 (oxidative phosphorylation) and M3 (TCA cycle) contain many genes that are 
down-regulated in elderly muscle, only module M2 was significantly enriched in genes up-regulated 
in response to training (FDR < 0.1%) while module M3 contained few genes. Module M6 (proteolysis) 
is significantly enriched in genes up-regulated in elderly muscle and down-regulated in response to 
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training (FDR < 0.1%). These results suggest that endurance training targets networks of genes that 
are more correlated in young muscle, and that a sub-network of energy metabolism genes in module 
M3 is refractory to induction by training despite being highly correlated in elderly muscle. 
 
 
Figure 2.12- Specific network modules are enriched with genes responsive to training 







2.4.1 The transcriptional signature of ageing skeletal muscle 
 
We have conducted the first meta-analysis of the transcriptional state of human skeletal muscle 
using a data integration approach. We show that there is a strong functional overlap between the 
transcriptional changes in ageing muscle in the meta-analysis and an independent study.  
Our results are consistent with previous studies analysing transcriptional differences between young 
and elderly muscle, and suggest a broad range of mitochondrial dysfunction in ageing muscle, 
suggested to be a driving force of ageing by the mitochondrial theory of ageing [58]. We see a down-
regulation of electron transport chain enzymes and transcription factors controlling mitochondrial 
biogenesis such as PGC-1α and TFAM. Interestingly, the intermediate step in the PGC-1α-TFAM 
pathway, nuclear respiratory factor 1 (NRF1), is up-regulated in elderly muscle. The increase in NRF1 
expression could be linked to the increased inflammatory status of elderly muscle [195] [196], as 
NRF1 overexpression has been shown to increase expression of cytokines [197]. We see a down-
regulation of genes related to anti-oxidant pathways such as glutaredoxin 2 (GLRX2), thioredoxin 
reductase (TXNRD1) and superoxide dismutase (SOD1), suggesting a decrease in the ability to 
respond to ROS via redox signalling and conversion of superoxides to oxygen and H2O2. SOD1 
deficient mice have recently been shown to have high levels of oxidative damage and accelerated 
sarcopenia [198]. The meta-analysis identified 38 genes related to ubiquitin-mediated protein 
catabolism that were down-regulated in elderly muscle. These include 11 ubiquitin specific 
peptidases and 7 proteasomal components (5 subunits of the 26S proteasome). This supports 
previous findings that the rate of protein turnover is decreased with age [199] and suggests that 
lower expression of these genes could play a role.   
Recent work by Timmons et al has shown that when levels of physical activity are normalized, the 
transcriptional signatures of ageing muscle are not consistent between their data and existing 
studies. They show that the overlap between the Melov ageing study [145] and their own (and very 
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likely our own data) is negligible. They suggest that the decline in expression of mitochondrial genes 
is a result of reduced physical activity and not the ageing process specifically. Interestingly, inhibition 
of MYC was predicted to be upstream of the age-related changes in expression. MYC mRNA is up-
regulated in elderly muscle of our meta-analysis. MYC is a known oncogene involved in control of 
transcription and cellular senescence through regulation of p16 [200] and CDK2 [201]. Further work 
utilizing large clinical studies are required to validate these findings and investigate the different role 
of transcription factors in ageing and muscle disuse atrophy. 
Skeletal muscle mass declines with age in humans, due to an increase in skeletal muscle atrophy. 
Atrophy related genes such as Atrogin-1 and Murf1 are thought to be controlled at the 
transcriptional level during ageing, however their exact role remains unclear [49] [50].  Modulation of 
Atrogin 1 in cardiomyocytes has recently been shown to alter the expression of genes related to cell 
death and inflammation, providing an interesting new hint to additional roles of atrophy related 
genes [202]. Neither Atrogin 1 (FBXO32) nor Murf1 (TRIM63) were differentially expressed between 
young and elderly muscle in our meta-analysis. However, no data was available for the meta-analysis 
regarding muscle mass or basal protein turnover, making it difficult to draw any conclusions. The 
functional profile of the genes up-regulated in elderly muscle did contain a large number of genes 
linked to protein catabolism. This included 95 genes linked to proteolysis such as 10 ubiquitin specific 
peptidases, 7 components of the proteasome, Calpain 3 and the mitochondrial protease Lonp1. The 
detailed transcriptional changes in proteolytic pathways during ageing have not been elucidated. Our 
data suggests that a large number of genes involved in proteolysis are up-regulated in a 
heterogenous elderly population. The factors controlling these genes can be revealed with further 
study. 
2.4.2 The construction of gene co-expression networks in young and elderly 
skeletal muscle  
 
We have used the skeletal muscle meta-analysis dataset to generate gene expression networks for 
young and elderly skeletal muscle. We chose a high statistical threshold to define the connections 
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within in the network in order to achieve a very low probability of false positive connections. Using a 
network community detection method we have identified distinct sub-networks which are enriched 
with genes relating to key molecular functions in skeletal muscle. The network analysis reveals a link 
between expression of energy metabolism related genes and the translational machinery. The 
analysis shows that the expression of a core sub-network of ribosomal genes and muscle fibre 
constituents is linked to distinct modules of genes related to energy metabolism via a set of age 
dependent connections that are either altered or uncoupled in elderly muscle. 
Our network analysis pipeline focused on the union of both the young and elderly muscle networks. 
However, it is important to note that the observation that elderly networks show a decoupling of a 
subset of metabolic genes is recapitulated in network modules generated from young and elderly 
muscle separately (Figure 2.13). These networks support the analysis of the union network. They 
show a decoupling of the translational machinery from a module comprised of oxidative metabolism 
genes in the elderly.  
Interestingly, we found that the network modules related to energy metabolism are highly enriched 
in genes that are down-regulated with age. Thus the coordinate down-regulation of energy 
metabolism genes is associated with a shift in correlation from one subset of genes in the young 
which are highly correlated to the translational machinery to another subset in the elderly that are 
decoupled from the translational machinery. The young subset is highly enriched with electron 
transport chain components only, while the elderly subset is highly enriched in TCA cycle 
components. This suggests a change in regulatory mechanisms controlling expression of energy 





Figure 2.13 – Modularisation of separate young and elderly networks recapitulates the findings of 
the union network 
GLay modules were identified in the young and elderly networks and represented as distinct sub-
networks. Functional annotation of the genes within the networks has been colour coded. These 
networks show a clear separation of energy metabolism genes in the elderly networks, and a striking 
uncoupling of many oxidative phosphorylation and TCA cycle genes from ribosomal genes. 
 
2.4.3 The expression of genes in distinct network modules responds to physical 
exercise 
 
A key question surrounding skeletal muscle ageing is the relative contribution of muscle disuse to the 
ageing muscle phenotype. Skeletal muscle is sensitive to physical activity, with just one bout of 
exercise sufficient to induce adaptations [203] [204], albeit short-lived ones. Most studies do not 
control specifically for long term physical activity levels in subjects, and thus reported differences in 
young and elderly muscle could be attributed to a decrease in physical activity and not ageing per se. 
In muscles subjected to 5 weeks of unloading, there is a coordinate down-regulation of genes related 
to oxidative metabolism [205]. In contrast, exercise training induces the expression of mitochondrial 
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genes [145], increases mitochondrial biogenesis [206] and increases neuromuscular junction 
hypertrophy in animal models [207].  
Level of physical activity was not a factor when selecting studies for inclusion into the meta-analysis, 
although we did not include recently trained individuals. Many of the samples integrated into the 
meta-analysis were therefore sedentary. The functional profile of elderly muscle we have identified 
could be attributed to the decrease in physical activity more likely to be seen in elderly individuals. 
We identified the genes that respond to six months of training in elderly individuals in the network. 
The most significant enrichment was in the electron transport chain components that are found in 
module M2, which are up-regulated in response to training. This leads to the interesting observation 
that resistance exercise in elderly people increases the expression of metabolic genes that are highly 
correlated in young muscle, and suggests the subset of metabolic genes in module M3 are more 
refractory to physical training. It could be potentially valuable to analyse in detail the networks 
surrounding these subsets of genes at a lower threshold, to identify potential regulatory mechanisms 
controlling their expression. 
 
2.4.4 Control of translation and metabolism in response to cellular signaling 
 
A key regulator of ribosome biogenesis and protein synthesis in response to multiple cellular signals 
such as nutrient availability [208], oxidative stress [209] and hypoxia [210] is the mTOR pathway. The 
mTOR pathway is also known to control mitochondrial oxidative metabolism through a PGC-1α 
dependent mechanism [75]. mTOR is a key regulator of ageing and age related diseases [211], 
however the many signaling pathways of mTOR are not completely understood. Further analysis of 
the skeletal muscle networks is needed, as they may allow us to identify potential regulatory 
mechanisms, either mTOR dependent or independent, that could explain the age related changes we 




EUKARYOTIC INITIATION FACTORS ARE POTENTIAL REGULATORS OF 




In the previous chapter we have described how a meta-analysis approach to study transcriptional 
profiling in skeletal muscle can allow us to determine the underlying networks in young and elderly 
skeletal muscle. Ageing is known to be a highly heterogeneous process, with many genetic and 
environmental factors influencing the progressive decline in functionality of many cellular processes. 
By analysing networks at a very stringent statistical threshold we have revealed a network with 
distinct age-dependent modules. Functional analysis of these modules revealed a decoupling of 
energy metabolism and translation related genes accompanied by a coordinate down-regulation of 
energy metabolism genes in elderly muscle. The mechanisms of coupling metabolism and translation 
such as the mTOR pathway have been increasingly studied in recent years due to its potential role in 
age-related diseases such as diabetes [212], COPD [213] [214] and obesity [215]. 
In this chapter we focus on the link between genes that form the translation machinery and energy 
metabolism pathways. We analyse the network modules in greater detail and identify key genes that 
could play a regulatory role linking these two functions. This analysis reveals that eukaryotic initiation 
factors (EIFs), which control translation at the step of ribosomal assembly and recycling, are found 
within the core network modules and are differentially expressed between young and elderly skeletal 
muscle. Using a correlation based analysis, we show that expression of EIFs and genes from energy 
metabolism pathways are linked in the meta-analysis data in an age dependent manner.  
By analysing the human muscle networks at a high level of detail we generate the hypothesis that 
EIFs control energy metabolism at the level of transcription in skeletal muscle. To test the hypothesis 
we chose one of the EIFs most strongly linked to energy metabolism pathways in the correlation 
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analysis, EIF6 (the gene is hereafter referred to as EIF6 in human, Eif6 in mouse and the protein eIF6), 
which controls 60s association to the 40s ribosomal pre-initiation complex (PIC) and which is 
necessary for insulin stimulated translation in MEFs [216]. In this study we have applied multiple 
omics and bioinformatics approaches to investigate the effect of eIF6 depletion in a heterozygous 
mice model. Using microarray profiling and MS proteomics we find that depletion of eIF6 controls 
the expression of a subset of genes and mitochondrial proteins as predicted by the network analysis. 
This includes many genes related to the function and control of energy metabolism pathways and 
metabolic homeostasis. Using knowledge-based network analysis tools we examine the possible 
mechanism of eIF6 regulation of transcription and find that there is a highly significant association 
between the transcriptional response to eIF6 depletion and treatment with HDAC inhibitors. HDACs 
are known to control metabolic homeostasis and are differentially expressed in the Eif6+/- mouse, 
providing an exciting hypothesis that a translation factor may regulate energy metabolism at the 






3.2.1 Inferring gene-gene correlations using Spearman’s rank correlation 
 
In order to better characterise the neighbourhood of each EIF factor we used Spearman’s rank 
correlation. This procedure is similar to a MI-based method (it has the advantage of being a scale free 
approach able to detect non-linear relationships) but in addition is able to detect the sign of the 
relationship. To estimate the statistical significance of each correlation we used a permutation 
approach. Briefly, a p-value was generated for each gene-gene correlation by comparing the 
correlation value against a large null distribution generated from randomized data. At least 50,000 
randomised variables were generated for each comparison. P-values were corrected for multiple 
testing by calculating the FDR using the Benjamini-Hochberg method [132]. 
3.2.2 Linear Discriminant Analysis 
 
The ability of expression of EIFs in the human muscle meta-analysis dataset and the Melov et al. 
dataset to correctly classify young and elderly skeletal muscle was tested using Linear Discriminant 
Analysis (LDA). First, principle component analysis was performed on the EIF expression data in both 
datasets. We then used the principle components as a classifier within the LDA algorithm. LDA was 
run within the R software package using the MASS library. 
3.2.3 Gene ontology and pathway enrichment 
 
The online gene ontology tool DAVID was used to detect functional terms enriched (FDR < 10%) 
within gene lists defined by the correlation analysis in the human meta-analysis data as well as 
differentially expressed genes and proteins in Eif6+/- skeletal muscle. The online tool Revigo [217] was 
used to reduce the complexity of Gene Ontology analysis by removing redundant terms. Gene lists 
ranked by correlation values or differential expression statistic (such as the t-statistic) were tested for 
enrichment of Gene Ontology terms and KEGG pathways using Gene Set Enrichment Analysis (GSEA). 
The enrichment of energy metabolism KEGG pathways within genes correlated to EIF gene 
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expression was tested using a fisher test followed by controlling the FDR at 10% using the Benjamini-
Hochberg method [132]. 
3.2.4 Collection of skeletal muscle 
 
Eif6 heterozygous mice were kindly donated by the lab of Stefano Biffo. These mice express half the 
normal amount of eIF6 protein in muscle [216]. All animal work has been conducted according to 
relevant national and international guidelines and approved by the University of Birmingham, 
Medical School ethics committee. Young (8-12 week) male mice were sacrificed by cervical 
dislocation and the skeletal muscles were immediately removed, cleaned of any excess fat or 
connective tissue and either flash frozen in liquid nitrogen or placed in ice-cold PBS supplemented 
with 10 mM EDTA and 0.05% trypsin for mitochondrial purification. Muscles placed in storage were 
stored at -80°C until further use. 
3.2.5 Transcriptional profiling of Eif6+/- mouse skeletal muscle 
 
Soleus and quadriceps muscles were homogenised in RLT buffer (Qiagen) with added β-
mercaptoethanol using a Precellys 24 tissue homogeniser system (Precellys, UK). The tissue lysate 
was centrifuged at 13,000rpm for 10 minutes and the supernatant removed for RNA extraction. RNA 
was extracted from the tissue homogenate using RNeasy (Qiagen) columns according to the 
manufacturer’s instructions. Sample purity was assessed by measuring absorbance at 260nm and 
280nm using a NanoDrop spectrophotometer, all absorbance ratios were within 1.8-2.0. Cy3 labelled 
cRNA was generated using the Agilent Low-Input QuickAmp kit according to the manufacturer’s 
instructions. Briefly, 50-100ng of RNA was used as input for the first round of cDNA synthesis, 
followed by a second step of amplification and Cy3 dye incorporation. 600ng of labelled cRNA was 
hybridised to Agilent Sureprint G3 Mouse whole genome microarrays. Microarrays were washed and 
scanned in an Agilent SureScan microarray scanner. 
Microarray data was log2 transformed and normalised using quantile normalisation. Differentially 
expressed genes were detected using Significance Analysis of Microarrays (SAM) [130] with a 5% FDR 
65 
 
cut-off. Probe IDs were linked to gene symbols using the manufacturer’s in-house annotation. Where 
needed, mouse gene names were converted to human homologs using the Mouse Genome 
Informatics (MGI) database. 
3.2.6 Proteomics analysis of mitochondria purified from Eif6+/- skeletal muscle 
 
The isolation of mitochondria was done by Dr Dan Tennant at the University of Birmingham Medical 
School. The proteomics analysis was done by the proteomics facility at the University of Liverpool 
Institute for Integrative Biology. 
Mitochondria were purified from fresh gastrocnemius muscle of Eif6+/+ and Eif6+/- muscle using the 
protocol described in [218]. Proteomics analysis of the purified mitochondrial was done using a 
Quadrupole-Orbitrap instrument (QExactive). Raw data was matched against the mouse UniProt 
database using the Mascot search engine (v2.4.1). The data set was analysed using Progenesis 4.1 
LCMS label-free quantification software. Peptide identification was adjusted to a false discovery rate 
of 1%. 
3.2.7 Connectivity Map and Ingenuity analysis 
 
The genes differentially expressed in the Eif6+/- skeletal muscle were analysed using the Ingenuity 
Pathway Analysis (IPA) application (Palo Alto, www.ingenuity.com) upstream analysis tool. 
The Connectivity Map (CM) tool (Broad Institute, www.broadinstitute.org/cmap) holds a collection of 
thousands of transcriptional profiles (known as signatures) generated from treatment of cell lines 
with a wide range of drugs and other compounds. CM was used to find transcriptional signatures 
significantly overlapping with the differentially expressed genes in the Eif6+/- skeletal muscle. The top 
1000 most significantly differentially expressed genes in the Eif6+/- muscle were submitted to CM in 
accordance with the gene set size limit. The top genes were chosen by ranking according to the d-





3.3.1 Correlation analysis links the expression of EIFs to energy metabolism and 
tissue remodelling 
 
In the previous chapter we identified network modules enriched in oxidative phosphorylation and 
TCA cycle genes. These modules show an age-specific topology in addition to a change in mRNA 
levels in elderly muscles. We also described that these were in close proximity of a module enriched 
with genes encoding for proteins involved in ribosome biogenesis and translation initiation. This 
raised the interesting hypothesis that the translational machinery may be linked to age-dependent 
decline in energy metabolism.   
We set to address this hypothesis by further characterising the correlation patterns in the 
neighbourhood (all genes significantly correlated to a given gene) of genes encoding for ribosome 
biogenesis. We focused on eukaryotic initiation factors as these play a crucial role in ribosomal 
assembly and recycling and have been shown to play a role in the control of cell growth [219] and 
extracellular signalling such as hypoxia [220].  
We identified 6 EIFs within the network modules M1, M2 and M3 (EIF2S2, EIF3H, EIF1, EIF3G, EIF3K, 
EIF3L). 15 EIFs were differentially expressed in elderly muscle in the meta-analysis dataset (8 up-
regulated, 7 down-regulated) (Figure 3.1). We decided to further investigate the linkage between 
EIFs and bioenergetics genes in skeletal muscle by developing a higher resolution map and including 
the sign of the interaction (positive or negative correlation).  
This analysis was performed on the full set of 15 differentially expressed EIFs and was at first focused 
on testing functional enrichment in 4 core energy metabolism pathways (oxidative phosphorylation, 





Figure 3.1 – Enrichment of energy metabolism KEGG pathways within genes correlated to 
expression of eukaryotic initiation factors 
This figure shows the number of energy metabolism genes in the correlation neighbourhood 
(positive correlation, negative correlation) of 15 differentially expressed EIF genes. Enrichment of 
energy metabolism pathways in negatively correlated genes (green box) and positively correlated 
genes (red box) has been colour coded. The net total of significant correlations in each age group is 
calculated and the difference between ages (‘Δ correlations’) is used to rank each EIF. Our 
observation that mRNA levels of energy metabolism genes is decreased with age is consistent with 
the inverse relationship between the change in level of expression of each EIF (‘change’) and the 
directionality of the correlation to energy metabolism pathways for 11/15 of the EIFs (‘inverse’). 
 
The results of this analysis were striking, providing evidence for an age dependent control of energy 
metabolism by EIFs. In young muscle, significant enrichment of energy metabolism genes was 
detected in the neighbourhood of only 5 EIFs. However, in elderly muscle the neighbourhood of all 
15 EIF genes was enriched with genes from energy metabolism pathways. We ranked the EIFs 
according to the increase or decrease in the number of significant correlations with age. Overall, the 
number of significant correlations increased with age, with only 3 EIFs showing an overall decrease. 
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We previously observed that energy metabolism genes are down-regulated with age. The direction 
of the change in expression of EIF genes and the correlation to energy metabolism was consistent 
with this observation for 11/15 EIFs (Figure 3.1). 
We noticed that one gene in particular, EIF6, had 0 significant correlations with energy metabolism 
genes in young muscle and ranked number 2 among the genes ranked by changes in correlation 
(Figure 3.2). We then performed a more in depth analysis of the EIFs using GSEA, a more sensitive 
functional analysis method. We focused on the top 3 EIFs (EIF2S2, EIF6, and EIF3J). This analysis 
confirmed that indeed EIF6 expression was not significantly associated to any KEGG pathways in 
young muscle (Figure 3.2B) even at a very permissive FDR (25%), but was associated to 29 pathways 
in elderly muscle (Figure 3.2A). EIF3J and EIF2S2 were linked to 27 and 30 KEGG pathways 
respectively in young muscle and 43 and 48 respectively in elderly muscle at this threshold (appendix 
3A). We mapped the genes from energy metabolism pathways that were correlated to EIF6 
expression on to the muscle network (Figure 3.2C). This revealed that 21 of the energy metabolism 
genes within module M3 of the network are linked to EIF6, consistent with the fact that 75% of the 
connections in M3 are significant only in elderly muscle (see Chapter 2 – Table 2.8). 
The KEGG pathways enriched within the correlation neighbourhood of EIF6 in elderly muscle 
revealed an interesting functional profile in addition to energy metabolism pathways (Figure 3.2A). 
Expression of EIF6 in elderly muscle is negatively correlated to KEGG pathways such as protein 
export, ubiquitin mediated proteolysis, insulin signalling and Wnt signalling. The inhibition of Wnt 
signalling by eIF6 has been previously shown in colon cancer cells and mice [221]. Genes positively 
correlated to EIF6 are enriched in ribosome subunits, cytokine receptor interaction pathways and 
neuroactive ligand receptor interaction pathways. This observation reveals that EIF6 is linked to 




Figure 3.2 – EIF6 is correlated to energy metabolism pathways in an age-dependent manner 
Panel A shows KEGG pathways enriched within the neighbourhood of EIF6 in elderly muscle. Panel B 
shows that no KEGG pathways are enriched within the correlation neighbourhood of EIF6 in young 
muscle. Panel C shows the energy metabolism genes correlated to EIF6 expression mapped to the 
central network modules (M1 = 0, M2 = 9, M3 = 21) (red – TCA cycle, green – Ox. Phos., blue – 
glycolysis). 
 
3.3.2 Eif6 inactivation in mice is consistent with the human muscle biopsies 
network 
 
The analysis of the human network reveals a link between EIF6 and expression of energy metabolism 
and cytokine receptor pathway genes in skeletal muscle in an age dependent manner. We chose to 
validate this prediction using an Eif6+/- heterozygous mouse. Using whole genome microarrays we 
have identified the transcriptional changes in soleus and quadriceps muscle of young Eif6+/- mice in 
which expression of eIF6 is reduced by half [216].  
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eIF6 is involved in ribosomal assembly and therefore its inactivation may affect protein synthesis. 
Biffo et al. [216] have shown that this is not the case in the haploinsufficient mouse suggesting that 
in this condition eIF6 is not rate limiting for protein synthesis. They show that the mTOR pathway is 
not activated in the haploinsufficient mouse. 
We could also verify that the morphology (fibre length and diameter) of Eif6+/- skeletal muscles were 
indistinguishable from wild type animals. Also qPCR comparing the ratio of nuclear DNA to 
mitochondrial DNA content in Eif6+/- gastrocnemius muscle did not show a significant difference (P = 
0.6, data supplied by Dr Tim Pearson, University of Liverpool). 
We could identify 1,984 up-regulated and 928 down-regulated genes (5% FDR) in the Eif6+/- soleus 
muscle (N = 4). Functional analysis reveals many functions enriched within these genes (Table 3.1). 
The most significant enrichment was up-regulation of genes linked to mitochondrial function. This 
included up-regulation of genes involved in the TCA cycle, mitochondrial transport, oxidative 
phosphorylation, mitochondrial ribosome and lipid metabolism.  Other functions enriched in up-
regulated genes included contractile fibre parts, protein kinase activity, apoptosis, and regulation of 
transcription. The down-regulated genes were not significantly enriched with functional terms, 
however analysis of the functional groups revealed genes related to cell migration such as Tgfbr1, 
blood vessel remodelling (integrins), cell adhesion (CD44), chemotaxis (Ccl2, Ccl5, Ccl8, Ccr2), 
regulation of transcription (Notch1, Hdac4) and cell cycle (Camk2a, Ccng2).  
A preliminary analysis of quadriceps muscle (N=2) from Eif6+/- mice showed a similar functional 
profile. 479 genes were expressed 50% higher on average in the Eif6+/- quadriceps muscle compared 
to Eif6+/+, and were enriched with genes which encode proteins that localise to the mitochondria, 
oxidative phosphorylation components, translation, protein catabolic process and contractile fibre 
constituents (Table 3.2). 288 genes were expressed at least 50% lower in the Eif6+/- quadriceps 




Table 3.1 – Functional analysis of differentially expressed genes in Eif6+/- soleus muscle 
 
soleus they also included genes related to cell cycle and integrin signalling. In summary, a reduction 
in eIF6 expression results in a transcriptional reprogramming of mouse skeletal muscle characterised 






Table 3.2 – Functional analysis of the Eif6+/- gastrocnemius muscle 
 
3.3.3 The transcriptional state of the Eif6 haploinsufficient mouse recapitulates 
the functional profile of the inferred human EIF6 network neighbourhood  
 
We assessed the accuracy of the predictions made by the correlation analysis in the human meta-
analysis data regarding the role of eIF6 in skeletal muscle. To do this we compared the functional 
profiles of genes correlated to EIF6 expression and differentially expressed genes in the Eif6+/- muscle 
in human and mouse respectively. A comparison of the gene counts between the functional profiles 
revealed many functional terms present in both analyses (Figure 3.3A). We identified all Gene 
Ontology terms with a positive gene count in both the correlation and Eif6+/- soleus analysis and 
submitted them to the semantic similarity tool Revigo [217] to identify key terms. In the case of up-
regulation in the Eif6+/- muscle and negative correlation to EIF6 expression this includes terms related 





Figure 3.3- Functional similarities between the human EIF6 correlation neighbourhood and the 
Eif6+/- soleus muscle in mice 
Panel A shows the comparison of gene counts for all KEGG pathways identified in the correlation and 
Eif6+/- muscle analysis. Functions are colour coded according to the change in expression (up – red, 
down – green) and direction of correlation (negative –red, positive – green). Panel B and C represent 
the semantic similarity analysis of gene ontology functional terms represented in both the human 





Figure 3.4 – Enrichment of eIF6 regulated genes in the human network modules 
This figure shows that module M1 (26 genes), M2 (11 genes) and M3 (22 genes) are enriched with 
genes differentially expressed in Eif6+/- soleus. 
 
including TCA cycle, energy derivation by oxidation (oxidative phosphorylation), mitochondrial 
organisation, glucose metabolism and acetyl-CoA metabolism (Figure 3.3B). On the other hand, 
genes down-regulated in Eif6+/- muscle and positively correlated to EIF6 expression were associated 
with terms such as cell adhesion, cell activation and regulation of apoptosis (Figure 3.3C).  Taken 
together, this suggests that the predictions made by the human muscle data are recapitulated in the 
mouse muscle with respect to energy metabolism functions. We identified modules in the human 
muscle network that were enriched (FDR < 0.01%) with genes differentially expressed in the Eif6+/- 
soleus. Modules M1 (ribosomes, translation initiation), M2 (oxidative phosphorylation) and M3 (TCA 
cycle, oxidative phosphorylation) were enriched with genes up-regulated in the Eif6+/- soleus muscle 
(Figure 3.4). However twice as many genes mapped to M3 (22) than M2 (11), suggesting that genes 
that are highly co-expressed in elderly muscle in an age-dependent manner (module M3) are 
regulated by eIF6. 
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3.3.4 Ingenuity Pathway Analysis of the Eif6+/- transcriptional signature 
 
To further investigate the role of eiF6 in controlling transcription in skeletal muscle we used the 
literature based interaction database Ingenuity (IPA). We analysed the differentially expressed genes 
from the Eif6+/- soleus muscle using the IPA upstream prediction tool. This identified 39 genes and 
compounds that are known to interact with genes differentially expressed in the Eif6+/- muscle where 
the overlap was highly significant (p < 0.005) (Table 3.3). Amongst these the known targets of insulin 
receptor (INSR) was the most highly enriched, and the status of insulin receptor is predicted to be 
activated in the Eif6+/- muscle (Table 3.3). 39/47 (83%) of genes with known activation/inhibition by 
INSR within the IPA network are consistent with activation. The overlap between eIF6 and INSR 
targets included increased expression of transcriptional factors related to mitochondrial biogenesis 
and lipid metabolism such as PPARA, NRF1, CPT1B and CPT2 and mitochondrial enzyme subunit 
genes (Figure 3.5A). Interestingly, 6 of the top 10 predicted inhibited factors based on the Eif6+/- 
upstream analysis are kinase inhibitors, and 4 of these are known to act on kinases within the INSR 
pathway (U0126, LY294002, PD98059 and Wortmannin target MEK1/2, PI3K, MEK1 and PI3K 
respectively). Taken together these results suggest an activation of the INSR pathway in the Eif6+/- 
muscle.  
Other effector genes predicted to be activated in the Eif6+/- soleus muscle include PGC-1α. 36/45 
(80%) of genes in the IPA network are predicted to be activated (Figure 3.5B). PGC-1α is up-regulated 
in the Eif6+/- soleus (linear fold change = 1.29) and is linked to important genes such as SOD2, CAT, 
NRF1, PPARA, TXN2, and FASN in the IPA networks (Figure 3.5B). Interestingly, the up-regulation of 
antioxidant enzymes superoxide dismutase 2 (SOD2) and catalase was highlighted by this analysis. 
Nitric oxide synthase 3 (NOS3/eNOS) is also up-regulated in the Eif6+/- muscle, suggesting a role of 
eIF6 in controlling oxidative stress. This analysis reveals some of the key regulators of metabolic 




Table 3.3 – Ingenuity Pathway Analysis predicts up-stream regulators of eIF6 targets 
The change in expression of upstream regulators differentially expressed in the Eif6+/- soleus is 








Figure 3.5 – Ingenuity networks showing genes down-stream of INSR and PGC-1α that are 
differentially expressed in Eif6+/- muscle 
Panel A and B show the enrichment of genes downstream of INSR (p = 2.83e
-16
) signalling and PGC-
1α (p = 6.13e
-9
) respectively that are differentially expressed in Eif6+/- muscle. Both INSR and PGC-1α 






3.3.5 Protein expression in Eif6+/- skeletal muscle mitochondria 
 
We have shown that there is differential expression of genes related to mitochondrial function in 
Eif6+/- muscle. However, mRNA changes are only partially correlated to protein abundance [222]. We 
have used mass spectrometry to obtain the expression of proteins in purified mitochondria from 
Eif6+/+ and EIf6+/- gastrocnemius muscle of young mice (N = 4). Mitochondria were isolated by Dr Dan 
Tennant at the University of Birmingham and mass spectrometry experiments were performed by 
the Liverpool University proteomics facility. We detected 850 proteins at a high confidence (1% FDR), 
of which 120 proteins were differentially expressed (10% FDR). Principle component analysis (PCA) 
was able to separate the wild type and heterozygous mice when applied to all detected proteins and 
differentially expressed proteins (Figure 3.6A-B).  
We compared the proteins detected in our samples to those in the mouse mitochondrial protein 
database Mitocarta [223] (www.broadinstitute.org/pubs/MitoCarta) and found a high level of 
overlap (> 50% for both detected and differentially expressed proteins) (Figure 3.6C-D). See 
appendix 3B for the full list of differentially expressed proteins. 
We have characterised the differentially expressed proteins using both existing literature to identify 
individual proteins linked to specific mitochondrial function and functional analysis to provide an 
overview of the functional classification of the proteins (Figure 3.7, Table 3.4). Functional analysis 
reveals that 72 out of 120 differentially expressed proteins are either known or predicted to 
associate with the mitochondria (the increase on the experimentally validated Mitocarta database is 
likely due to predicted functionality within the Gene Ontology database).  This includes components 
of the oxidative phosphorylation pathway, mitochondrial ribosome, and mitochondrial inner 
membrane. We also find enrichment of cytosolic ribosomal components, proteins associated to the 
sarcoplasmic reticulum and components of voltage-gated calcium channel complex. A closer 
inspection of the functions of the differentially expressed proteins (Figure 3.7) reveals up-regulation 




Figure 3.6 – Mitochondrial protein expression separates wild type and heterozygous samples in a 
PCA  
Panel A and B are the results of PCA applied to the protein expression data of all detected proteins 
(Panel A) and differentially expressed proteins (Panel B). Panel C and D show the overlap between 
the detected and differentially expressed proteins respectively and the mitochondrial protein 
database Mitocarta. 
 
(ANT4). We see up-regulation of the translocation factor Pam16 (TIMM16), and down-regulation of 
Tim9 and Pmpca. Mitochondrial translation factors Taco1, Guf1, Gfm2 and Qrsl1 are down-regulated. 
Mitochondrial protein complex assembly chaperones Cox20, Cox11, Ndufa11 are down-regulated, 
while Bcs1l is up-regulated. Proteins related to heme metabolism Cox15, Tmem14c and Cpox are all 
down-regulated. TCA cycle and oxidative phosphorylation proteins are up-regulated except for Sdhd, 
MT-Nd4 and Cox15. Eif6 haploinsufficiency therefore regulates the expression of mitochondrial 
proteins including energy metabolism enzyme subunits. Interestingly this also reveals regulation of 




Table 3.4 – Functional analysis of differentially expressed proteins 
 
 
Figure 3.7 – Mapping the differentially expressed proteins to mitochondrial functions. 
Up-regulated (red) and down-regulated (green) proteins have been colour coded. The full table of 
differentially expressed proteins is available in appendix 3B. Image adapted from ref [224] 
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3.3.6 Lysine acetylation is a predicted mechanism of eIF6 control of transcription 
 
We have identified a role of eIF6 in controlling transcription of specific mRNAs. We have used the 
knowledge base tool Connectivity Map (CM) to investigate potential mechanisms by which eIF6 
controls transcription. CM analysis identified 47 transcriptional signatures associated with treatment 
by a specific compound that had a significant overlap with the Eif6+/- signature (p < 0.01) (Table 3.5). 
Where possible we have classified the compounds based on existing literature. Interestingly, we 
noticed that among the significant signatures were 3 histone deacetylase inhibitors, Scriptaid, 
Trichostatin A (TSA) and Valproic acid (VPA). Scriptaid is a general histone deacetylase (HDAC) 
inhibitor known to regulate the expression of genes related to cell cycle and apoptosis [225], two of 
the functions associated to eIF6 in our analysis. TSA and VPA have been shown to inhibit class 1 and 
class 2 HDACs [226] [227]. The class 2 HDACs 5 and 7, class 3 sirtuins SIRT4 and SIRT7 are up-
regulated in the Eif6+/- soleus microarray data while histone acetyl transferase 1 (HAT1) and HDAC4 
are down-regulated. The CM analysis predicts that eIF6 mediated transcriptional control could be 




Table 3.5 – Transcriptional signatures with significant overlap to the Eif6+/- signature. 
A positive connectivity score represents a similar transcriptional response to treatment with a 
compound and depletion of Eif6; a negative connectivity score represents an inverse transcriptional 





3.4.1 The role of eukaryotic initiation factors 
 
Eukaryotic initiation factors control translation at the step of ribosome assembly and recycling. 
Several EIFs have previously been linked to important cellular signalling events. EIF2-α 
phosphorylation plays a key role in controlling translation during hypoxia [228]. EIF4E is well 
documented as the target of EIF4E binding proteins which are under the control of the nutrient 
sensing mTOR signalling pathway and insulin [229] [230]. These mechanisms allow preferential 
translation of a set of mRNAs, enabling the cell to better adapt to environmental changes. The role of 
EIF2-α and EIF4E in signalling pathways is linked to their rate limiting role in translation initiation 
during the formation of the 43S and 48S ribosomal complex respectively and as such they act as 
downstream targets of signalling pathways. We have identified a subset of EIF genes in human 
muscle which show both age dependent expression and correlation with energy metabolism genes. 
We focused on EIF genes that were differentially expressed with age. It is worth noting that in a 
separate analysis these 15 EIFs obtained an accuracy of 72.5% when used as a classifier in a linear 
discriminant analysis applied to young and elderly muscle samples from the independent Melov et al. 
study. This was only 2.5% lower than previous attempts to develop dedicated classifiers of ageing 
muscle [148]. EIF2-β showed the greatest change in the number of significant correlations with age. 
Consistent with EIF2-β linkage to energy metabolism genes is the fact that it is regulated by NRF1 
[231]. NRF1 controls the expression of genes necessary for mitochondrial metabolism, and is itself 
induced by PGC-1α. Several subunits of the EIF4F complex, EIF4A1, EIF4A2 and EIF4E also increased 
correlation with energy metabolism genes with age. These results suggest an age-dependent 




3.4.2 Eif6 haploinsufficiency controls expression of energy metabolism genes 
and proteins 
 
Based on the functional profiling of the network neighbourhood of the most age-specific EIF genes 
we selected EIF6 to investigate further. eIF6 acts as an anti-association factor by sequestering 
ribosomal 60s subunits prior to 80s ribosome assembly, thus controlling translation at the step of 40s 
and 60s binding [232] (Figure 3.8, adapted from [233]). Multiple theories outlining the mechanism of 
eIF6 release from the 60S subunit have been discussed including phosphorylation by RACK1 and Efl1 
mediated conformational changes of the 60s subunit, however further evidence is required to 
confirm these models [232]. The known properties of yeast and mammalian eIF6 are outlined in 
Table 3.6 (adapted from [233]).  
 
Figure 3.8 – The role if eIF6 in ribosome 80S assembly 
eIF6 controls the rate of translation by preventing the association of the 40S and 60S ribosomal 
subunits prior to translation. Phosphorylation induces eIF6 dissociation from the 60S which is then 
available for translation. The phosphorylation status of eIF6 controls its localisation. Phosphorylation 
of eIF6 in the nucleus by casein kinase 1 promotes its export while calcineurin phosphatase promotes 




Eif6 heterozygous mice are viable and show no visible differences to wild type mice during the first 
month of life. In adulthood the only biometric differences are a reduction in the weight/body ratio of 
liver and adipose tissue in Eif6+/- mice [216]. This was associated with decreased cell proliferation and 
an increased resistance to insulin stimulated translation [216]. Eif6+/- fibroblasts show normal 
ribosome biogenesis and unaltered basal levels of translation. Both Eif6+/- fibroblasts and 
hepatocytes are resistant to insulin stimulated translation [233].  
 
Table 3.6 – Properties of eIF6 in yeast and mammalian systems 
We have identified Eif6 as a novel regulator of a set of mRNAs and protein expression in skeletal 
muscle that is highly enriched in energy metabolism functions. This is a particularly surprising finding 
considering that eIF6 is not associated with the 40S subunit, and thus should not interfere with the 
translation of specific mRNAs. This is suggesting that eIF6 has an addition role in control of 
transcription. Ingenuity network analysis suggests that eIF6 is acting up-stream to repress 
transcription factors such as PGC-1α, NRF1 and PPARA, and that activation of insulin signalling 
pathways is a feature of eIF6 depletion. These results are consistent with the link between eIF6 and 
energy metabolism revealed by the human muscle network. Furthermore, EIF6 is up-regulation in 
elderly skeletal muscle, consistent with findings that elderly muscle has higher insulin resistance [90] 
and lower expression of energy metabolism genes.  
 
 
Properties Yeast Mammalian 
Essential Yes Yes 
Nucleolar localization Yes Yes 
Cytoplasmic localization A minor pool Up to 70% 
Function in ribosome biogenesis Yes, predominant Likely, not demonstrated 
Anti-association activity Yes Yes 
Role in translation No Yes 
Expression Constitutive Broad variation among cells and 
tissues 
Phosphorylation 




3.4.3 Depletion of eIF6 produces a signature associated with HDAC inhibitor 
treatment 
 
Using the online Connectivity Map tool we found that the transcriptional signature following 
treatment with histone deacetylase inhibitors in vitro was significantly overlapping with that of Eif6 
haploinsufficiency. Inhibitors of class II HDACs have been linked to improved glucose homeostasis in 
mouse models of type 2 diabetes [235]. HDACs regulate gene expression by controlling the 
acetylation of lysine residues on histones. However more recent proteomics analysis has revealed 
that acetylation status is a key regulator of many diverse proteins [236]. HDACs have been shown to 
act on lysine residues on proteins as well as histones [237]. Acetylation status has recently been 
revealed to be an important mechanism of post-translational regulation of metabolic enzymes [238]. 
This includes enzymes involved in glycolysis, the TCA cycle, fatty acid metabolism and glycogen 
metabolism [239]. In the past few months, an important study by Still et al. has identified the 
acetylation sites within the mitochondrial proteome that are regulated during alterations in 
nutritional status [81], and this has been linked to specific sites of SIRT3 regulation [240]. Expression 
of a set of five HDACS (HDAC4, 5, & 7, SIRT4 & 7) are up-regulated in Eif6+/- muscle. SIRT4 knock-
down in myotubes has been shown to increase fatty acid oxidation, cellular respiration and AMPK 
activity [241]. HDAC5 inhibition in muscle cells has been shown to increase glucose uptake and 
insulin activity [242]. On the contrary, expression of other HDACs such as SIRT2 and SIRT3 has been 
shown to correlate positively with VO2 max in healthy muscle, indicating a positive effect on 
respiration [174]. In future experiments it will be important to distinguish between specific HDACs 
activities, as they play contrasting roles. Together, this presents strong motivation for further analysis 
of the acetylation status of metabolic enzymes in response to eIF6 depletion, as this could represent 
a key regulatory mechanism linking a translation factor and energy homeostasis.  
It is important to note that the data integration process described in chapter two did not distinguish 
between trained and detrained muscle. However, EIF6 expression was unchanged in the Melov 
training study which reported up-regulation of many genes involved in oxidative metabolism, 
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suggesting that physical activity is not a controller of EIF6 expression.  In the future, a comparison 
between young and elderly Eif6+/- and wild type mice will be an important step in deciphering the 
role of eIF6 in ageing, as the present analysis relies on young mice only. This should be supported by 





SIGNALS LINKING EIF6 TO MITOCHONDRIAL FUNCTION, OXIDATIVE 




Our analysis has revealed that eIF6 controls a switch in the expression of genes involved in 
mitochondrial energy metabolism. The model developed from human muscle biopsies (Chapter 2) 
suggests that this mechanism may be important in ageing individuals, where the expression of this 
gene increases. Since ageing is a complex process it is unclear what may be regulating the expression 
of eiF6 in ageing muscles. In this chapter, we focus on identifying stress signals that may regulate 
Eif6.  
We start by examining the effects of oxygen tension in live mice and oxidative stress (generated in 
cultured myotubes) on Eif6 expression. Hypoxia, a key regulator of mitochondrial respiration [243] 
and tissue remodelling [244] in skeletal muscle has been previously linked to inhibition of eukaryotic 
initiation factors such as EIF2α and EIF4F [228] through the unfolded protein response and mTOR 
kinase respectively. Consistent with these observations, our analysis has revealed that hypoxia is also 
a potent regulator of Eif6 mRNA expression, which is coupled to a coordinate regulation of many of 
the genes modulated in the eIF6 depleted muscle. One possible consequence of hypoxia in skeletal 
muscle is the formation of reactive oxygen species from the electron transport chain, causing 
oxidative damage and activation of antioxidant, angiogenesis and metabolic signalling pathways such 
as AMPK activation of PGC-1α [245] and expression of HIF1α [246]. Regulation of Eif6 during hypoxia 
could be because of a ROS stimulated pathway. We show that Eif6 is regulated in an environment of 
very high oxidative stress in vitro; however this was not coupled to differential expression of genes 
regulated during depletion of eIF6 in a consistent manner.  
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The results of our transcriptional profiling of eIF6 depleted muscle revealed differential expression of 
transcription factors and genes involved in skeletal muscle regeneration and growth, such as NOTCH1 
[247], IGF1 [53], FGF2 [248], chemokines [249], cell cycle regulators and cell adhesion molecules. The 
response to skeletal muscle injury involves the activation, proliferation and differentiation of muscle 
stem cells (satellite cells) into myotubes, which then fuse to damaged fibres or form new ones. 
Satellite cells exist under the basal lamina of all muscle fibres in a quiescent state. Recently, inhibitors 
of mitochondrial activity have been shown to regulate differentiation of satellite cells [250]. 
Together, these observations lead us to hypothesise that eIF6 plays a role in satellite cell function by 
controlling transcription within satellite cells. In the second part of this chapter, we investigate the 
transcriptional state of quiescent, activated and differentiating wild type satellite cells using existing 
studies, followed by transcriptional profiling of satellite cells from Eif6+/- skeletal muscle in a 
proliferative state and after induction of differentiation. We show that activation and differentiation 
in satellite cells involves up and down-regulation of Eif6 expression respectively. The transcriptional 
state of Eif6+/- satellite cells reveals differential expression of genes related to cell cycle and 
mitochondrial activity demonstrating that eif6 controls the expression of energy metabolism genes in 





4.2.1 Use of existing microarray studies 
 
Six independent studies were used in this analysis. The raw data for each one was downloaded from 
the NCBI Gene Expression Omnibus (GEO) or provided by the author. The study ID, study title, 
platform, normalisation method, statistical analysis and experimental conditions of each study are 
summarised in table 4.1. 
 
Table 4.1 – Summary of the studies used in this analysis. 






4.2.2 Additional procedures applied to existing studies 
 
Clustering of the differentially expressed genes in response to H2O2 treatment was done using the 
HOPACH algorithm using the standard parameters (criteria function = median split silhouette (MSS), 
cluster identification level = MSS, distance matrix = absolute correlation distance). All analysis was 
performed using the R statistical software package. 
To enable us to calculate correlation between physiological measurements and gene expression in 
the COPD study by Turan et al. the data was transformed into z-scores using the QuantPsych package 
in the R software. Correlation was calculated using Spearman’s rank method. In order to calculate 
the significance of correlation we used a resampling procedure, as described in chapter 3.2.1. 
 
4.2.3 Eif6+/- satellite cell culture and transcriptional profiling 
 
Young Eif6+/- and wild type mice were sacrificed using cervical dislocation according to the safety and 
ethical guidelines of the University of Liverpool. Whole hind limb skeletal muscle tissue was 
dissected. Primary satellite cells were obtained using a pre-plating procedure as described previously 
[251]. Satellite cells were cultured using DMEM + 20% FCS + 1nM FGFb. Cells were differentiated by 
switching to differentiation media consisting of DMEM + 2% Horse Serum. All culture media 
contained antibiotics. Cells were lysed prior to and 24 hours after induction of differentiation by 
direct addition of RLT buffer (Qiagen) after removal of the media. Each genotype was done in 
duplicate. RNA was extracted from the cell lysate using RNeasy columns (Qiagen). RNA concentration 
and purity was assessed using a NanoDrop spectrophotometer, the ratio of 260/280nm was within 
1.7-2 for all samples. Amplified cRNA labelled with fluorescent Cy3 dye was generated using the Low-
Input Agilent QuickAmp (Agilent, UK) kit as per the manufacturer’s instructions. 50ng of labelled 
cRNA was hybridised to Agilent Mouse G3 Whole Genome microarrays. 
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Microarrays were scanned using an Agilent SureScan microarray scanner. Raw data was normalised 
using the Loess method, in which each possible combination of Eif6+/- and Eif6+/+ samples were used 
to calculate fold change ratios. After inspection of the background intensities any probe with a signal 
intensity of less than 6 across all samples was considered not sufficiently above background and was 
removed from further analysis. The resulting dataset contains 24,616 probes representing 12,769 
unique genes. Differentially expressed genes were detected using a one-sample t-test followed by 
Benjamini-Hochberg FDR correction with a 10% cut-off. Principle component analysis (PCA) was 
performed using the R software package. 
4.2.4 Functional enrichment analysis 
 
The online gene ontology tool DAVID was used to test for enrichment of functional terms within lists 
of differentially expressed genes. Terms were deemed significant if the enrichment threshold was 
less than 10% FDR. Enrichment of transcriptional signatures within network modules was tested 






4.3.1 Eif6 is up-regulated in mouse hypoxic skeletal muscle 
 
Having demonstrated that eIF6 can induce a coordinated metabolic reprogramming at the gene 
expression level and that this may be relevant in human muscle ageing we set to identify a micro 
environmental signal that may be responsible for its transcriptional regulation. We reasoned that 
elderly individuals show reduced VO2max, a feature that is linked to reduction in muscle 
oxygenation. Oxygen acts as a potent signalling molecule which controls transcription of hypoxia 
responsive genes. Hypoxia induces ROS production and acts through the HIF-1α pathway to control 
transcription of energy metabolism genes [252]. To determine if eIF6 could be a component of the 
hypoxic response we have analysed a publically available microarray dataset investigating the effect 
of hypoxia on quadriceps in mice. 
Differential expression analysis revealed 3,244 and 3,009 genes up and down-regulated respectively 
in response to hypoxia (FDR < 1%). Functional analysis (Table 4.2) reveals a down-regulation of genes 
enriched with energy metabolism (TCA cycle, oxidative phosphorylation, glycolysis) and skeletal 
muscle remodelling (extracellular matrix, collagen, muscle tissue development, actin cytoskeleton 
organization, regulation of cell adhesion) functions. Up-regulated genes were enriched in terms 
related to RNA processing, translation and protein processing (proteolysis, RNA splicing, ribosomal 
subunits, translation initiation, protein transport, protein folding, mTOR signalling). Interestingly, we 
found that hypoxia stimulates expression of Eif6 by 2.51 fold compared to normoxia (Figure 4.1A). In 
accordance with an increase in expression of Eif6, we found a highly significant overlap between 
genes down-regulated in response to hypoxia and the genes up-regulated in Eif6+/- muscle (N = 398, 
23.8%, p < 0.001). Functional analysis of the overlapping genes (Table 4.3) revealed enrichment of 
terms related to energy metabolism (mitochondrion, TCA cycle, oxidative phosphorylation, fatty acid 
metabolism). The expression ratios of these genes in response to hypoxia was consistent with the 
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change in expression of Eif6 (Figure 4.1A). The expression of PGC-1α was stable between normoxic 
and hypoxic mice (FDR = 41%). 
 





Figure 4.1 – Hypoxia modulates Eif6 expression and targets distinct network modules 
Panel A shows the change in expression of Eif6 and putative Eif6 targets in hypoxic muscle. Panel B 
shows genes modulated by hypoxia mapped to the human muscle network. ** FDR < 1% 
 
 





We mapped the differentially expressed genes to the human muscle network modules and found 
that a striking 57% (365) of the genes within the network modules are also modulated by hypoxia 
(Figure 4.1B). In accordance with the previously described functional analysis of both the network 
modules and hypoxic muscle, we found that module M1 (translation) and module M2 (Ox Phos.), M3 
(TCA cycle) and M4 (extracellular matrix remodelling and inflammation) in the network were 
enriched with up and down-regulated genes respectively (p < 0.001).  
4.3.2 eIF6 acts up-stream of PGC-1α 
 
Transcription factors such as PGC-1α are known to control expression of genes related to 
mitochondrial function and mitochondrial biogenesis. In Eif6+/- soleus muscle PGC-1α is up-regulated 
and Ingenuity network analysis revealed up-regulation of many PGC-1α targets, as shown in the 
previous chapter. To investigate whether eIF6 is explicitly acting up-stream of PGC-1α to control 
expression of mitochondrial related genes we analysed two existing microarray studies assessing the 
transcriptional response to over expression or knock-out of PGC-1α [253] [254]. In muscle specific 
PGC-1α knock-out mice, the expression of a large subset of 402 genes linked to mitochondrial 
function is co-ordinately down-regulated, as described in Finley et al. [254]. However in the same 
study Eif6 expression is comparable to wild type (p = 0.4455) (Figure 4.2A). 
In a study conducted by Calvo et al. [253] the effects of overexpression of PGC-1α in cultured C2C12 
cells differentiated into myotubes was investigated. Three days after induction of PGC-1α expression 
1165 and 217 up and down-regulated genes respectively were differentially expressed. However, no 
change in Eif6 expression was seen (p = 0.4788). There is a highly significant overlap between the 
genes up-regulated by PGC-1α overexpression and the genes up-regulated in Eif6+/- soleus muscle 
(N= 221, 20.1%, p = 1.27e-20), and as expected this overlap is highly enriched with genes related to 
energy metabolism (TCA Cycle, oxidative phosphorylation, mitochondrial ribosomes, mitochondrial 
protein targeting) (Table 4.4). In the human muscle network, module M2 (ox. phos.) and module M3 





Figure 4.2 – PGC-1α is down-stream of eIF6 and targets module M2 and M3 in the muscle network 
Panel A shows differential expression of PGC-1α in Eif6+/- muscle and stable expression of Eif6 in 
response to lentiviral induced PGC-1α overexpression in myotubes (C2C12) and muscle specific PGC-
1α knock-out in mice. Panel B shows enrichment of PGC-1α targets in module M2 and M3 (FDR < 
0.01%). * FDR < 5% 
 
 




4.3.3 Expression of Eif6 is increased in response to high levels of hydrogen 
peroxide 
 
The production of reactive oxygen species (ROS) is intrinsic to mitochondrial oxidative metabolism. 
Damage to proteins caused by ROS builds up as we age. This is thought to be caused by an inability to 
increase expression of antioxidant proteins.  In the Eif6+/- soleus muscle there is increased mRNA 
expression of genes with antioxidant function such as superoxide dismutase 2 (SOD2) and catalase 
(CAT), which act in the mitochondria to convert superoxide and hydrogen peroxide to water and 
oxygen. To determine if expression of Eif6 is regulated by oxidative stress we have analysed an 
existing microarray dataset in which C2C12 cells were differentiated into myotubes and then 
exposed to a range of concentrations of hydrogen peroxide. We identified 1,845 differentially 
expressed genes in response to H2O2 treatment (FDR < 5%). Clustering of these genes revealed 4 
clusters each representing a distinct transcriptional response to H2O2 treatment. Eif6 is significantly 
up-regulated in response to H2O2 treatment (Figure 4.4) and is found in cluster 2 (Figure 4.3). We 
have used functional analysis to further characterise each cluster. Cluster 2 represents genes strongly 
up-regulated in response to high concentrations of H2O2 and is enriched with terms such as 
apoptosis, oxidative phosphorylation, glucose metabolism, response to oxidative stress and cytokine 
activity. We identified 182 and 76 genes up and down-regulated respectively in the Eif6+/- soleus 
muscle that were also differentially expressed in response to H2O2 treatment. However the overlap 
was not significant for either (up: p = 0.2939, down: p = 0.26088), neither was there a clear indication 
that these genes may respond to H2O2 and eIF6 depletion in a similar way. It is worth noting that 
although expression of Eif6 is significantly increased in response to H2O2, the dynamic range across all 
samples is low (maximum fold change 1.25) compared to the dynamic range across the clinical 
samples in the muscle meta-analysis dataset (young fold change= 2.39, elderly fold change = 2.58). In 
conclusion, Eif6 expression is induced by very high concentrations of H2O2 in myotubes, but there is 




Figure 4.3 – Cluster analysis of genes modulated by H2O2 
This figure shows the cluster analysis of genes differentially expressed in response to H2O2 treatment 






Figure 4.4 – Eif6 expression in response to H2O2 treatment 
Expression of Eif6 was dose-dependent (ANOVA p = 2.78e-5) 
 
 
4.3.4 Expression of EIF6 modulates genes linked to an increase in serum protein 
carbonylation 
 
One consequence of ROS induced damage is irreversible carbonylation of proteins, which can be 
detected in tissues and serum. Using a clinical study incorporating transcriptional profiling and 
physiological measurements across 49 individuals, published by Turan et al. [174], we have 
investigated whether EIF6 expression is predictive of ROS induced protein carbonylation. The study 
includes COPD patients with normal (n = 14) and low BMI (n = 12) as well as healthy volunteers (n = 
23).  
We found that EIF6 expression is not correlated to levels of protein carbonylation in muscle or serum 
from healthy volunteers, or COPD patients. However, 59 genes from mitochondrial energy 
metabolism pathways (TCA cycle, ox. phos., fatty acid metabolism) such as UQCRC1 (Figure 4.5C) and 
NDUFV1 (Figure 4.5D) are negatively correlated to serum protein carbonylation in healthy muscle 
(FDR < 5%). This is reduced to 18 genes in COPD patients with normal BMI and 0 in COPD patients 
with low BMI. We found that 26/59 (44%, p = 0.007) of the energy metabolism genes correlated to 
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serum protein carbonylation in healthy muscle are also up-regulated in the Eif6+/- soleus muscle 
(Figure 4.5A). This number is reduced to 4/14 (28.6%, p = 0.84) in COPD patients with normal BMI 
(Figure 4.5B), and 0% overlap in patients with low BMI. There was some evidence at a nominal p-
value threshold that expression of EIF6 was correlated with 55 energy metabolism genes such as 
ATP5J (Figure 4.5E), which is significantly correlated to carbonylation levels (Figure 4.5F). However 
after correction for multiple testing these correlations were non-significant (FDR > 10%).  
In summary, genes involved in mitochondrial metabolism are highly correlated to serum protein 
carbonylation and there is a significant overlap with genes regulated by Eif6 haploinsufficiency. From 
this we could predict that increased Eif6 expression in elderly muscle could be indicative of increased 
ROS damage, and individuals with lower Eif6 expression may benefit from increased expression of 




Figure 4.5 – Energy metabolism genes linked to ROS damage are regulated by Eif6 
haploinsufficiency 
Panel A and B show the overlap of genes up-regulated in Eif6+/- muscle (red) and genes correlated to 
carbonylation measurements in the clinical data (blue). Panel C and D show scatter plots of oxidative 
phosphorylation subunit gene expression and carbonylation in healthy muscle. Panel E and F show 
scatter plots of EIF6 expression and carbonylation in healthy muscle. * Significant at < 5% FDR, ‡ 
Significant at < 5% FDR. † Significant overlap, p = 0.007. 
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4.3.5 Eif6 is up-regulated during skeletal muscle satellite cell activation 
 
So far we have focused on the effects of Eif6 haploinsufficiency within a whole muscle environment. 
However, an important component of muscle biology with implications for muscle growth and 
regeneration is proliferation and differentiation of skeletal muscle satellite cells (myoblasts). Genes 
important for satellite cell proliferation and differentiation are differentially expressed in Eif6+/- 
soleus muscle such as IGF1 [255], and NOTCH1 [247]. Furthermore, eIF6 regulates many genes 
related to mitochondrial activity, which has recently been shown to regulate myogenic 
differentiation [256] [257]. We decided to investigate if eIF6 could play a role in satellite cell function. 
We identified a microarray study available in the GEO database [258] to investigate the 
transcriptional profile of quiescent and activated satellite cells. 
We identified 758 and 620 up and down-regulated genes respectively in activated satellite cells 
compared to quiescent cells (FDR < 1%). Consistent with re-entry of the satellite cells into the cell 
cycle, functional analysis (Table 4.5)  of the up-regulated genes revealed enrichment of terms 
relating to proliferation and growth (cell cycle, tRNA metabolism, rRNA processing, mRNA transport),  
metabolism (glutathione metabolism, mitochondrion, protein catabolic process) and nuclear 
functions (Nucleolus, response to DNA damage stimulus, chromatin modification, DNA packaging). 
The down-regulated genes are enriched in terms related to tissue remodelling (extracellular matrix, 
cell adhesion, regulation of inflammatory response, vasculature development) and development 
(developmental growth, skeletal system development, cell fate commitment).  
Interestingly, we found that Eif6 expression is up-regulated in activated satellite cells (fold change = 
1.58) (Figure 4.6A). Consistent with inverse Eif6 expression, this is accompanied by a significant 
overlap of genes up-regulated in Eif6+/- soleus muscle and down-regulated in activated satellite cells 
(373, p = 2.64e-10). We examined the overlapping genes using functional analysis (Figure 4.6B). This 
analysis suggests that eIF6 may play a role in regulating gene expression during the activation of 
quiescent satellite cells by down-regulating genes related to apoptosis, extracellular matrix processes 










Figure 4.6 – Activation of satellite cells induces expression of Eif6 and genes modulated by Eif6 
haploinsufficiency  
Panel A shows Eif6 expression is increased in activated (in culture for 72 hours) satellite cells. Panel B 
shows enrichment of functional terms in genes overlapping between satellite cell activation (down-
regulated) and Eif6 haploinsufficiency (up-regulated). *** p < 0.001 
 
4.3.6 Eif6 is down-regulated during muscle satellite cell differentiation 
 
The process of satellite cell activation, proliferation and differentiation is a dynamic process involving 
distinct transcriptional reprogramming at each stage [259] [248]. One of the key properties of muscle 
regeneration is an overall increase in mitochondrial biogenesis, expression of mitochondria related 
genes and respiration [260]. In fact, inhibiting mitochondrial function in myoblasts blocks 
differentiation [256]. We reasoned that Eif6 could be regulated during satellite cell differentiation. 
We analysed transcriptional profiles of differentiating satellite cells from 0hrs to 7 days. 
We utilised a study created by the Ontario Genomics Innovation Centre which is available in the GEO 
database (GSE10424). We found that 2098 and 1624 genes are up and down-regulated respectively 




Figure 4.7 – The functional profile of differentiating satellite cells is consistent with the expression 
of Eif6 and PGC-1α 
Panel A shows the functional profile of differentiating satellite cells, ranked by the number of genes 
in each functional term. Panel B shows the expression profile of Eif6 and PGC-1α during satellite cell 
differentiation (FDR < 10%). 
 
 





the differentially expressed genes (Figure 4.7A). Genes up-regulated during differentiation were 
enriched with terms related to energy metabolism (mitochondrion, oxidative phosphorylation, 
glucose metabolic process, fatty acid metabolism, glycogen metabolic process  and lipid localisation), 
muscle development (contractile fibre, muscle tissue development, blood vessel development, 
transmission of nerve impulse). The down-regulated genes were enriched with terms relating to cell 
cycle (DNA replication, chromosome, cell cycle), translation (ribosomal subunits, RNA transport, 
ribosome biogenesis), response to DNA damage stimulus and cell redox homeostasis. 
Importantly, we found that expression of Eif6 is down-regulated during the satellite cell 
differentiation time course (Figure 4.7B). This was accompanied by a co-ordinate up-regulation of 
PGC-1α. This matches our prediction that Eif6 could control energy metabolism genes in 
differentiating satellite cells. We examined the overlap between genes differentially expressed in the 
Eif6+/- soleus and during satellite cell differentiation. We found that the only significant overlap (n = 
366, p < 0.001) is between genes up-regulated both in response to eIF6 depletion and during satellite 
cell differentiation. Functional analysis of the 366 overlapping genes (Table 4.6) confirmed that these 
were enriched with terms related to mitochondrial function (oxidative phosphorylation, TCA cycle, 
fatty acid metabolism). Also included in the overlap were genes related to adherens junctions and 
regulation of cell division, which includes the growth factors FIGF (VEGFD), FGF5, PDGFB, TGFB1 and 
VEGFB.  
Expression of Eif6 is increased during satellite cell activation, where it appears to be uncoupled from 
expression of genes related to mitochondrial function. However during satellite cell differentiation 
Eif6 expression is decreased, accompanied by a coordinate increase in expression of genes related to 
mitochondrial function and respiration, which significantly overlap with genes differentially 




4.3.7 Transcriptional profiling of Eif6+/- primary satellite cells reveals 
differential expression of energy metabolism genes 
 
We have shown that Eif6 haploinsufficiency causes a significant transcriptional reprogramming in 
whole muscle. To investigate whether Eif6 haploinsufficiency may cause cell autonomous effects in 
satellite cells we analysed Eif6+/- and Eif6+/+ primary satellite cells during proliferation (0 hours) and 
after induction of differentiation (24 hours). 
We used principle component analysis (PCA) to visually assess the variation between the samples. 
The wild type and Eif6+/- cell were separated, and there was a similar response to induction of 
differentiation in both cell types (Figure 4.8).  
 
Figure 4.8 – PCA reveals a similar response to induction of differentiation in Eif6+/+ and Eif6+/- 
satellite cells 
 
We identified differentially expressed genes between Eif6+/- and Eif6+/+ cells at 0 and 24 hours and 
between 0 hours and 24 hours in each genotype respectively (FDR < 10%). Eif6 expression was not 
significantly altered between 0 and 24 hours in either cell type. We found that the largest numbers of 




Table 4.7 – Differentially expressed genes between satellite cells 
 
 
Figure 4.9 – The functional profiles of Eif6+/- satellite cells reveal cell autonomous effects 
Box A and B summarise the functional analysis between wild type and Eif6+/- cells at both time points. 
Box C and D summarise the functional changes between 0hrs and 24hrs in both cell types. 
 
there are a significant number of genes differentially expressed between the Eif6+/+ and Eif6+/- cells at 
both time points (Table 4.7). We characterised these differentially expressed genes using functional 
analysis. This revealed substantial transcriptional reprogramming in both proliferating and 
differentiating cells. The functional profiles of cells at 0 and 24 hours in both cell types was consistent 
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with induction of differentiation, with both cell types up-regulating muscle fibre components and 
mitochondrial genes and down-regulating transcription factors and cell cycle linked genes (Figure 
4.9C-D).  
A comparison of proliferating Eif6+/- and Eif6+/+ cells (Figure 4.9A) revealed genes related to 
mitochondrial function, including components of energy metabolism enzymes (Atp5d, Uqcrc2, 
Ndufs2, Ndufc1), ribosomal subunits and muscle cell differentiation were up-regulated. Interestingly, 
genes involved in apoptosis and cell cycle were down-regulated. This suggests a potential alteration 
in proliferative capacity in Eif6+/- satellite cells. Remarkably, functional analysis of the genes 
differentially expressed at 24 hours in Eif6+/- compared to Eif6+/+ cells (Figure 4.9B) revealed up-
regulation of 22 oxidative phosphorylation enzyme subunits and enrichment of ribosomal subunits 
and genes associated to mitochondrion, apoptosis and skeletal system development (including 
Myod1 and myogenin). The down-regulated genes were associated with regulation of transcription 
(including c-Myc, calcineurin), chromatin organisation, nuclear transport, RNA splicing and cell cycle. 
We noticed that functional profiles between genotypes at 24 hours have terms in common with the 
changes seen between 0 and 24 hours (oxidative phosphorylation, mitochondrion, regulation of 
transcription and cell cycle) (Figure 4.9C-D), and that this was specific to the differentiating cells. This 
suggests that the Eif6+/- cells could have altered differentiation capacity. This is supported by the fact 






4.4.1 Eif6 expression is controlled by hypoxia 
 
The transcriptional profiling of hypoxic skeletal muscle in mice has revealed a co-ordinate down-
regulation of genes involved in mitochondrial metabolism, consistent with a decrease in 
mitochondrial content [252]. Eif6 expression is induced by hypoxia in a manner consistent with our 
results revealing reprogramming of energy metabolism genes in Eif6 haploinsufficient muscle. The 
expression of PGC-1α is up-regulated by depletion of eIF6, and we were able to show that eIF6 acts 
up-stream of PGC-1α in muscle. PGC-1α is activated in response to increased ATP demand, and is 
induced by exercise and hypoxia [261] [102]. However, in the study we analysed chronic hypoxia 
failed to module PGC-1α expression. ATP demand in mice kept in chronic hypoxic conditions is likely 
to be low due to severely decreased activity levels. This suggests that up-regulation of PGC-1α in 
Eif6+/- muscle could be due to an ATP dependent mechanism. We have shown that eIF6 controls a 
metabolic reprogramming at the transcriptional and protein level in healthy, unchallenged, young 
mice. Future experiments investigating the metabolic capacity of muscle from Eif6+/- mice during 
hypoxia and exercise will be valuable in determining the physiological consequences of Eif6 
haploinsufficiency. 
Hypoxia is thought to be a cause of ROS formation in skeletal muscle during exercise and disease 
states such as COPD exacerbations [262]. There is some evidence for ROS mediated expression of 
Eif6 in myotubes treated with hydrogen peroxide. However this modest change in expression was 
achieved at a very high concentration of H2O2 unlikely to be found in skeletal muscle. We did identify 
a link between genes regulated by Eif6 haploinsufficiency and serum protein carbonylation, a marker 
of oxidative stress [61], in a clinical study of healthy, elderly muscle.  Energy metabolism genes that 
are highly negatively correlated to levels of carbonylation are up-regulated in Eif6+/- muscle. This 
suggests that levels of ROS formation in muscles under-expressing Eif6 could be reduced. This is 
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supported by the up-regulation of mRNA for anti-oxidant enzymes such as catalase and superoxide 
dismutase 2 (Sod2) in Eif6+/- muscle.  
 
4.4.2 Eif6 controls gene expression in satellite cells in a cell-autonomous manner 
 
By examining two existing expression profiling studies of satellite cells we revealed that Eif6 
expression is increased in activated satellite cells and reduced during differentiation. PGC-1α 
expression was reduced in line with Eif6 during differentiation. The reason for an up-regulation of 
Eif6 in activated satellite cells remains unclear. Activation of satellite cells involves re-entry in to the 
cell cycle and therefore an increase in translation and growth. The increase in expression of Eif6 
could facilitate this growth by increasing the availability of mature 60S ribosomal subunits [232] 
[234]. 
Analysis of a time-course of satellite cell differentiation revealed a down-regulation of Eif6 in 
differentiated cells. This was in parallel with an up-regulation of PGC-1α and a significant number of 
putative eIF6 targets involved in energy metabolism. The analysis of the existing studies led us to 
hypothesise that eIF6 could play a role in satellite cell differentiation. We generated transcriptional 
profiles of proliferating and differentiating Eif6 haploinsufficient satellite cells and discovered an 
extensive transcriptional reprogramming. This was characterised by alterations in mitochondrial 
genes consistent with the changes seen in the whole muscle. We also found a large number of 
transcription factors and genes related to cell cycle and apoptosis were altered. This included the 
myogenic factors myogenin and Myod which were expressed higher in the Eif6+/- cells 24 hours after 
inducing differentiation. The expression of myogenin is a marker of terminal differentiation in 
myoblasts and is necessary for the exit of the cell cycle [263]. Higher expression of myogenin was 
consistent with the functional analysis which revealed down-regulation of 52 cell cycle related genes 




During myogenic differentiation there is an increase in mitochondrial complex activity, suggesting 
that the shift from glycolytic metabolism to oxidative phosphorylation occurs during differentiation. 
A number of studies have highlighted the importance of mitochondrial biogenesis and oxidative 
phosphorylation during stem cell differentiation [264] [256]. Inhibitors of mitochondrial RNA 
synthesis, protein synthesis and mtDNA replication have negative effects on myogenesis. A recent 
study by Jash and Adhya [265] has shown that artificial introduction of the mitochondrial genome 
into injured muscle increases expression of mitochondrially encoded genes, respiratory capacity and 
ATP levels while promoting muscle recovery. It also increases differentiation capacity of satellite cells 
and expression of myogenic factors including myogenin and Myod. We found that expression of c-
Myc, which is an important player in preventing the differentiation of myoblasts [266], is significantly 
lower in differentiating Eif6+/- satellite cells. Seyer et al. have shown that inhibition of mitochondrial 
activity with chloramphenicol prevents the down-regulation of c-Myc normally associated with 
satellite cell differentiation [257]. In a follow up study Seyer et al. revealed that inhibition of 
mitochondrial protein synthesis reduces calcineurin expression [267]. Calcineurin stimulates 
myoblast differentiation and increases expression of myogenin. The expression of the alpha and beta 
subunit of calcineurin is higher in Eif6+/- satellite cells compared to wild type 24hours after inducing 






MODELLING THE INTERACTION BETWEEN TUMOUR AND STROMA IN 
AN IN VIVO MODEL OF ANGIOGENESIS 
 
The work presented in this chapter represents a collaborative project between the labs of Francesco 
Falciani (Liverpool), Roy Bicknell (Birmingham) and Andreas Bikfalvi (CNRS). The Bikfalvi lab 
completed the in vivo implantation of glioblastomas on the CAM, collected tissue samples, provided 
the raw microarray data for VEGF treatment of the CAM and provided morphological data (published 
previously [268]). Sarah Durant (jointly in Falciani and Bicknell laboratories) completed the 
microarray expression profiling of the glioblastoma implantation time-course and the cell culture 
work for the U87 treatments. Rita Gupta in the Falciani lab developed the ODE-based network 
inference methodology and applied it to the implantation time-course data. Kim Clarke (Falciani lab) 
performed all the computational analysis described in this chapter, performed the microarray 
expression profiling analysis of the U87 cytokine and growth factor treatments, validated the ODE-
based models and formulated the biological interpretation and hypothesis formulation. 
 
5.1 Introduction 
Angiogenesis is the process by which new blood vessels form from the existing vasculature. This 
process is vital for a range of processes including wound healing, response to aerobic exercise and 
tumour development. Tumours are unable to grow larger than 1-2mm3 [269] without the initiation of 
angiogenesis to increase oxygen availability.  
Angiogenesis is controlled by a complex network of pro and anti-angiogenic factors that regulate the 
“angiogenic switch” between vascular growth and regression [270]. Despite intensive research 
efforts the precise mechanism underlying the network of interactions between growth factors, 
cytokines and extracellular matrix proteins remains only partially understood. Functional genomics 
technologies have enabled measurements of genes, proteins and metabolites to an unprecedented 
level of resolution.  The application of transcriptomics technologies such as microarrays to the study 
of angiogenesis has generally been used to investigate the role of a single protein or compound of 
interest in a model system, primarily endothelium in vitro (e.g. VEGF [271], angiopoietin-1 [272], TGF-
β [273], BMP6 [274], stem cell factor [275]. More recently, hypothesis generating transcriptomics 
approaches have successfully identified angiogenesis related expression signatures in a physiological 
setting such as the chorio-allantoic membrane [276] and tumours [156]. This has revealed novel 
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biomarkers of tumour status such as insulin-like growth factor receptor and epidermal growth factor 
receptor [277]. A recent proteomics study [278] addressed the important question of whether blood 
vessels within tumours exhibit specific protein expression by analysing the entire proteome of micro-
dissected capillaries. Despite the challenge of obtaining sufficient material from micro-dissected 
blood vessels, they were able to identify a protein signature specific for tumour angiogenesis. Other 
proteomics studies have so far focused on endothelial cells outside of the context of angiogenesis. 
However, none of these approaches have truly provided novel mechanistic understanding of this 
important biological process. In order to address this issue we have applied a reverse engineering 
approach to a well-established in vivo model of angiogenesis, the chicken egg chorio-allantoic 
membrane (CAM) [279]. The CAM forms the equivalent of the mammalian placenta in eggs of some 
amniotes.  
The CAM is an attractive model to study angiogenesis compared to other existing animal models. 
Morphological and gene expression data can be obtained easily in a short time frame throughout the 
development of the vascularised tumour with minimal levels of animal suffering. Glioblastomas 
implanted on the CAM show many of the hallmarks of the human tumour [268]. We have implanted 
glioblastoma cells on to the chicken egg CAM, which rapidly form a solid tumour and progressively 
becomes vascularised during the first week of implantation, as previously described [268] (Figure 
5.1A). Using whole genome transcriptional profiling and network inference methods we set out to 
develop a detailed analysis of the changes underlying tumour vascularisation and shed light on the 
interactions between the tumour and stromal tissue. 
We discovered a substantial transcriptional reprogramming in both the tumour and the stroma 
during the vascularisation of the tumour. We show that genes linked to hallmarks of tumour 
progression including cell proliferation and angiogenesis are modulated in both the tumour and the 
stroma. Gene clustering revealed a complex pattern of transcriptional response during the course of 
the implantation. The analysis of co-expression networks constructed using expression profiles from 
both the tumour and stroma has shed light on the temporal dynamics of the transcriptional changes 
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underlying angiogenesis. Furthermore, application of a novel ODE-based network inference method 
links expression of key growth factors, cytokines and extracellular matrix (ECM) remodelling factors 
and suggests a central role for IL1α during angiogenesis. 
 
Figure 5.1- Overview of the implantation and analysis strategy 
Panel A (inset) shows the progression of implantation (adapted from Bikfalvi et al. [268]). 
Angiogenesis is visible from 48 hours after implantation. The microarray expression profiling time-
course starts at day 10 (pre-implantation), implantation occurs at day 11 and tumours are collected 







5.2.1 Overview of the Analysis Strategy 
 
The analysis strategy is outlined in Figure 5.1. Briefly, we have used microarrays to generate 
transcriptional profiles of tumour and stroma tissue at 10 time points over 5 days following tumour 
deposition on the chicken egg CAM. We have identified genes differentially expressed in the tumour 
and the stroma. Cluster analysis has been used to identify groups of differentially expressed genes 
with similar expression profiles. Expression profiles representative of the behaviour of each cluster 
have been used to infer correlation based co-expression networks. Simultaneously, functional 
analysis has informed the selection of 15 differentially expressed genes in the tumour or the stroma 
consisting of growth factors, cytokines and extracellular remodelling proteins. We have generated 
transcriptional profiles of tumour cells treated with these factors in vitro. These profiles have been 
used to validate the interactions inferred from the networks. 
5.2.2 Cells and Embryos 
 
Fertilised chicken eggs were maintained as previously described [280]. To assess the response of the 
CAM to VEGF treatment 3μg of VEGF165 was deposited on the CAM at developmental day 10 (n = 3). 
CAM tissue was excised following 24 hours of treatment and snap frozen for RNA extraction and 
microarray profiling (performed by Martin Hagedorn, University of Bordeaux). 
U87 glioblastoma cells were maintained in DMEM, 10% FBS, antibiotics and L-glutamine. U87 cell 
pellets were deposited on the chicken egg CAM at developmental day 10 as previously described 
[268]. Tumours were dissected from the CAM and snap frozen every 12 hours following implantation 
until developmental day 15 (10 time points). Each time point was done in triplicate. 
U87 cells were treated with a panel of recombinant growth factors, cytokines and extracellular 
matrix remodelling proteins. Proteins were dissolved according to the manufacturer’s instructions 
and deposited on the cells to a final concentration of 100ng/ml. This concentration represented a 
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consensus of the existing literature of cell culture experiments, with the aim of selecting a 
concentration with high probability of effectiveness. After 24 hours the media was removed and the 
cells were washed with PBS followed by direct lysis of the cells using RLT buffer (Qiagen, UK). Each 
treatment was done in triplicate and then pooled for microarray profiling, with the exception of the 
controls which were profiled in triplicate. 
5.2.3 Microarray profiling 
 
RNA was extracted from cells and tissue using RNeasy columns (Qiagen, UK). RNA purity was 
assessed using a NanoDrop spectrophotometer. RNA was reverse transcribed and the cDNA was 
labelled with fluorescent Cy3 dye using the Agilent Low-input Quick Amp Kit (Agilent, UK). cRNA was 
purified using RNeasy columns (Qiagen, UK) and hybridised overnight to Agilent Human 4x44k Whole 
Genome or Agilent Chicken V1 Whole Genome microarrays according to the manufacturer’s 
protocol. Microarrays were scanned using an Agilent SureScan microarray scanner and processed 
using Agilent Feature Extraction software.  
In order to remove probes from the analysis that could potentially hybridise to both chicken and 
human cRNA we performed a separate microarray analysis. We created separate pools of RNA from 
chicken CAM and U87 cells to create chicken and human reference samples. The chicken and human 
reference RNA was then analysed using both human and chicken whole genome microarrays. RNA 
extraction, generation of fluorescently labelled cRNA, microarray hybridisation and scanning 
protocols were identical to those used for the implanted tumour tissue. After subtraction of the 
background signal, the relative contribution of the human cRNA to the total fluorescence observed 
for each chicken probe was calculated, and vice versa for the chicken cRNA. Any probe for which the 
cross-hybridisation of cRNA from the other species resulted in a fluorescent signal > 64 or the relative 
contribution to the total signal was greater than 15% was removed. 5,272 probes were removed 




5.2.4 Differential expression and cluster analysis 
 
For the tumour implantation time-course the microarray data was log transformed and normalised 
using quantile normalisation [126]. Differentially expressed genes were identified using 2 steps. 
Firstly, genes with at least a 2-fold change (linear scale) in expression between time points were 
selected. Secondly, the Bayesian Estimation of Temporal Regulation (BETR) [131] method was 
applied to remove noisy genes, using an alpha value (analogous to a p-value) of 1e-5. This 
corresponds to a false discovery rate (FDR) < 1% when corrected using the Benjamini-Hochberg 
method [132]. 
For the U87 in vitro treatments, microarray data was LOESS normalised in order to generate fold 
change ratios versus the controls. For the VEGF treatment of the CAM the raw data was provided as 
Affymetrix CEL files. The data was summarised and normalised using the RMA algorithm with a 
quantile normalisation step. Differentially expressed genes were identified using a one-class T-test 
followed by Benjamini-Hochberg FDR correction [132] and applying a threshold of 10%. 
Functional analysis was done by applying the Gene Set Enrichment Analysis (GSEA) [135] tool to gene 
lists ranked by fold change values versus the respective controls. Additional functional analysis was 
done using the online tool DAVID [134]. Terms in the Gene Ontology database with an FDR < 10% 
were defined as functionally enriched unless otherwise stated.  
Genes differentially expressed during the tumour implantation time-course were clustered using the 
HOPACH algorithm [129]. Clusters containing less than 10 genes were removed from further analysis. 
The medoid gene of each cluster was chosen as a representative expression profile. In order to 
increase the number of available data points for network inference the cluster profiles were fitted to 
5th degree polynomials using interpolation with a total of 1 data point per hour of the implantation 
time course (108 hours). Clusters were categorised into distinct time domains according to the 
amount of time needed for 50% of the total change in expression within the interpolated expression 
profile of the cluster to occur. The time domains were chosen to represent the first five 12 hour 
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intervals within the time-course, as we found that all clusters fell within this range. The average 
expression profile of genes within clusters and with the same functional annotation was calculated 
by conversion of the expression value to Z scores and averaging. The transcriptional data from the 
panel of U87 treatments were clustered using a hierarchical clustering as implemented by the hclust 
function in the R software package. 
5.2.5 Constructing correlation based co-expression networks 
 
Co-expression networks were generated using spearman correlation between the interpolated 
cluster expression profiles. In order to integrate our knowledge of the temporal properties of the 
cluster expression profiles we have introduced a time-delay element to the network, such that two 
clusters are identified as co-expressed if the expression profiles are highly correlated given a 12-24 
hour shift (1 or 2 time domains) of either cluster. A high correlation threshold of 0.9 was chosen to 
filter insignificant network connections. We then applied a stratified layout to the network such that 
the time domains were sorted from fast to slow and groups of clusters within the same time domain 
were within the same strata of the network. We then selected only network connections that were 
consistent with this hierarchy, such that connections represent a significant correlation between a 
faster responding cluster and a slower responding cluster. Clusters with similar expression profiles 
were grouped within the network by applying the HOPACH clustering algorithm to the cluster 
expression profiles. 
5.2.6 Constructing ODE-based networks 
 
The ordinary differential equation (ODE) networks were constructed by Dr Rita Gupta by applying a 
novel ODE-based network inference method to data selected by Kim Clarke. The inference procedure 
models networks of directed interactions between genes as ordinary differential equations, as 
described previously [281]. The method includes a recursive network shrinkage procedure which is 
able to effectively remove edges that do not contribute to the stability of the network. As such, all 
connections within the resulting networks are considered significant, as removing them significantly 
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perturbs the network. However, as this can be a large number of connections that are difficult to 
interpret we have used a recently developed method [282] to estimate the FDR of each edge and 
applied a 5% FDR threshold. Consensus networks were generated in each case by taking only edges 
significant in 4/4 replicated networks. 
5.2.7 Validation of the network connections using the in vitro treatment 
expression profiles 
 
The genes encoding for the panel of recombinant proteins used for the in vitro U87 treatments are 
located within gene clusters found in the co-expression network. Gene Set Enrichment Analysis 
(GSEA) was used to test for enrichment (FDR < 10%) of the gene clusters found down-stream of the 
network modules containing the recombinant proteins within the transcriptional signature of each 
treatment. The transcriptional profiles of the U87 cells in response to each treatment were ranked 





5.3.1 Transcriptional response of normal and tumour tissues in the CAM model 
 
In order to characterise the transcriptional response of normal and tumour cells during development 
of a vascularised tumour we first developed a bioinformatics pipeline to identify differentially 
expressed genes, and then simplified the complexity of the transcriptional response in a relatively 
small number of clusters representing genes with similar expression profiles. Each cluster was 
assigned to a specific time domain, defined by the time necessary to reach 50% of the range of 
expression.  
We identified 2240 and 2998 genes differentially expressed in the chicken stroma and in the tumour 
tissue respectively. Cluster analysis identified 26 and 16 gene clusters in the stroma and tumour 
tissues respectively which were organised into 5 time domains (see methods). Interestingly, we 
noticed that a much larger proportion of stroma clusters (Figure 5.2A, 14 out of 26, 43%) are 
assigned to the rapid response group (50% of the range reached within 12 hours post-implantation) 
compared to the tumour clusters (Figure 5.3A, 4 out of 16, 15%). 
Functional analysis of the clusters from each time domain revealed enrichment of distinct sets of 
functional terms (Figure 5.2B, 5.3B). In the stroma (Figure 5.2B), functional enrichment was found in 
4/5 of the time domains and represented a diverse set of transcriptional reprogramming that occurs 
during tumour vascularisation. This was characterised by an early, rapid up-regulation of genes 
related to stress response and wounding, followed by a down-regulation of genes related to 
mitochondrial function and cell cycle in the next groups. In the latest time domain functions related 
to angiogenesis and tissue remodelling are enriched within up-regulated genes.  
The functional analysis of the tumour clusters (Figure 5.3B) revealed an early up-regulation of genes 




Figure 5.2 – Cluster analysis and functional profiling of the five time domains (stroma) 
This figure shows the cluster analysis and functional profiles of the 5 time domains in the stromal 
tissue. Time domains have been colour coded yellow to blue in panel A and B. Panel A shows the 
cluster expression profiles as a heatmap divided into the 5 time domains. The beginning of the 
implantation time course (red arrow) and the time domain (black arrow) are marked. Preceding the 
red arrow is the average expression before implantation. Panel B shows the functional profiles of the 
genes within each time domain represented as the number of genes assigned to each functional 






Figure 5.3 – Cluster analysis and functional profiling of the 5 time domains (tumour) 
This figure shows the cluster analysis and functional profiles of the 5 time domains in the tumour 
tissue. Time domains have been colour coded yellow to blue in panel A and B. Panel A shows the 
cluster expression profiles as a heatmap divided into the 5 time domains. The beginning of the 
implantation time course (red arrow) and the time domain (black arrow) are marked. Preceding the 
red arrow is the average expression before implantation. Panel B shows the functional profiles of the 
genes within each time domain represented as the number of genes assigned to each functional 
term. Significant enrichment (light box, FDR < 10%) is highlighted. 
 
regulation of genes related to the response to wounding. Strikingly, the largest transcriptional 
changes seen in the tumour are found in the 4th response group, representing an alteration in 
expression of 2006 genes (69% of total differentially expressed genes) centred around 37-48 hours 
after implantation. The functional profile is consistent with the onset of angiogenesis and escape 
125 
 
from apoptosis observed after tumour implantation [268]. We also find up-regulation of genes 
related to specific signalling pathways such as SMAD binding, activation of MAPK activity, IGF binding 
and Wnt receptor signalling. In addition, there is a significant down-regulation of genes related to IL1 
receptor binding, IL6 receptor binding and SMAD binding. 
 
5.3.2 Inference of a high-level dynamical model representing stroma-tumour 
interaction 
 
The results of the expression profiling and functional analysis highlight the complex transcriptional 
reprogramming that occurs during vascularisation in both stroma and tumour tissues. In order to 
identify the relationship between the dynamics of the transcriptional response in these two tissues 
we inferred the underlying structure of a co-expression network representing the relationship 
between the overall transcriptional activity (defined by the average expression profile of the genes 
represented in each cluster) of the stroma and tumour gene clusters. This approach inferred a 
network representing 34 out of 42 of the gene clusters described above. We visualised the 34 
clusters connected by 117 directional edges with a hierarchical layout where nodes were positioned 
within 5 time domains (Figure 5.4). We characterised each time domain within the network using 
functional analysis.  The functional profile of each time domain was consistent with the overall 
analysis shown in Figure 5.2 & 5.3, indicating that the clusters contained in the network are the main 
contributors to the functional profiles. This includes the first time domain which is enriched with 
genes related to cellular response to stress, and response to wounding in the stroma and extracellular 
matrix in the tumour. Functions enriched within the second time domain include cell adhesion and 
mitochondrion in the stroma and regulation of transcription and induction of apoptosis in the 
tumour. Functional terms related to angiogenesis such as blood vessel development, cell adhesion 



























































































































































































































































































5.3.3 CAM transcriptional response to VEGF is predicted by the high-level 
dynamical model 
 
The dynamics of expression of tumour VEGFA is cyclic, with a maximum up-regulation at 36 hours 
post implantation (Figure 5.5B). However, in the long term, the expression of VEGFA decreases. 
Consistent with this expression profile, VEGF is assigned to cluster T59 (Figure 5.5A). 
 
Figure 5.5 – VEGF targets are enriched down-stream of VEGF in the network 
Panel A shows the cluster containing VEGFA in the co-expression network and the clusters enriched 
in VEGF down-stream targets. Panel B shows the modulation of VEGFA expression in the tumour. 
Panel C is a heatmap representing the expression of VEGFA targets in the clusters down-stream of 
VEGFA in the co-expression network. Panel D shows the number of VEGF targets in each cluster and 





The model we developed suggests that genes responding to an increase in VEGFA would be found in 
gene clusters downstream of T59, specifically genes in cluster T64, S0 and S19 (Figure 5.5A). In order 
to assess whether this hypothesis was correct, we set to ascertain whether clusters T64, S0 and S19 
were enriched of transcriptional targets of VEGF.  
 
Table 5.1 – Functional analysis of VEGF responsive genes in the CAM 
 
We could verify that this was indeed the case. By exposing the CAM to recombinant VEGF we could 
identify 2300 VEGF regulated genes (876 and 1424 down and up-regulated genes respectively). We 
found that clusters predicted to be downstream VEGF (T6, S0 and S19) were enriched with VEGF 
responsive genes (Figure 5.5D, Figure 5.5C). Functional analysis of the VEGF expression signature 
revealed up-regulation of terms related to cell cycle, angiogenesis, cell adhesion and extracellular 
matrix remodelling (Table 5.1), a functional profile that was very similar to cluster T64 and S0 (Table 
5.2). These results validate the model we have developed and suggest that the transcriptional  
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response of the CAM to tumour cells implantation is indeed only partially dependent on VEGF 
expression. 
 
Table 5.2 – Summary of the functional profiles of key clusters 
 
         
5.3.4 Defining transcriptional signatures of cytokines and growth factors in 
tumour cells 
 
Having demonstrated that the time-delay co-expression networks can correctly identify the 
transcriptional targets of VEGF in the CAM, we set out to systematically apply this strategy, focusing 
on the effects of other secreted factors on tumour cells. We therefore first identified relevant stroma 
and tumour secreted factors represented within the network modules (Table 5.3). We then exposed 
U87 tumour cells to a selection of these cytokines in vitro and performed expression profiling 




Table 5.3 – Growth factors, cytokines, chemokines and receptors in the stroma and tumour 




Table 5.4 – Transcriptional profiling of U87 cells following treatment with 15 soluble factors 
NES – Normalised enrichment score, an alternative measure of enrichment provided by GSEA. Lo – 




Figure 5.6 – Hierarchical clustering of transcriptional and functional profiles of the U87 treatments 
Panel A shows the hierarchical clustering of the entire transcriptional profile of each treatment. 
Panel B shows the hierarchical clustering of treatments based on GSEA enrichment scores for all 
functional terms. Terms were enriched at 1% FDR (light boxes) and were selected at a minimum of 
10% FDR (dark boxes) 
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Hierarchical clustering analysis of the expression profiling data identified 3 main clusters of cytokines 
and growth factors (Figure 5.6A).  We have characterised each expression profile using functional 
analysis. The gene level clustering was consistent with a similar hierarchical clustering analysis 
performed on functional enrichment scores selected at a high level of confidence (FDR < 10%) (Figure 
5.6B). Both analyses revealed a high similarity in the transcriptional response to the inflammatory 
cytokines TNFα, IL1β and IL1α (cluster 1 in Figure 5.6A). More specifically, the up-regulated genes in 
response to TNFα, IL1β and IL1α treatment are significantly enriched with terms related to 
inflammatory response and cell activation (chemokine receptor binding, inflammatory response, 
cytokine activity, cell cycle and extracellular space). In addition to these terms, TNFα treatment 
induced genes related to calcium mediated signalling. Interestingly, IL1α induced the up-regulation of 
genes enriched in response to stress, wound healing, cytokine production and vasculature 
development. IL1β induced expression of genes related to leukocyte migration, and negative 
regulation of programmed cell death.  
Cluster 2 and 3 were primarily characterised by extracellular matrix remodelling factors (FGFb, 
TGFB3, GCSF, CXCL12, HGF). HGF treatment repressed expression of genes related to glucose 
metabolic processes, consistent with previous observations that HGF production is linked to high 
glucose conditions [283]. Both MIP3α (CCL20) and MIP5 (CCL15) treatment decreased the expression 
of genes related to the response to hypoxia, a process in which both of these chemokines have been 
shown to play a role [284] [285].  
We were puzzled to note each expression profile was either linked to up or down-regulated 
functional terms. We reasoned that this could be due to the high statistical threshold used for the 
analysis. Reducing the threshold revealed that the up and down-regulated genes in response to 
treatment were both enriched with functional terms (Table 5.4).  We reasoned that this could also 
explain why the transcriptional signatures linked to VEGF were not enriched in functional terms 
linked to angiogenesis (e.g. vasculature development) (Figure 5.6B). VEGF treatment induced genes 
related to cytokine and chemokine activity, G protein coupled receptors and B-cell activation. Due to 
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the importance of VEGF in angiogenesis we examined genes differentially regulated by VEGF using a 
second functional enrichment tool (DAVID) using a strict selection for differential expression (10% 
FDR). We found that terms related to angiogenesis were enriched within genes induced and 
repressed by VEGF (Table 5.5), including inflammatory response, angiogenesis, blood vessel 
development, wound healing, response to oxygen levels and ECM-receptor interaction. Taken 
together, this suggests that VEGF treatment of U87 cells does induce a transcriptional signature 
consistent with extracellular matrix remodelling and induction of angiogenesis by cytokine and 
chemokine activity. 
 
Table 5.5 – Functional analysis of genes regulated by VEGF treatment of U87 cells in vitro 
 
5.3.5 Validating sub-networks of the co-expression network using the in vitro 
treatments 
 
Next, we set to compare the transcriptional response predicted by our time-course model with the 
tumour in vitro experimentally defined transcriptional signatures. Using the approach pioneered in 
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the analysis of the response to VEGF treatment on the CAM (see Figure 5.5) we could identify 124 
cases of gene clusters being enriched with transcriptional targets of secreted factors, as defined by 
the U87 treatments (see appendix 5A for the full table of hits). Of these 124 cases, 13 (10.4%) were 
matching edges of our high level network model (Figure 5.7). Since these connections represent both 
co-expression in vivo and experimentally validated transcriptional regulation in response to 
treatment in vitro, we hypothesized that these connections may represent key events in the 
development of the vascularised tumour, and therefore examined them in more detail.  
We have shown that cluster T64 is highly enriched with genes induced by VEGF treatment of the 
CAM, and thus we predicted that treatment of U87 cells with VEGF in vitro would produce a similar 
result. Contrary to this prediction, genes down-regulated in response to VEGF treatment of U87 cells 
were enriched within cluster T64. However, closer examination revealed that this is consistent with 
the expression of VEGF in the tumour during the CAM time-course. VEGF expression decreases 
between 36- 48 hours after implantation, consistent with the up-regulation of genes in T64 within 
the 36-48 hour time domain. Furthermore, two clusters within the same time domain as VEGF, T8 
and T14, are highly enriched with genes activated and repressed by VEGF respectively. This is 
consistent with an activation of VEGF targets coinciding with the transient increase in expression of 
VEGF in the tumour between 24-36 hours after implantation. In comparison the VEGF treatment of 
the CAM represents 24 hours of acute VEGF target activation, consistent with the significant 
enrichment of VEGF targets within cluster T64, S19 and S0. Taken together, this reinforces the role of 
VEGF signalling, however it also suggests that other factors could play a key role in controlling 
angiogenesis such as those in cluster T8 and T14.  
Cluster T14 contains IL1α and is connected to cluster T64 and T28 in the co-expression networks. 
Cluster T64 and T28 are enriched with genes repressed and induced by IL1α treatment respectively, 
consistent with the expression patterns of IL1α, T64 and T28 in the tumour (Figure 5.7B, Figure 5.7C). 
However, this data does not provide knowledge on the very early changes in IL1α expression,  
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Figure 5.7 – Sub-network of the co-expression network validated by the U87 in vitro treatments 
The edges in the network in panel A represent both co-expression between two clusters and a link 
between a secreted factor and its target genes, defined by the U87 treatments. The up-stream 
clusters contain the indicated factors while the down-stream clusters are significantly enriched with 
genes modulated by treatment with the upstream protein. With the exception of VEGF which is 
discussed in the text, edges within the same time domain have been removed in order to represent 
only temporal relationships. Panel B and C show the expression of IL1α and the medoid expression 





as the first tumours were sampled after 12 hours of implantation. It is possible that IL1α expression is 
induced between implantation and the first time point.  
Cluster T64 contains 80% of the up-regulated genes in the tumour. Functional analysis of T64 reveals 
enrichment of terms related to proliferation, extracellular matrix remodelling and angiogenesis. 
Functional analysis of cluster T28 reveals enrichment of genes related to regulation of cell death and 
response to wounding (Table 5.2). Combined with the analysis of the transcriptional profiles of IL1α 
and VEGF treatment of U87 cells in vitro this analysis presents two hypotheses. Firstly, the transient 
increase in expression of VEGF and the initial expression of IL1α by the tumour acts as a signalling 
mechanism to induce pro-inflammatory and pro-angiogenic pathways. Secondly, this expression 
precedes alterations in expression of a large subset of genes related to cell proliferation, 
angiogenesis and cell death found in clusters T64 and T28. 
 
5.3.6 High resolution, gene-level dynamical modelling identifies IL1α as a key 
factor driving tumour implantation in the CAM 
 
Having developed a correlation based co-expression model of tumour expansion and shown that it 
successfully captures the response of the tumour and stroma to important soluble proteins, we 
decided to apply a more sophisticated ODE-modelling approach to infer higher resolution (gene 
level) dynamical models. 
We have applied a new ODE-based network inference method, developed by Dr Rita Gupta, to infer 
connections between secreted factors in the tumour and stroma (Figure 5.8). In the first case, we 
have inferred networks from expression profiles of secreted factors in the tumour and stroma for 





Figure 5.8 – ODE-based networks representing gene level interactions in the tumour and stroma 
Panel A is the network constructed with integration of the U87 in vitro treatment data into the 
network inference pipeline. Panel B is the network constructed using just the expression profiles 
from the tumour implantation time-course. Edges are labelled with the log2 fold change of the target 
gene in response to in vitro treatment with the up-stream factor. 
 
have been integrated into the network inference methodology in order to further constrain the 
network reconstruction (network 1). Secondly, a network was generated using the same selection of 
genes without the integration of the in vitro treatment profiles (network 2).  
While the modelling approach employs a recursive method to identify sparse networks, these are still 
of difficult biological interpretation as they represent an average of 40% of a fully connected 
network. We therefore used an additional thresholding procedure developed by Scutari and 
Nagarajan [282] to further decrease network complexity by selecting only connections which 
represent a strong interaction. Both networks reinforced the role of IL1α as a hub gene within the 
network, as it is linked to the expression of IL6, IL6R, TNFRSF1B, CXCL12, IL1β and CXCR7 (Figure 5.8). 
Of these connections, 2 were consistent with the in vitro treatments, specifically IL1α induction of 
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IL1β and IL6 expression, which were both induced by over 32 fold (linear scale) in response to IL1α 
treatment of U87 cells. This is consistent with the expression changes seen in the CAM implantation 
time-course, in which IL1α, IL1β and IL6 expression is correlated. In addition, the expression network 
predicts a role of CXCL12 in inducing expression of VEGF. VEGF expression in U87 cells was up-
regulated in response to CXCL12 treatment (fold change 1.47). This interaction is well known, CXCL12 
signalling induces VEGF expression at the mRNA level [286] and both act synergistically in response 
to hypoxia to promote angiogenesis [287]. This interaction may represent a key early signalling event 
between the tumour and the stroma, as CXCL12 is found within stroma cluster S21 which is induced 
rapidly in response to implantation. 
 
5.3.7 High resolution dynamical modelling linking soluble factor gene expression 
to effector functions, confirms IL1α as a key factor driving tumour implantation in 
the CAM 
 
We reasoned that the expression of soluble factors known to control transcription could be up-
stream of effector functions over-represented in the gene clusters. We generated an ODE-based 
network using gene expression profiles combined with the average expression profiles of genes sets 
representing biological functions present within gene clusters in the tumour and stroma (Table 5.6). 
Functional terms were aggregated from groups of gene clusters identified with HOPACH (see Figure 
5.4). The network contained 29 nodes and 43 edges representing 10 biological functions and 19 
soluble factors (Figure 5.9A). We extracted sub-networks consisting of the network neighbourhood 
of secreted factors which contained functional terms. We found that IL1α expression was linked to 
regulation of cell migration, blood vessel development and cell adhesion (Figure 5.9B). We further 
tested these connections by using GSEA to test for enrichment of the genes comprising the 
functional terms within the genes regulated by IL1α treatment of U87 cells. We found that genes 
comprising the regulation of cell migration and blood vessel development terms were significantly 




Table 5.6 – Functional terms used in the ODE-networks 
 
TNFRSF1B expression in the stroma was linked to genes involved in the inflammatory response 
(Figure 5.9D). GSEA analysis confirmed that the inflammatory response gene set was enriched within 
genes up-regulated in response to TNFα treatment, consistent with expression in the stroma. A third 
sub-network linking IL6R expression in the tumour to expression of genes related to regulation of 
apoptosis and cell migration was identified (Figure 5.9C). These connections were also consistent 
with GSEA analysis which showed that genes making up both these functional groups are activated in 
response to IL6 treatment. In summary, the genes belonging to effector functions predicted to be 





Figure 5.9 – ODE-based networks of soluble factor gene expression and effector functions 
Panel A is the entire network organised using a hierarchical layout. Panel B – D are sub-networks of 
Panel A which link soluble factor expression with effector function. Edge weights indicate GSEA 
enrichment scores. * Significant enrichment of genes comprising an effector function in the targets 





We have described the first in-depth gene expression profiling study of a model of angiogenesis in 
which the state of both the avascular tumour and surrounding stroma has been captured. This has 
revealed a complex pattern of transcriptional reprogramming during angiogenesis involving 
differential expression of many growth factors, cytokines, chemokines, and extracellular remodelling 
factors controlling angiogenesis, cell migration, cell proliferation, apoptosis and other effector 
functions. Co-expression networks reveal a dynamic hierarchy to these events in which early and 
delayed changes are linked. Interestingly, the delayed changes appear to be central to the angiogenic 
process, while the earlier changes appear to represent adaptations to the microenvironment and 
preceding signalling events. These adaptations may represent key events in the transition from a 
stable tumour towards the recruitment of the vasculature and tumour growth. 
VEGF is perhaps the most well characterised pro-angiogenic factor due to its potent stimulation of 
both pathological and physiological angiogenesis, as well as the availability of VEGF inhibitors that 
are effective anti-cancer drugs. Our analysis suggests that VEGF gene expression is not constitutively 
induced during tumour angiogenesis in the CAM, rather there is a transient increase in expression 
that precedes the expression of a large number of pro-angiogenic genes. The regulation of VEGFA 
mRNA stability and translation is complex, with many factors such as stabilising proteins and miRNA 
targeting able to post-transcriptionally regulate VEGF expression [288]. Further experiments utilising 
proteomics approaches could provide valuable information allowing the correlation of mRNA 





5.4.1 The role of IL1α in controlling angiogenesis 
 
One of the key inflammatory cytokines expressed in the tumour is IL1α. IL1α exists as both a 
precursor and a mature form, however unlike IL1β both forms of IL1α are active. In contrast to IL1β, 
it appears that IL1α acts primarily through intracellular or juxtracrine signalling pathways, as it is 
rarely secreted and only in its mature form [289]. IL1α signalling appears to play an important role in 
a variety of pathologies. IL1α knock-out mice injected with a melanoma cell line show a 50% 
reduction in vascular growth and microvessel density in matrigel plugs and reduced tumorigenicity 
compared to wild type mice [290]. In contrast, fibrosarcomas expressing IL1α that were injected into 
mice have shown reduced tumorigenicity and increased immune response [291]. Consistent with our 
observations, treatment of cardiac myofibroblasts with recombinant IL1α induces expression of pro-
inflammatory markers including IL1β and IL6 [292]. Co-culture of a pancreatic cancer cell line 
expressing IL1α with fibroblasts induced expression of pro-inflammatory factors, which was reduced 
when IL1α signalling was blocked [293]. The same study identified a significant link between IL1α 
gene expression and clinical outcome of pancreatic cancer patients. Importantly, by blocking IL1R 
signalling one study was able to show how intracellular IL1α pre-cursor is able to cause 
transcriptional re-programming including induction of pro-inflammatory cytokines in an IL1 receptor 
independent manner [294]. 
Our findings reveal IL1α as a hub within networks describing the transcriptional reprogramming that 
occurs during glioblastoma induced angiogenesis. IL1α is up-stream of effector functions and 
important secreted factors such as IL6, IL1β and CXCL12. In addition, the co-expression networks 
place IL1α in the second time domains representing a fast transcriptional response to implantation, 
up-stream of important effector functions related to angiogenesis and tumour proliferation. This 
suggests that expression of IL1α may play a key role in controlling angiogenesis in human 
glioblastoma.  
Based on this analysis we propose further experiments to investigate the role of IL1α in glioblastoma 
development. Using the CAM model we aim to address the questions of whether IL1α signalling in 
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glioblastoma is necessary for angiogenesis and tumour growth and to shed light on the relative 
contribution of intracellular and extracellular IL1α signalling. By generating IL1α knock-out 
glioblastoma cell lines and implanting them on the CAM we will be able to investigate further the 
role of IL1α. 
5.4.2 Angiogenesis in skeletal muscle 
 
Skeletal muscle relies on the efficient and plentiful delivery of oxygen and nutrients via the blood to 
maintain normal function. In this respect skeletal muscle adapts relatively rapidly to changes in 
oxygen and nutrient demand by development of additional capillaries. Pro-angiogenic stimuli such as 
hypoxia, NO release and shear stress activate the angiogenic program [295] [296] by regulating 
expression of key transcription and growth factors, cytokines and tissue remodelling factors such as 
VEGF  and HIF1A [297], amongst many others.  
Recent findings show that muscle regeneration and angiogenesis in response to injury and exercise 
training is not altered in muscle of elderly individuals [298]. However, in COPD patients versus 
sedentary controls the angiogenic response to exercise training is blunted [299]. Two hallmarks of 
COPD exacerbations are hypoxia [300] and inflammation [301] in the muscle, both of which are also 
important processes controlling angiogenesis. Therefore, it is important to understand how the 
angiogenic switch is altered in conditions such as COPD, for which very little information exists. We 
have shown that many growth factors and inflammatory cytokines are differentially expressed during 
glioblastoma induced angiogenesis, and these factors can be mapped to complex networks. However 
it is uncertain how applicable this model is to skeletal muscle angiogenesis. Further work will be 
necessary to build the biological networks underlying skeletal muscle angiogenesis from clinical data, 
such as identifying the network neighbourhood of IL1α, IL1β and VEGFA, as this represents a 





CONCLUDING STATEMENT AND FUTURE DIRECTIONS 
 
This thesis has presented the first analysis of transcriptional networks in young and elderly muscle 
based on a meta-analysis of clinical data. The utilisation of a statistical integration platform to 
perform the meta-analysis has allowed us to use standard statistical analysis techniques to expand 
our knowledge of the transcriptional changes between young and elderly muscle. The application of 
this method to within network inference pipelines is a powerful tool that can extract valuable 
information form the wealth of data that is currently available. 
The network analysis has revealed distinct differences in the underlying structure of networks 
representing skeletal muscle ageing.  We have revealed that energy metabolism genes are both 
under-expressed and decoupled from sub-networks representing translation and ribosome 
biogenesis in elderly muscle. These networks represent a valuable resource for investigating the 
response of skeletal muscle to stressors such as hypoxia, inflammation and exercise. This is 
highlighted by identifying specific modules within the network that respond to an exercise program 
in elderly people. This revealed that while core modules representing energy metabolism respond to 
exercise there is a subset of genes that do not respond to exercise training, and these genes are part 
of a sub-network highly co-expressed in elderly muscle. 
Future interrogation of the networks can shed light on the molecular response to popular 
intervention strategies to target sarcopenia. In parallel to this, the recent pace of data generation 
means sufficient data will be available to generate networks specifically from trained and untrained 
muscle. By comparing these networks across age groups we can further distinguish the effects of 
ageing from ageing related muscle disuse.  
By careful analysis of the network topology and functional profiles of the core modules we identified 
a link between eukaryotic initiation factors and expression of energy metabolism genes. While 
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previous work has linked 40S associated eIFs to stress-response pathways such as hypoxia [228] and 
mTOR signalling [230], very little has been revealed regarding the function of the majority of eIFs 
outside ribosome assembly. Our analysis suggests that expression of EIF genes is controlled by an 
age-dependent mechanism coupled to the control of energy metabolism. We validated the network 
predictions using an Eif6 heterozygous mouse model. Eif6 is one of the most highly age-dependent 
factors highlighted by the network analysis and is up-regulated in elderly muscle. By using 
transcriptional profiling and MS proteomics we revealed that Eif6+/- muscle shows a substantial 
transcriptional reprogramming which is coupled to changes in protein expression in mitochondria. As 
predicted by the human network the alterations were characterised by increased expression of 
energy metabolism genes. This represents the first evidence of a 60S associated EIF able to affect 
global gene expression in muscle tissue. 
Future efforts will be directed towards revealing the nature of the metabolic reprogramming within 
eIF6 haploinsufficient muscle. Recent experiments conducted by the Falciani lab but not covered in 
this thesis have revealed several intriguing results. Firstly, we have found that in Eif6+/- whole muscle 
the respiratory control ratio is significantly decreased compared to wild type. This is indicative of 
mitochondrial dysfunction characterised by a lower capacity for substrate oxidation and reduced ATP 
turnover. The precise impact of this on ATP availability in the muscle is not yet known. Motivated by 
the link between eIF6 and serum protein carbonylation levels in clinical data, we have measured ROS 
generation in Eif6+/- isolated fibres in response to contraction stimulation. This has revealed a striking 
reduction in ROS generation compared to wild type fibres to the point where stimulated and un-
stimulated Eif6+/- fibres are indistinguishable. This suggests an exciting line of enquiry consistent with 
our analysis of clinical data. Further experiments will be needed to ascertain whether Eif6+/- mice 
show altered respiratory capacity and ROS generation during exercise, hypoxia and old age, as this 




Protein acetylation has emerged as a key player in the regulation of metabolism in recent years 
[238]. The transcriptional signature of Eif6 haploinsufficiency was recapitulated by histone 
deacetylase inhibitors. Recent proteomics analysis has revealed a significant alteration in the 
acetylome of Eif6+/- muscle. This is characterised by hyperacetylation of NADH dehydrogenase 
subunits and deacetylation of glycolysis enzymes. Acetylation status regulates both metabolic 
enzyme abundance and activity, and has divergent effects dependent on the individual enzyme [84]. 
Future experiments will aim to delineate the effects of acetylation in Eif6 haploinsufficient muscle by 
assessing the expression and activity of metabolic enzymes. 
Eif6 haploinsufficient satellite cells have cell autonomous alterations in transcriptional state. This was 
characterised by increased expression of energy metabolism genes, an effect that was increased 
dramatically in differentiating cells. This was accompanied by differential expression of factors known 
to control myogenic differentiation such as Myod and myogenin. We hypothesise that Eif6 
haploinsufficient muscle may show altered regenerative capacity in response to injury. On-going 
experiments addressing this question include histochemical analysis of an injury model in Eif6+/- and 
wild type mice as well as characterisation of Eif6+/- satellite cell proliferation and differentiation 
signalling pathways in vitro. 
Understanding tissue remodelling processes such as angiogenesis are vital to reducing the impact of 
age-related diseases such as cancer. The process of angiogenesis has been intensively studied for 
many years, but the complexity of the process is only recently emerging with the application of 
systems level analysis [156] [157]. We have constructed the first detailed networks of tumour-stroma 
expression during angiogenesis based on observational data. By using multiple network inference 
approaches we are able to predict both high level and gene level interactions between the tumour 
and stroma. In the future, we will focus on validating the predictions made by the model, such as the 
central role of IL1α in glioblastoma development, by utilising knock-out cell lines and proteomics 








KEGG pathway enrichment within the neighbourhood of EIF2S2 (FDR < 25%) 
 
 
Appendix 3A - Young muscle – positive correlation to EIF2S2 
 
 




Appendix 3A - Elderly muscle – positive correlation to EIF2S2 




Appendix 3A - Elderly muscle – negative correlation to EIF2S2 
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KEGG pathway enrichment within the neighbourhood of EIF3J (FDR < 25%) 
 
 
Appendix 3A - Young muscle – positive correlation to EIF3J 
 
 




























Appendix 5A – This table shows all U87 treatments which resulted in transcriptional signatures 
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